

**CUMULATIVE
SUPPLEMENT 7
JULY 2002**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

22nd EDITION

Department of Health and Human Services

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

RM
301.45
.A66
2002
July
suppl.

2002

CBG
Scribbling

1.0 IN
1.1
1.2
1.3
1.4
1.5
1.6

DRUG

PAT

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

or

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS
22ND EDITION

Cumulative Supplement 7

July 2002

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Applicant Name Changes	iv
1.3 Waived Exclusivity	v
1.4 Availability of the Edition	vi
1.5 Report of Counts for the Prescription Drug Product List	vii
1.6 Cumulative Supplement Change Legend	x
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

Library Use Only

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

22ND EDITION

**CUMULATIVE SUPPLEMENT 7
July 2002**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 22nd Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 22nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 23rd Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

DANBURY PHARMACEUTICALS INC
(DANBURY PHARMA)

DURAMED PHARMACEUTICALS INC
(DURAMED)

DERMIK LABORATORIES INC
(DERMIK LABS)

DERMIK LABORATORIES INC SUB RORER
(DERMIK LABS)

JANSSEN RESEARCH FDN
(JANSSEN)

JANSSEN RESEARCH FDN DIV
JOHNSON AND JOHNSON
(JANSSEN)

JOHNSON AND JOHNSON PHARMACEUTICAL
RESEARCH AND DEVELOPMENT LLC
(JOHNSON AND JOHNSON)

RW JOHNSON PHARMACEUTICAL RESEARCH
INSTITUTE DIV ORTHO PHARMACEUTICAL CORP
(JOHNSON RW)

RW JOHNSON PHARMACEUTICAL RESEARCH
INSTITUTE DIV ORTHO PHARMACEUTICAL CORP
(JOHNSON RW)

MCNEIL CONSUMER HEALTHCARE DIVISION
(MCNEIL CONS)

MOVA PHARMACEUTICALS CORPORATION
(MOVA)

PARKE DAVIS PHARMACEUTICALS LTD
(PARKE DAVIS PHARMS)

THAMES PHARMACAL COMPANY INC
(THAMES)

WHITEHALL LABORATORIES INC DIV AMERICAN HOME
PRODUCTS CORP
(WHITEHALL LABS)

WHITEHALL ROBINS HEALTHCARE
(WHITEHALL LABS)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

WATSON LABORATORIES INC
(WATSON LABS)

DURAMED PHARMACEUTICALS INC SUB OF BARR
LABORATORIES INC
(DURAMED PHARM BARR)

DERMIK LABORATORIES DIVISION OF AVENTIS
PHARMACEUTICALS INC
(DERMIK LABS)

DERMIK LABORATORIES DIVISION OF AVENTIS
PHARMACEUTICALS INC
(DERMIK LABS)

JANSSEN PHARMACEUTICA PRODUCTS LP
(JANSSEN PHARMA)

JANSSEN PHARMACEUTICA PRODUCTS LP
(JANSSEN PHARMA)

ORTHO MCNEIL PHARMACEUTICAL INC
(ORTHO MCNEIL PHARM)

ORTHO MCNEIL PHARMACEUTICAL INC
(ORTHO MCNEIL PHARM)

ORTHO MCNEIL PHARMACEUTICAL INC
(ORTHO MCNEIL PHARM)

MCNEIL CONSUMER AND SPECIALTY PHARMACEUTICALS
DIVISION MCNEIL PPC
(MCNEIL CONS SPECLT)

CLONMEL HEALTHCARE LTD
(CLONMEL HLTH)

PFIZER PHARMACEUTICALS LTD
(PFIZER PHARM LTD)

TARO PHARMACEUTICALS NORTH AMERICA INC
(TARO PHARMS US)

WYETH CONSUMER HEALTHCARE
(WYETH CONS)

WYETH CONSUMER HEALTHCARE
(WYETH CONS)

1.3 WAIVED EXCLUSIVITY

Waived exclusivity - If a new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (Act) qualifies for exclusivity under sections 505(c)(3)(D) and 505(j)(5)(D), the exclusivity is listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, the FDA will delay the approval of a 505(b)(2) application or an abbreviated new drug application (ANDA) under section 505(j) of the Act until the expiration of the exclusivity. If the listed drug is also protected by one or more patents, the approval date for the 505(b)(2) application or ANDA will be determined by the latest expiring patent or exclusivity listed in the Orange Book.

However, the holder of the NDA may waive its exclusivity as to any or all 505(b)(2) and ANDA applications referencing the protected drug product. If an NDA sponsor waives its right to the exclusivity protection, qualified 505(b)(2) or ANDA applications may be approved without regard to the NDA holder's exclusivity. An NDA for which the holder has waived its exclusivity as to all 505(b)(2) and ANDA applications will be coded with a W in the Patent and Exclusivity Section of the Orange Book and be referred to this section. The applicant referencing this listed drug should indicate in the exclusivity statement that the holder of the listed drug has waived its exclusivity

1.4 AVAILABILITY OF THE EDITION

The 22nd Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is \$105.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at <http://www.fda.gov/cder/ob>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at
<http://www.fda.gov/cder/orange/adp.htm>.

The Internet version of the hard copy monthly supplement is at
<http://www.fda.gov/cder/orange/supplement/cspreface.htm>. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at
<http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 22nd annual edition of the 2001 Orange Book Patent and Exclusivity List is at
<http://www.fda.gov/cder/orange/22bookpub.pdf>.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at <http://www.fda.gov/cder/orange/supplement/patents.pdf>.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at
<http://www.fda.gov/cder/orange/docket.pdf>. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
<http://www.fda.gov/cder/orange/patdecl.pdf>
<http://www.fda.gov/cder/orange/patdecl.html>

The current listing of the Orphan Product Designations and Approvals is available at
<http://www.fda.gov/orphan/designat/list.htm>.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2001) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2001</u>	<u>MAR 2002</u>	<u>JUN 2002</u>	<u>SEP 2002</u>
DRUG PRODUCTS LISTED	10166	10357	10193	
SINGLE SOURCE	2665 (26.2%)	2645 (25.5%)	2400 (23.5%)	
MULTISOURCE	7391 (72.7%)	7602 (73.4%)	7687 (75.4%)	
THERAPEUTICALLY	7105 (69.9%)	7309 (70.6%)	7402 (72.6%)	
EQUIVALENT	286 (2.8%)	293 (2.8%)	285 (2.8%)	
NOT THERAPEUTICALLY	110 (1.1%)	110 (1.1%)	106 (1.0%)	
EQUIVALENT EXCEPTIONS ¹	10	1	5	
NEW MOLECULAR ENTITIES APPROVED	574	574	574	
NUMBER OF APPLICANTS				

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

>A>
>A>
>D>
>D>

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form;Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form;route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 22ND EDITION
RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

1-1

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL		
SECTRAL		
>A> AB ESP PHARMA	EQ 200MG BASE	N18917 001 DEC 28, 1984 JUL CAHN
>A> AB +	EQ 400MG BASE	N18917 003 DEC 28, 1984 JUL CAHN
>D> AB WYETH AYERST	EQ 200MG BASE	N18917 001 DEC 28, 1984 JUL CAHN
>D> AB +	EQ 400MG BASE	N18917 003 DEC 28, 1984 JUL CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL		
ACETAMINOPHEN, BUTALBITAL, CAFFEINE, AND CODEINE PHOSPHATE		N75929 001 APR 22, 2002 APR NEWA
AB VINTAGE PHARMS	325MG;50MG;40MG;30MG	

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL		
PHENAPHEN W/ CODEINE NO. 2		N84444 001 MAY DISC
@ ROBINS AH	325MG;15MG	
SOLUTION; ORAL		
ACETAMINOPHEN AND CODEINE PHOSPHATE		N85861 001 MAY CRLD
AA + ALPHARMA	120MG/5ML;12MG/5ML	
TYLENOL W/ CODEINE		N85057 001 MAY DISC
@ JOHNSON RW	120MG/5ML;12MG/5ML	
TABLET; ORAL		
ACETAMINOPHEN AND CODEINE PHOSPHATE		N86683 001 MAY DISC
@ PUREPAC PHARM	300MG;60MG	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL		
HYDROCODONE BITARTRATE AND ACETAMINOPHEN		N40366 001 JAN 23, 2002 JAN NEWA
AA KV PHARM	500MG/15ML;7.5MG/15ML	
TABLET; ORAL		
>D> ANEXSIA		N40084 003 JUL 29, 1996 JUL CTNA
>D> AA + MALLINCKRODT	660MG;10MG	
>A> HYDROCODONE BITARTRATE AND ACETAMINOPHEN		N40084 003 JUL 29, 1996 JUL CTNA
>A> AA + UCB	660MG;10MG	N40210 001 AUG 13, 1997 JUN CAHN
AA NORCO	500MG;10MG	
AA + WATSON LABS	325MG;5MG	N40099 001 JUN 25, 1997 MAY CTNA

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL		
DARVOCET	325MG;32.5MG	N16844 001 JUN CAHN
@ AAIPHARMA LLC		

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL		
DARVOCET-N 100		N17122 002 JUN CAHN
AB + AAIPHARMA LLC	650MG;100MG	
DARVOCET-N 50		N17122 001 JUN CAHN
AB AAIPHARMA LLC	325MG;50MG	

ACYCLOVIR

TABLET; ORAL

ACYCLOVIR

>D>	AB	AESGEN	400MG	N74946 001	NOV 19, 1997	JUL	CAHN
>D>	AB		800MG	N74946 002	NOV 19, 1997	JUL	CAHN
>A>	AB	NEOSAN PHARMS	400MG	N74946 001	NOV 19, 1997	JUL	CAHN
>A>	AB		800MG	N74946 002	NOV 19, 1997	JUL	CAHN

ALBUMIN CHROMATED CR-51 SERUM

INJECTABLE; INJECTION

CHROMALBIN

@ ISO TEX 100uCi/VIAL

N17835 001

JUN DISC

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125

@ MALLINCKRODT 6.67uCi/ML

N17844 003

JUN DISC

@ 100uCi/ML

N17844 002

JUN DISC

ALBUTEROL

AEROSOL, METERED; INHALATION

PROVENTIL

BN + SCHERING 0.09MG/INH

N17559 001

JUN CRLD

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

PROVENTIL-HFA

BX + 3M EQ 0.09MG BASE/INH

N20503 001 AUG 15, 1996 MAR CTEC

VENTOLIN HFA

BX + GLAXOSMITHKLINE EQ 0.09MG BASE/INH

N20983 001 APR 19, 2001 MAR CTEC

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

>D> AP + AKORN EQ 0.5MG BASE/ML

N19353 001 DEC 29, 1986 JUL CAHN

>A> AP + GD SEARLE LLC EQ 0.5MG BASE/ML

N19353 001 DEC 29, 1986 JUL CAHN

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

@ GENZYME 10 UNITS/ML

N20057 004 MAY 08, 1992 JUN DISC

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALOPRIM

+ DSM PHARMS EQ 500MG BASE/VIAL

N20298 001 MAY 17, 1996 JUN CAHN

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE
INJECTABLE; INJECTION

MULTI-12
+ SABEX 2002
2 IU/ML; 20MG/ML; 12UGM/ML; 40
IU/ML; 1UGM/ML; 3MG/ML; 80UGM/ML; 8MG/M
L; 0.8MG/ML; 0.72MG/ML; 0.6MG/ML; 600
IU/ML

N21163 001 MAY 18, 2000 APR CAHN

ALPROSTADIL
INJECTABLE; INJECTION
CAVERJECT
PHARMACIA AND UPJOHN
0.01MG/VIAL
0.02MG/VIAL

N21212 001 JUN 11, 2002 JUN NEWA
N21212 002 JUN 11, 2002 JUN NEWA

AMIFOSTINE
INJECTABLE; INJECTION
ETHYOL
@ MEDIMMUNE ONCOLOGY
375MG/VIAL

N20221 002 SEP 10, 1999 JUN DISC

AMINO ACIDS
INJECTABLE; INJECTION
AMINOSYN 7%
@ ABBOTT
7% (7GM/100ML)
AMINOSYN 8.5%
@ ABBOTT
8.5% (8.5GM/100ML)
AMINOSYN II 3.5%
@ ABBOTT
3.5% (3.5GM/100ML)
BRANCHAMIN 4%
@ BAXTER HLTHCARE
4% (4GM/100ML)

N17673 002 JUN DISC
N17673 004 JUN DISC
N19438 001 APR 03, 1986 JUN DISC
N18678 001 SEP 28, 1984 JUN DISC

AMLEXANOX
PASTE; DENTAL
APHTHASOL
>D> + GLAXOSMITHKLINE 5%
>A> + GLAXOSMITHKLINE CONS 5%

N20511 001 DEC 17, 1996 JUL CAHN
N20511 001 DEC 17, 1996 JUL CAHN

AMMONIUM LACTATE
CREAM; TOPICAL
AMMONIUM LACTATE
AB CLAY PARK EQ 12% BASE
LAC-HYDRIN
AB + WESTWOOD SQUIBB EQ 12% BASE
LOTION; TOPICAL
AMMONIUM LACTATE
AB PADDICK EQ 12% BASE
LAC-HYDRIN
AB + WESTWOOD SQUIBB EQ 12% BASE

N75774 001 MAY 01, 2002 MAY NEWA
N20508 001 AUG 29, 1996 MAY CFTG
N75575 001 JUN 11, 2002 JUN NEWA
N19155 001 APR 24, 1985 JUN CFTG

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

1-4

AMOXICILLINTABLET, CHEWABLE; ORAL
AMOXICILLIN

>D>	AB	APOTHECON	125MG	N64131 001	MAY 06, 1996	JUL	DISC
>A>	@		125MG	N64131 001	MAY 06, 1996	JUL	DISC
>D>	AB		250MG	N64131 002	MAY 06, 1996	JUL	DISC
>A>	@		250MG	N64131 002	MAY 06, 1996	JUL	DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	GENEA PHARMS	200MG/5ML;EQ 28.5MG BASE/5ML	N65066 001	JUN 05, 2002	JUN	NEWA
AB		400MG/5ML;EQ 57MG BASE/5ML	N65066 002	JUN 05, 2002	JUN	NEWA
AB	AUGMENTIN '200'					
AB	GLAXOSMITHKLINE	200MG/5ML;EQ 28.5MG BASE/5ML	N50725 001	MAY 31, 1996	JUN	CFTG
AB	AUGMENTIN '400'					
AB	GLAXOSMITHKLINE	400MG/5ML;EQ 57MG BASE/5ML	N50725 002	MAY 31, 1996	FEB	CRLD
AB	TABLET; ORAL	400MG/5ML;EQ 57MG BASE/5ML	N50725 002	MAY 31, 1996	JUN	CFTG
AB	AMOXICILLIN AND CLAVULANATE POTASSIUM					
AB	GENEA PHARMS	500MG;EQ 125MG BASE	N65064 001	MAR 15, 2002	MAR	NEWA
AB		875MG;EQ 125MG BASE	N65063 001	MAR 14, 2002	MAR	NEWA
AB	AUGMENTIN '500'					
AB	GLAXOSMITHKLINE	500MG;EQ 125MG BASE	N50564 002	AUG 06, 1984	MAR	CFTG
AB	AUGMENTIN '875'					
AB	+ GLAXOSMITHKLINE	875MG;EQ 125MG BASE	N50720 001	FEB 13, 1996	MAR	CFTG
AB	TABLET, CHEWABLE; ORAL					
AB	AMOXICILLIN AND CLAVULANATE POTASSIUM					
AB	GENEA PHARMS	200MG;EQ 28.5MG BASE	N65065 001	APR 18, 2002	APR	NEWA
AB		400MG;EQ 57MG BASE	N65065 002	APR 18, 2002	APR	NEWA
AB	AUGMENTIN '200'					
AB	GLAXOSMITHKLINE	200MG;EQ 28.5MG BASE	N50726 001	MAY 31, 1996	APR	CFTG
AB	AUGMENTIN '400'					
AB	+ GLAXOSMITHKLINE	400MG;EQ 57MG BASE	N50726 002	MAY 31, 1996	APR	CFTG

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 15

SHIRE LABS

ADDERALL XR 25

SHIRE LABS

ADDERALL XR 5

SHIRE LABS

TABLET; ORAL

ADDERALL 10

AB SHIRE LABS

ADDERALL 20

AB SHIRE LABS

ADDERALL 30

AB + SHIRE LABS

ADDERALL 5

3.75MG;3.75MG;3.75MG;3.75MG

N21303 006 MAY 22, 2002 JUN NEWA

6.25MG;6.25MG;6.25MG;6.25MG

N21303 004 MAY 22, 2002 JUN NEWA

1.25MG;1.25MG;1.25MG;1.25MG

N21303 005 MAY 22, 2002 JUN NEWA

2.5MG;2.5MG;2.5MG;2.5MG

N11522 007 FEB 13, 1996 FEB CFTG

5MG;5MG;5MG;5MG

N11522 008 FEB 13, 1996 FEB CFTG

7.5MG;7.5MG;7.5MG;7.5MG

N11522 010 MAY 12, 1997 FEB CFTG

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE;
DEXTROAMPHETAMINE SULFATE

TABLET; ORAL							
ADDERALL 5							
AB SHIRE LABS	1.25MG;1.25MG;1.25MG;1.25MG		N11522 009	MAY 12, 1997	FEB	CFTG	
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE							
AB BARR	1.25MG;1.25MG;1.25MG;1.25MG		N40422 001	FEB 11, 2002	FEB	NEWA	
	2.5MG;2.5MG;2.5MG;2.5MG		N40422 002	FEB 11, 2002	FEB	NEWA	
	5MG;5MG;5MG;5MG		N40422 003	FEB 11, 2002	FEB	NEWA	
	7.5MG;7.5MG;7.5MG;7.5MG		N40422 004	FEB 11, 2002	FEB	NEWA	
AB COREPHARMA	1.25MG;1.25MG;1.25MG;1.25MG		N40444 001	JUN 19, 2002	JUN	NEWA	
	2.5MG;2.5MG;2.5MG;2.5MG		N40444 002	JUN 19, 2002	JUN	NEWA	
	5MG;5MG;5MG;5MG		N40444 003	JUN 19, 2002	JUN	NEWA	
	7.5MG;7.5MG;7.5MG;7.5MG		N40444 004	JUN 19, 2002	JUN	NEWA	
AB EON	2.5MG;2.5MG;2.5MG;2.5MG		N40439 001	JUN 14, 2002	JUN	NEWA	
	5MG;5MG;5MG;5MG		N40439 002	JUN 14, 2002	JUN	NEWA	
AB	7.5MG;7.5MG;7.5MG;7.5MG		N40439 003	JUN 14, 2002	JUN	NEWA	

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION							
ABELCET							
+ ELAN PHARMS	5MG/ML		N50724 001	NOV 20, 1995	JAN	CAHN	
SUSPENSION; ORAL							
FUNGIZONE							
@ BRISTOL MYERS SQUIBB	100MG/ML		N50341 003		JUN	DISC	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION							
AMPICILLIN AND SULBACTAM							
AP ESI LEDERLE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL		N65074 001	MAR 19, 2002	MAR	NEWA	
AP	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL		N65074 002	MAR 19, 2002	MAR	NEWA	
AP	EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL		N65076 001	MAR 19, 2002	MAR	NEWA	
UNASYN							
AP + PFIZER	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL		N50608 002	DEC 31, 1986	MAR	CFTG	
AP +	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL		N50608 001	DEC 31, 1986	MAR	CFTG	
AP +	EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL		N50608 005	DEC 10, 1993	MAR	CFTG	

AMPRENAVIR

CAPSULE; ORAL							
AGENERASE							
@ GLAXOSMITHKLINE	50MG		N21007 001	APR 15, 1999	MAY	DISC	
@	150MG		N21007 002	APR 15, 1999	MAY	DISC	
SOLUTION; ORAL							
@ GLAXOSMITHKLINE	15MG/ML		N21039 001	APR 15, 1999	MAY	DISC	

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID;
NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)							
INFUVITE PEDIATRIC							
+ SABEX 2002	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14M G/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIA L;1.2MG/VIAL;7 IU/VIAL;2,300						

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

1-6

IU/VIAL;0.2MG/VIAL

N21265 001 FEB 21, 2001 APR CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;
NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE
HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

>A> + AAIPHARMA

80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;
 5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17
 MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/V
 IAL;EQ 1.2MG

>D> + NEOSAN PHARMS

BASE/VIAL;0.7MG/VIAL;7MG/VIAL
 80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;
 5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17
 MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/V
 IAL;EQ 1.2MG
 BASE/VIAL;0.7MG/VIAL;7MG/VIAL

N18920 001 SEP 21, 2000 JUL CAHN

N18920 001 SEP 21, 2000 JUL CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;
NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE
HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

>A> AP + AAIPHARMA

10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/
 ML;20
 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.3
 6MG/ML;0.3MG/ML;330 UNITS/ML;1
 IU/ML
 10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/
 ML;20
 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.3
 6MG/ML;0.3MG/ML;330 UNITS/ML;1
 IU/ML

N08809 004 AUG 08, 1985 JUL CAHN

N08809 004 AUG 08, 1985 JUL CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON COMPOUND

+ AAIPHARMA LLC

DARVON COMPOUND-65

AA + AAIPHARMA LLC

389MG;32.4MG;32MG

389MG;32.4MG;65MG

N10996 006 MAR 08, 1983 JUN CAHN

N10996 007 MAR 08, 1983 JUN CAHN

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN COMPOUND

@ SANOFI SYNTHELABO

325MG;EQ 12.5MG BASE

N16891 001

JUN DISC

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON W/ ASA

+ AAIPHARMA LLC

325MG;65MG

N10996 005

JUN CAHN

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE; ORAL

DARVON-N W/ ASA

@ AAIPHARMA LLC

325MG;100MG

N16829 001

JUN CAHN

TABLET; ORAL

@ AAIPHARMA LLC

325MG;100MG

N16863 001

JUN CAHN

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

ATNAA

+ @ US ARMY

2.1MG/0.7ML;600MG/2ML

N21175 001 JAN 17, 2002 JAN NEWA

@

2.1MG/0.7ML;600MG/2ML

N21175 001 JAN 17, 2002 FEB NEWA

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OPTIVAR

+ MURO

0.05%

N21127 001 MAY 22, 2000 MAY CAHN

AZITHROMYCIN DIHYDRATE

TABLET; ORAL

ZITHROMAX

+ PFIZER

EQ 500MG BASE

N50784 001 MAY 24, 2002 MAY NEWA

AZTREONAM

INJECTABLE; INJECTION

AZACTAM

@ BRISTOL MYERS SQUIBB

500MG/VIAL

N50580 001 DEC 31, 1986 JUN DISC

@

1GM/VIAL

N50580 002 DEC 31, 1986 JUN DISC

@

2GM/VIAL

N50580 003 DEC 31, 1986 JUN DISC

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT ALTANA 500 UNITS/GM;10,000 UNITS/GM N65022 001 FEB 27, 2002 FEB NEWA

BENDROFLUMETHIAZIDE

TABLET; ORAL

NATURETIN-10

@ APOTHECON

10MG

N12164 003

JUN DISC

NATURETIN-5

+ APOTHECON

5MG

N12164 002

JUN CRLD

BENZONATATE

CAPSULE; ORAL

TESSALON

+ FOREST LABS

200MG

N11210 003 JUN 25, 1999 MAR NEWA

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

AA COREPHARMA 0.5MG N72264 001 FEB 27, 1989 MAY CAHN

AA 1MG N72265 001 FEB 27, 1989 MAY CAHN

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

1-8

AA	2MG			
		N72266 001 FEB 27, 1989 MAY CAHN		
		>D>		
		>A>		
		BENZYL PENICILLOYL-POLYLYSINE INJECTABLE; INJECTION PRE-PEN + HOLLISTER STIER LABS 60UMOLAR + SCHWARZ PHARMA 60UMOLAR	N50114 001 N50114 001	JUL CAHN JUL CAHN
		BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE TABLET; ORAL KERLEDEX @ LOREX @ 5MG;12.5MG 10MG;12.5MG	N19807 001 OCT 30, 1992 JUN DISC N19807 002 OCT 30, 1992 JUN DISC	
		BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE SUSPENSION/DROPS; OPHTHALMIC BETOPTIC PILO @ ALCON		
		EQ 0.25% BASE;1.75%		
		BIPERIDEN LACTATE INJECTABLE; INJECTION AKINETON @ ABBOTT	N20619 001 APR 17, 1997 JUN DISC	
		5MG/ML		
		BITOLTEROL MESYLATE AEROSOL, METERED; INHALATION TORNALATE @ SANOFI SYNTHELABO SOLUTION; INHALATION @ SANOFI SYNTHELABO	N12418 002 N18770 001 DEC 28, 1984 JUN DISC	
		0.37MG/INH 0.2%		
		BROMOCRIPTINE MESYLATE TABLET; ORAL BROMOCRIPTINE MESYLATE AB LEK SVCS PARLODEL	N19548 001 FEB 19, 1992 JUN DISC	
		EQ 2.5MG BASE EQ 2.5MG BASE		
		AB + NOVARTIS	N74631 001 JAN 13, 1998 JAN CMFD	
		BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE SYRUP; ORAL BROMANYL @ ALPHARMA	N17962 001 N88343 001 AUG 15, 1984 MAY DISC	
		12.5MG/5ML;10MG/5ML		
		BUPIVACAINE HYDROCHLORIDE INJECTABLE; INJECTION BUPIVACAINE HCL KIT @ ABBOTT		
		0.075%	N19978 001 SEP 03, 1992 JUN DISC	
		0.114%	N19978 002 SEP 03, 1992 JUN DISC	
		0.23%	N19978 003 SEP 03, 1992 JUN DISC	
AP		BUPIVACAINE HCL PRESERVATIVE FREE INTL MEDICATED		
AP		0.25%	N76012 001 JAN 09, 2002 JAN NEWA	
AP		0.5%	N76012 002 JAN 09, 2002 JAN NEWA	
		0.75%	N76012 003 JAN 09, 2002 JAN NEWA	

>D>
>A>
>A>

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

WELLBUTRIN SR

>D>	+	GLAXOSMITHKLINE	150MG	N20358 003	OCT 04, 1996	JUL	CRLD
>A>			150MG	N20358 003	OCT 04, 1996	JUL	CRLD
>A>	+		200MG	N20358 004	JUN 14, 2002	JUL	NEWA

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL

BUSPAR

☺	BRISTOL MYERS SQUIBB	5MG	N21190 001	DEC 20, 2000	JUN	DISC
☺		7.5MG	N21190 002	DEC 20, 2000	JUN	DISC
☺		10MG	N21190 003	DEC 20, 2000	JUN	DISC
☺		15MG	N21190 004	DEC 20, 2000	JUN	DISC

TABLET; ORAL

BUSPIRONE HCL

AB	EGIS	5MG	N75119 001	MAR 14, 2002	MAR	NEWA
AB		10MG	N75119 002	MAR 14, 2002	MAR	NEWA
AB	GENEVA PHARMS	5MG	N75413 001	MAR 19, 2002	MAR	NEWA
AB		10MG	N75413 002	MAR 19, 2002	MAR	NEWA
AB		15MG	N75413 003	MAR 19, 2002	MAR	NEWA
AB	KV PHARM	5MG	N75572 001	FEB 27, 2002	FEB	NEWA
AB		10MG	N75572 002	FEB 27, 2002	FEB	NEWA
AB		15MG	N75572 003	FEB 27, 2002	FEB	NEWA
AB	MYLAN	5MG	N75272 001	MAR 01, 2002	MAR	NEWA
AB		10MG	N75272 002	MAR 01, 2002	MAR	NEWA
AB		30MG	N76008 001	JUN 28, 2001	MAY	CAHN
AB	PAR PHARM	5MG	N75467 001	FEB 28, 2002	FEB	NEWA
AB		10MG	N75467 003	FEB 28, 2002	FEB	NEWA
AB		15MG	N75467 004	FEB 28, 2002	FEB	NEWA
AB	PHARMEX PRODS	5MG	N75388 001	MAY 09, 2002	MAY	NEWA
AB		10MG	N75388 002	MAY 09, 2002	MAY	NEWA
AB		15MG	N75388 003	MAY 09, 2002	MAY	NEWA
AB	TEVA	5MG	N75022 001	FEB 28, 2002	FEB	NEWA
AB		10MG	N75022 002	FEB 28, 2002	FEB	NEWA
AB		15MG	N75022 003	FEB 28, 2002	FEB	NEWA
AB	TORPHARM	5MG	N75521 001	APR 05, 2002	APR	NEWA
AB		10MG	N75521 002	APR 05, 2002	APR	NEWA
AB		15MG	N75521 003	APR 05, 2002	APR	NEWA
AB	ZENITH GOLDLINE	5MG	N75385 001	MAR 01, 2002	MAR	NEWA
AB		10MG	N75385 002	MAR 01, 2002	MAR	NEWA
AB		15MG	N75385 003	MAR 01, 2002	MAR	NEWA

BUTORPHANOL TARTRATE

SPRAY, METERED; NASAL

BUTORPHANOL TARTRATE

AB	ROXANE	1MG/SPRAY	N75824 001	MAR 12, 2002	MAR	NEWA
----	--------	-----------	------------	--------------	-----	------

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

ERCATAB

+ GENEVA PHARMS

100MG;1MG

N84294 001

JUN CTEC

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

WIGRAINE

@ ORGANON

100MG;1MG

N86562 001

CALCIFEDIOL

CAPSULE; ORAL

CALDEROL

@ ORGANON

0.02MG

N18312 001

@

0.05MG

N18312 002

CALCIPOTRIENE

OINTMENT; TOPICAL

DOVONEX

+ BRISTOL MYERS SQUIBB

0.005%

N20273 001 DEC 29, 1993

SOLUTION; TOPICAL

+ BRISTOL MYERS SQUIBB

0.005%

N20611 001 MAR 03, 1997

CAPTOPRIL

TABLET; ORAL

CAPOTEN

AB	PAR PHARM	12.5MG	N18343 005	JAN 17, 1985
AB		25MG	N18343 002	
	@	37.5MG	N18343 006	SEP 17, 1986
AB		50MG	N18343 001	
	@	75MG	N18343 007	JUN 13, 1995
AB	+	100MG	N18343 003	
	@	150MG	N18343 004	JUN 13, 1995

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBATROL

>D>	+ SHIRE LABS	100MG	N20712 003	DEC 22, 1999
>A>	@	100MG	N20712 003	DEC 22, 1999
>D>	+	200MG	N20712 001	SEP 30, 1997
>A>	@	200MG	N20712 001	SEP 30, 1997
>D>	+	300MG	N20712 002	SEP 30, 1997
>A>	@	300MG	N20712 002	SEP 30, 1997

SUSPENSION; ORAL

CARBAMAZEPINE

AB	MORTON GROVE	100MG/5ML	N75714 001	JUN 05, 2002
AB	TABLET; ORAL			
AB	APOTEX	200MG	N75948 001	FEB 27, 2002
>A>	TABLET, CHEWABLE; ORAL			
>A>	+ TARO PHARM INDS	200MG	N75687 002	JUL 29, 2002

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HCL

AT	NOVEX	1%	N76097 001	FEB 06, 2002
----	-------	----	------------	--------------

CEFAZOL
TABLET, EXTENDED RELEASE; ORALCECLOR CD
@ LILLY

EQ 375MG BASE

N50673 001 JUN 28, 1996 JUN DISC

JUN DISC

JUN DISC

DEC 29, 1993

FEB CAHN

MAR 03, 1997

FEB CAHN

JAN 17, 1985

MAY CAHN

MAY CAHN

SEP 17, 1986

MAY CAHN

MAY CAHN

JUN 13, 1995

MAY CAHN

MAY CAHN

JUN 13, 1995

MAY CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

DURICEF

@ GALEN CHEM

EQ 250MG BASE

N50512 002

JUL CAHN

@

EQ 250MG BASE

N50512 002

MAY CAHN

>D> AB + @ WARNER CHILCOTT

EQ 250MG BASE

N50512 001

JUL CAHN

>A> AB +

EQ 500MG BASE

N50512 002

JUL CAHN

FOR SUSPENSION; ORAL

GALEN CHEM

EQ 125MG BASE/5ML

N50527 002

JUL CAHN

>D>

EQ 125MG BASE/5ML

N50527 003

MAY CAHN

>D>

EQ 250MG BASE/5ML

N50527 003

JUL CAHN

>A> +

EQ 500MG BASE/5ML

N50527 001

MAY CAHN

>D> +

EQ 125MG BASE/5ML

N50527 001

JUL CAHN

>A> +

EQ 250MG BASE/5ML

N50527 002

JUL CAHN

>A> +

EQ 500MG BASE/5ML

N50527 003

JUL CAHN

>A> +

EQ 250MG BASE/5ML

N50527 001

JUL CAHN

>A> +

EQ 500MG BASE/5ML

N50528 001

JUL CAHN

>D> AB + GALEN CHEM

EQ 1GM BASE

N50528 001

MAY CAHN

>A> +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB + WARNER CHILCOTT

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +

EQ 1GM BASE

N50528 001

JUL CAHN

>A> AB +</div

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
CEFIZOX

>D>	+	FUJISAWA HLTHCARE	EQ 500MG BASE/VIAL	N50560 001 SEP 15, 1983 JUL DISC
>A>	@		EQ 500MG BASE/VIAL	N50560 001 SEP 15, 1983 JUL DISC

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION
ROCEPHIN KIT

@ HLR	EQ 500MG BASE/VIAL;1%	N50585 007 MAY 08, 1996 JUN DISC
@	EQ 1GM BASE/VIAL;1%	N50585 006 MAY 08, 1996 JUN DISC

CEFUROXIME AXETIL

TABLET; ORAL
CEFTIN

AB	GLAXOSMITHKLINE	EQ 125MG BASE	N50605 001 DEC 28, 1987 FEB CFTG
AB		EQ 250MG BASE	N50605 002 DEC 28, 1987 FEB CFTG
AB	+	EQ 500MG BASE	N50605 003 DEC 28, 1987 FEB CFTG
CEFUROXIME AXETIL			
AB	RANBAXY	EQ 125MG BASE	N65043 003 FEB 15, 2002 FEB NEWA
AB		EQ 250MG BASE	N65043 002 FEB 15, 2002 FEB NEWA
AB		EQ 500MG BASE	N65043 001 FEB 15, 2002 FEB NEWA

CEPHALEXIN

FOR SUSPENSION; ORAL
CEPHALEXIN

@ TEVA	EQ 125MG BASE/5ML	N62873 001 MAY 23, 1988 APR DISC	
@	EQ 250MG BASE/5ML	N62867 001 APR 15, 1988 APR DISC	
TABLET; ORAL			
TEVA	EQ 500MG BASE	N63024 001 JAN 12, 1989 JUN CTEC	
KEFLET			
@ LILLY	EQ 500MG BASE	N50440 001 JUN DISC	
>D>	+	EQ 1GM BASE	N50440 002 JUL DISC
>A>	@	EQ 1GM BASE	N50440 002 JUL DISC

CEPHALOGLYCIN

CAPSULE; ORAL
KAFOCIN

+ @ LILLY	250MG	N50219 001 MAY DISC
-----------	-------	---------------------

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION
KEFLIN

@ LILLY	EQ 20GM BASE/VIAL	N50482 007 JUN DISC
---------	-------------------	---------------------

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION
CEFADYL

APOTHECON	EQ 500MG BASE/VIAL	N62961 001 SEP 20, 1988 JUN DISC
@	EQ 1GM BASE/VIAL	N62961 002 SEP 20, 1988 JUN DISC
@	EQ 2GM BASE/VIAL	N62961 003 SEP 20, 1988 JUN DISC
@	EQ 4GM BASE/VIAL	N62961 004 SEP 20, 1988 JUN DISC

CHLORTETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

AUREOMYCIN

@ LEDERLE

1%

N50404 001

JUN DISC

CHLORTHALIDONE; RESERPINE

>D> TABLET; ORAL

>D> DEMI-REGROTEN

>D> AVENTIS PHARMS

25MG;0.125MG

N15103 002

JUL DISC

>A> @

25MG;0.125MG

N15103 002

JUL DISC

>D> REGROTEN

>D> + AVENTIS PHARMS

50MG;0.25MG

N15103 001

JUL DISC

>A> @

50MG;0.25MG

N15103 001

JUL DISC

CHOLESTYRAMINE

TABLET; ORAL

QUESTRAN

@ APOTHECON

EQ 800MG RESIN

N73403 002 DEC 27, 1999 JUN DISC

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION

OIDREL

+ SERONO INC

0.25MG/VIAL

N21149 001 SEP 20, 2000 FEB CAHN

CHYMOPAPAIN

INJECTABLE; INJECTION

CHYMODIACTIN

@ ABBOTT

4,000 UNITS/VIAL

N18663 002 AUG 21, 1984 JUN DISC

CHYMOTRYPSIN

FOR SOLUTION; OPHTHALMIC

ZOLYSE

@ ALCON

750 UNITS/VIAL

N11903 001

JUN DISC

CICLOPIROX

SOLUTION; TOPICAL

PENLAC

+ DERMIL LABS

8%

N21022 001 DEC 17, 1999 JUN CAHN

CIMETIDINE

TABLET; ORAL

CIMETIDINE

AB LEK LJUBLJANA

300MG

N74250 002 JUN 29, 1995 FEB CMFD

AB

400MG

N74250 003 JUN 29, 1995 FEB CMFD

AB

800MG

N74250 004 JUN 29, 1995 FEB CMFD

CINOXACIN

CAPSULE; ORAL

CINOBAC

@ LILLY

250MG

N18067 001

JUN DISC

@

500MG

N18067 002

JUN DISC

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

CLADRIBINE
INJECTABLE; INJECTION
LEUSTATIN
+ ORTHO BIOTECH

1MG/ML

N20229 001 FEB 26, 1993 MAR CAHN

CLARITHROMYCIN
FOR SUSPENSION; ORAL
BIAXIN
@ ABBOTT

187MG/5ML

N50698 003 SEP 30, 1998 JUN DISC

CLINDAMYCIN PHOSPHATE
LOTION; TOPICAL
CLEOCIN T
AB + PHARMACIA AND UPJOHN
CLINDAMYCIN PHOSPHATE
AB ALTANA
SWAB; TOPICAL
AT CLAY PARK

EQ 1% BASE

EQ 1% BASE

EQ 1% BASE

N50600 001 MAY 31, 1989 JAN CFTG

N65067 001 JAN 31, 2002 JAN NEWA

N65049 001 MAY 25, 2000 FEB CDFR

CLOBETASOL PROPIONATE
GEL; TOPICAL
EMBELINE
AB HEALTHPOINT

0.05%

N76141 001 APR 12, 2002 APR NEWA

CLOFAZIMINE
CAPSULE; ORAL
LAMPRENE
@ NOVARTIS

100MG

N19500 001 DEC 15, 1986 JUN DISC

CLONAZEPAM
TABLET; ORAL
KLOPIN
@ ROCHE
@
TABLET, ORALLY DISINTEGRATING; ORAL
KLOPIN RAPIDLY DISINTEGRATING
@ ROCHE
@
@
@
@
@
@

0.125MG

0.25MG

@

0.125MG

0.25MG

@

0.5MG

@

1MG

@

2MG

N17533 005 APR 09, 1997 JUN DISC
N17533 006 APR 09, 1997 JUN DISC

N20813 001 DEC 23, 1997 JUN DISC
N20813 002 DEC 23, 1997 JUN DISC
N20813 003 DEC 23, 1997 JUN DISC
N20813 004 DEC 23, 1997 JUN DISC
N20813 005 DEC 23, 1997 JUN DISC

CLOZAPINE
TABLET; ORAL
CLOZARIL
AB NOVARTIS
AB +

25MG

100MG

N19758 001 SEP 26, 1989 MAY CRLD
N19758 002 SEP 26, 1989 MAY CRLD

JUN CRLD

COLCHICINE; PROBENECID
TABLET; ORAL
COL-PROBENECID
BP + WATSON LABS

0.5MG;500MG

N84279 001

COLCHICINE; PROBENECID

TABLET; ORAL

COLBENEMID

@ MERCK

0.5MG;500MG

N12383 001

JUN DISC

COLESEVELAM HYDROCHLORIDE

CAPSULE; ORAL

WELCHOL

@ SANKYO

375MG

N21141 001 MAY 26, 2000 JUN DISC

CORTICOTROPIN

INJECTABLE; INJECTION

H.P. ACTHAR GEL

>D> BC + QUESTCOR PHARMS

>A> @

40 UNITS/ML

40 UNITS/ML

N08372 006

JUL DISC

N08372 006

JUL DISC

CORTISONE ACETATE

INJECTABLE; INJECTION

CORTONE

@ MERCK

@

25MG/ML

50MG/ML

N07110 002

JUN DISC

N07110 003

JUN DISC

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

AN NOVEX

10MG/ML

N75333 001 APR 30, 2002 APR NEWA

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58

N/A; N/A

DICOPAC KIT

@ AMERSHAM HLTH

N/A;N/A;N/A

N17406 001

FEB DISC

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

N/A; N/A

CYANOCOBALAMIN CO 57 SCHILLING TEST KIT

@ MALLINCKRODT

0.1MG;0.5uci;60MG

N16635 001

JUN DISC

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

FLEXERIL

@ MCNEIL CONS SPECLT

5MG

AB +

10MG

N17821 001

JUN CAHN

N17821 002

JUN CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

AP BAXTER HLTHCARE

100MG/VIAL

N88371 001 JUL 03, 1986 JUN CAHN

AP

200MG/VIAL

N88372 001 JUL 03, 1986 JUN CAHN

AP

500MG/VIAL

N88373 001 JUL 03, 1986 JUN CAHN

AP

1GM/VIAL

N88374 001 SEP 24, 1986 JUN CAHN

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

<u>CYCLOSPORINE</u>				
CAPSULE; ORAL				
CYCLOSPORINE				
AB1 ABBOTT	25MG	N65003 001	MAY 12, 2000	MAY CTEC
BX	50MG	N65003 002	MAY 12, 2000	MAY CTEC
AB1 EON	100MG	N65003 003	MAY 12, 2000	MAY CTEC
AB1 SIDMAK LABS	25MG	N65017 002	JAN 13, 2000	MAY CTEC
AB1 TORPHARM	100MG	N65017 001	JAN 13, 2000	MAY CTEC
AB2 NEORAL	25MG	N65044 002	DEC 20, 2000	MAY CTEC
AB1 NOVARTIS	100MG	N65044 001	DEC 20, 2000	MAY CTEC
AB1 + SANDIMMUNE	25MG	N65040 001	MAY 09, 2002	MAY CTEC
AB2 NOVARTIS	100MG	N65040 002	MAY 09, 2002	MAY NEWA
AB2 + SOLUTION; ORAL		N50715 001	JUL 14, 1995	MAY CTEC
CYCLOSPORINE	100MG/ML	N50715 002	JUL 14, 1995	MAY CTEC
AB ABBOTT		N50625 001	MAR 02, 1990	MAY CTEC
DALFOPRISTIN; QUINUPRISTIN		N50625 002	MAR 02, 1990	MAY CTEC
INJECTABLE; IV (INFUSION)		N65025 001	MAR 03, 2000	JAN CMFD
SYNERCID	350MG/VIAL; 150MG/VIAL			
+ AVENTIS	420MG/VIAL; 180MG/VIAL			
@				
<u>DANAPAROID SODIUM</u>				
INJECTABLE; INJECTION				
ORGARAN	750 UNITS/0.6ML	N20430 001	DEC 24, 1996	JUN DISC
@ ORGANON				
<u>DEFEROXAMINE MESYLATE</u>				
INJECTABLE; INJECTION				
DESFERAL	2GM/VIAL	N16267 002	MAY 25, 2000	FEB CPOT
+ NOVARTIS				
<u>DEMECARIUM BROMIDE</u>				
SOLUTION/DROPS; OPHTHALMIC				
HUMORSOL	0.125%	N11860 002		JUN DISC
@ MERCK	0.25%	N11860 001		JUN DISC
@				
<u>DEMECLOCYCLINE HYDROCHLORIDE</u>				
TABLET; ORAL		N50261 001		JUN DISC
DECLOMYCIN	75MG			
@ LEDERLE				

DESLORATADINE

TABLET, ORALLY DISINTEGRATING; ORAL
 CLARINEX
 + SCHERING 5MG

N21312 001 JUN 26, 2002 JUN NEWA

DESMOPRESSIN ACETATE

SOLUTION; NASAL
 CONCENTRAID
 @ FERRING 0.01%
 SPRAY, METERED; NASAL
 DDAVP
 @ AVENTIS 0.01MG/SPRAY
 DESMOPRESSIN ACETATE
 AB + BAUSCH AND LOMB 0.01MG/SPRAY

N19776 001 DEC 26, 1990 JUN DISC

N17922 002 FEB 06, 1989 MAY DISC

N74830 001 JAN 25, 1999 MAY CRLD

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
 KARIVA
 AB BARR 0.15MG;0.02MG;0.01MG
 MIRCETTE
 AB + ORGANON 0.15MG;0.02MG;0.01MG

N75863 001 APR 05, 2002 APR NEWA

N20713 001 APR 22, 1998 APR CFTG

DESONIDE

LOTION; TOPICAL
 DESONIDE
 AB ALTANA 0.05%
 DESOWEN
 AB + GALDERMA LABS LP 0.05%

N75860 001 MAR 19, 2002 MAR NEWA

N72354 001 JAN 24, 1992 MAR CFTG

DESOXIMETASONE

OINTMENT; TOPICAL
 DESOXIMETASONE
 @ ALTANA 0.25%

N73440 001 APR 01, 1998 MAY DISC

DEXAMETHASONE

AEROSOL; TOPICAL
 DECASPRAY
 @ MERCK 0.04%

N12731 002 JUN DISC

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION
 DECADRON-LA
 @ MERCK EQ 8MG BASE/ML
 DEXAMETHASONE ACETATE
 @ STERIS EQ 8MG BASE/ML
 @ EQ 16MG BASE/ML

N16675 001 APR DISC

N84315 001 APR DISC

N87711 001 MAY 24, 1982 APR DISC

DEXAMETHASONE SODIUM PHOSPHATE

OINTMENT; OPHTHALMIC
 MAXIDEX
 @ ALCON EQ 0.05% PHOSPHATE

N83342 001 JUN DISC

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
DECADRON W/ XYLOCAINE
© MERCK

EQ 4MG PHOSPHATE/ML; 10MG/ML

N13334 002

JUN DISC

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
DEXEDRINE

AB	+	GLAXOSMITHKLINE	5MG
AB	+		10MG
AB	+		15MG
DEXTROAMPHETAMINE SULFATE			
AB		BARR	5MG
AB			10MG
AB			15MG
TABLET; ORAL			
AA		MALLINCKRODT	5MG
AA			10MG

N17078 001

JAN CFTG

N17078 002

JAN CFTG

N17078 003

JAN CFTG

N76137 001	JAN 18, 2002	JAN NEWA
N76137 002	JAN 18, 2002	JAN NEWA
N76137 003	JAN 18, 2002	JAN NEWA

N40436 001	JAN 29, 2002	JAN NEWA
N40436 002	JAN 29, 2002	JAN NEWA

N10040 017

JUN DISC

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION
DIATRIZOATE MEGLUMINE
© BRACCO

76%

N10040 017

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION
RENOVIST

34.3%;35%

N10040 020

JUN DISC

© BRACCO

RENOVIST II

28.5%;29.1%

N10040 019

JUN DISC

DIATRIZOATE SODIUM

INJECTABLE; INJECTION
HYPaque

© AMERSHAM HLTH

25%

N09561 003

JUN DISC

>D> SOLUTION; ORAL, RECTAL

AMERSHAM HLTH

40%

N11386 003

JUL DISC

>D> AMERSHAM HLTH

40%

N11386 003

JUL DISC

>A> SOLUTION; URETERAL

HYPaque SODIUM 20%

20%

N09561 002

JUN DISC

© AMERSHAM HLTH

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

1-20

DICLOFENAC SODIUM

GEL; TOPICAL

SOLARAZE

>A>	+ BIOGLAN PHARMA	3%
>D>	+ BIOGLAN PHARMA PLC	3%
	TABLET, DELAYED RELEASE; ORAL	
	DICLOFENAC SODIUM	
AB	ALPHAPHARM	50MG
AB		75MG
	TABLET, EXTENDED RELEASE; ORAL	
AB	PUREPAC PHARM	100MG

N21005 001	OCT 16, 2000	JUL CAHN
N21005 001	OCT 16, 2000	JUL CAHN

N75281 002	FEB 12, 2002	FEB NEWA
N75281 003	FEB 12, 2002	FEB NEWA

N75910 001	JAN 07, 2002	JAN NEWA
------------	--------------	----------

DICUMAROL

TABLET; ORAL

DICUMAROL

@ ABBOTT

25MG

N05545 003

JUN DISC

DIENESTROL

CREAM; VAGINAL

DIENESTROL

+ ORTHO MCNEIL

0.01%

>A>

N06110 005

JUN CAHN

DIGOXIN

TABLET; ORAL

DIGOXIN

>A> AB

STEVENS J

0.125MG

>A> AB

0.25MG

N76268 001 JUL 26, 2002 JUL NEWA

N76268 002 JUL 26, 2002 JUL NEWA

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

XCEL PHARMS

1MG/ML

SPRAY, METERED; NASAL

MIGRANAL

>D>

+ NOVARTIS

0.5MG/INH

>A>

+ XCEL PHARM

0.5MG/INH

N05929 001

JUN CAHN

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

CARDIZEM

AP + BIOVAIL

5MG/ML

+

25MG/VIAL

DILTIAZEM HCL

+ GENSIA SICOR PHARMS

10MG/ML

N20027 001 OCT 24, 1991 JUN CAHN

N20027 003 AUG 18, 1995 JUN CAHN

N74894 002 APR 19, 2002 APR NEWA

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE; ORAL

TECZEM

+ BIOVAIL

EQ 180MG HCL;5MG

N20507 001 OCT 04, 1996 JUN CAHN

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS

IMAGENT

+ ALLIANCE PHARM 0.92MG/VIAL;0.092MG/VIAL

N21191 001 MAY 31, 2002 MAY NEWA

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HCL

AP AM PHARM PARTNERS 50MG/ML

N40466 001 MAY 28, 2002 MAY NEWA

DIPHENIDOL HYDROCHLORIDE

TABLET; ORAL

VONTROL

@ GLAXOSMITHKLINE EQ 25MG BASE

N16033 001 JUN DISC

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DEPAKOTE ER

>A> ABBOTT EQ 250MG VALPROIC ACID

N21168 002 MAY 31, 2002 JUL NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

ARICEPT

EISAI MEDCL RES 5MG

N20690 002 NOV 25, 1996 MAY CAHN

+ 10MG

N20690 001 NOV 25, 1996 MAY CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HCL

@ LEDERLE EQ 10MG BASE

N71685 001 JAN 05, 1988 MAY DISC

@ EQ 25MG BASE

N71686 001 JAN 05, 1988 MAY DISC

@ EQ 50MG BASE

N71673 001 JAN 05, 1988 MAY DISC

@ EQ 75MG BASE

N71674 001 JAN 05, 1988 MAY DISC

@ EQ 100MG BASE

N71675 001 JAN 05, 1988 MAY DISC

@ EQ 150MG BASE

N71676 001 JAN 05, 1988 MAY DISC

CREAM; TOPICAL

ZONALON

+ BIOGLAN PHARMS 5%

N20126 001 APR 01, 1994 JUN CAHN

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

PERIOSTAT

@ COLLAGENEX EQ 20MG BASE

N50744 001 SEP 30, 1998 JUN DISC

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

+ ABBOTT 2.5MG/ML;EQ 0.05MG BASE/ML

N71982 001 MAY 04, 1988 JUN CTEC

@ ASTRAZENECA 2.5MG/ML;EQ 0.05MG BASE/ML

N72026 001 APR 13, 1989 JUN DISC

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

1-22

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC
PHOSPHOLINE IODIDE

@ AYERST

@

@

0.03%

0.06%

0.25%

N11963 002

N11963 004

N11963 003

JUN DISC

JUN DISC

JUN DISC

EDETADE DISODIUM

INJECTABLE; INJECTION
EDETADE DISODIUM

>A> AP

PHARMAFORCE

150MG/ML

N40437 001 JUL 09, 2002 JUL NEWA

EFAVIRENZ

TABLET; ORAL

SUSTIVA

BRISTOL MYERS SQUIBB + 300MG
600MG

N21360 001 FEB 01, 2002 FEB NEWA

N21360 002 FEB 01, 2002 FEB NEWA

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL

VANIQA

>D>

>A>

+ WESTWOOD SQUIBB CLTN 13.9%
+ WOMEN FIRST HLTHCARE 13.9%

N21145 001 JUL 27, 2000 JUL CAHN
N21145 001 JUL 27, 2000 JUL CAHN

ENALAPRIL MALEATE

TABLET; ORAL

VASOTEC

AB BIOVAIL

AB

AB

AB +

2.5MG

5MG

10MG

20MG

N18998 005 JUL 26, 1988 MAY CAHN

N18998 001 DEC 24, 1985 MAY CAHN

N18998 002 DEC 24, 1985 MAY CAHN

N18998 003 DEC 24, 1985 MAY CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

VASERETIC

AB BIOVAIL

AB +

5MG;12.5MG

10MG;25MG

N19221 003 JUL 12, 1995 MAY CAHN

N19221 001 OCT 31, 1986 MAY CAHN

ENALAPRILAT

INJECTABLE; INJECTION

VASOTEC

AP + BIOVAIL

1.25MG/ML

N19309 001 FEB 09, 1988 MAY CAHN

ENOXACIN

TABLET; ORAL

PENETREX

@ AVENTIS

@

200MG

400MG

N19616 004 DEC 31, 1991 JUN DISC

N19616 005 DEC 31, 1991 JUN DISC

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX

@ AVENTIS

90MG/0.6ML

N20164 006 JUN 02, 2000 JUN DISC

EPINEPHRINE

INJECTABLE; INJECTION

SUS-PHRINE SULFITE-FREE

@ FORREST LABS

1.5MG/AMP

N07942 003 FEB 05, 1999 JUN DISC

@

5MG/ML

N07942 001 JUN DISC

INJECTABLE; INTRAMUSCULAR

EPI E Z PEN JR

@ MERIDIAN MEDCL TECHN

0.15MG/DELIVERY

N19430 004 AUG 03, 1995 JUN DISC

EPIPEN E Z PEN

@ MERIDIAN MEDCL TECHN

0.3MG/DELIVERY

N19430 003 AUG 03, 1995 JUN DISC

EPROSARTAN MESYLATE

TABLET; ORAL

TEVETEN

BIOVAIL PHARMS

EQ 300MG BASE

N20738 004 DEC 22, 1997 JUN CAHN

EQ 400MG BASE

N20738 005 DEC 22, 1997 JUN CAHN

+

EQ 600MG BASE

N20738 006 MAY 27, 1999 JUN CAHN

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEVETEN HCT

BIOVAIL PHARMS

600MG;12.5MG

N21268 001 NOV 01, 2001 JUN CAHN

+

600MG;25MG

N21268 002 NOV 01, 2001 JUN CAHN

EPTIFIBATIDE

INJECTABLE; INJECTION

INTEGRILIN

+ MILLENNIUM PHARMS

2MG/ML

N20718 001 MAY 18, 1998 FEB CAHN

+

75MG/100ML

N20718 002 MAY 18, 1998 FEB CAHN

ERGOLOID MESYLATES

CAPSULE; ORAL

HYDERGINE LC

@ NOVARTIS

1MG

N18706 001 JAN 18, 1983 JUN DISC

SOLUTION; ORAL

HYDERGINE

@ NOVARTIS

1MG/ML

N18418 001 JUN DISC

ERYTHROMYCIN

GEL; TOPICAL

E-GLADES

AT GLADES PHARMS

2%

N65009 001 MAR 18, 2002 MAR NEWA

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ALORA

BX WATSON LABS

0.025MG/24HR

N20655 004 APR 16, 2002 APR NEWA

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

1-24

BX	TABLET; ORAL	0.025MG/24HR	N20655 004 APR 05, 2002 MAY CMS
AB	ESTRADIOL USL PHARMA	0.5MG	N40297 001 APR 17, 2002 APR NEWA
AB		1MG	N40297 002 APR 17, 2002 APR NEWA
AB		2MG	N40297 003 APR 17, 2002 APR NEWA
	<u>ESTRADIOL; NORETHINDRONE ACETATE</u>		
	TABLET; ORAL		
	ACTIVELLA		
+ NOVO NORDISK		1MG;0.5MG	
	<u>ESTRADIOL; NORGESTIMATE</u>		N20907 001 NOV 18, 1998 JUN CTNA
	TABLET; ORAL		
	ORTHO-PREFEST		
+ KING PHARMS		1MG;1MG;0.09MG	
	<u>ESTROGENS, CONJUGATED SYNTHETIC A</u>		N21040 001 OCT 22, 1999 MAY CAHN
	TABLET; ORAL		
>A>	CENESTIN		
	DURAMED PHARM BARR	0.3MG	
	<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE</u>		N20992 001 JUN 21, 2002 JUL NEWA
	TABLET; ORAL-28		
	PREMPHASE (PREMARIN;CYCRIN 14/14)		
@ WYETH AYERST		0.625MG;0.625MG;5MG	
	PREMPRO (PREMARIN;CYCRIN)		N20303 002 DEC 30, 1994 JUN DISC
@ WYETH AYERST		0.625MG;0.625MG;2.5MG;2.5MG	
	<u>ESTROGENS, CONJUGATED; MEPROBAMATE</u>		N20303 001 DEC 30, 1994 JUN DISC
	TABLET; ORAL		
	PMB 200		
@ WYETH AYERST		0.45MG;200MG	
PMB 400			N10971 005 JUN DISC
@ WYETH AYERST		0.45MG;400MG	
	<u>ETHCHLORVYNOL</u>		N10971 003 JUN DISC
	CAPSULE; ORAL		
	PLACIDYL		
@ ABBOTT		200MG	
@		500MG	N10021 007 JUN DISC
@		750MG	N10021 002 JUN DISC
	<u>ETHINYL ESTRADIOL; LEVONORGESTREL</u>		N10021 010 JUN DISC
	TABLET; ORAL-21		
	ALESSE		
AB + WYETH AYERST		0.02MG;0.1MG	N20683 001 MAR 27, 1997 MAR CTEC
AB1 + AVIANE-21		0.02MG;0.1MG	N20683 001 MAR 27, 1997 MAY CTEC
AB1 DURAMED PHARM BARR		0.02MG;0.1MG	
LESSINA-21 BARR		0.02MG;0.1MG	N75796 002 APR 30, 2001 MAR CTEC
		0.02MG;0.1MG	N75803 001 MAR 20, 2002 MAR NEWA

>D>
>A>
>D>
>A>
>A>
>A>

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21
LEVLITE
AB2 + BERLEX LABS 0.02MG;0.1MG N20860 001 JUL 13, 1998 MAR CTEC
PORTIA-21
AB BARR 0.03MG;0.15MG N75866 001 MAY 23, 2002 MAY NEWA
TABLET; ORAL-28
ALESSE
AB1 WYETH AYERST 0.02MG;0.1MG N20683 002 MAR 27, 1997 MAR CTEC
AVIANE-28
AB1 DURAMED PHARM BARR 0.02MG;0.1MG N75796 001 APR 30, 2001 MAR CTEC
LESSINA-28
AB BARR 0.02MG;0.1MG N75803 002 MAR 20, 2002 MAR NEWA
LEVLITE
AB BERLEX LABS 0.02MG;0.1MG N20860 002 JUL 13, 1998 MAR CTEC
PORTIA-28
AB BARR 0.03MG;0.15MG N75866 002 MAY 23, 2002 MAY NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21
ESTROSTEP 21
@ PARKE DAVIS 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG N20130 001 OCT 09, 1996 JUN DISC

ETHOTOIN

TABLET; ORAL
PEGANONE
+ ABBOTT 250MG N10841 001 JUN CRLD
@ 500MG N10841 003 JUN DISC

ETODOLAC

CAPSULE; ORAL
ETODOLAC
>D> AB AESGEN 300MG N74929 001 JAN 30, 1998 JUL CAHN
>A> AB NEOSAN PHARMS 300MG N74929 001 JAN 30, 1998 JUL CAHN
TABLET; ORAL
>D> AB AESGEN 400MG N74927 001 OCT 30, 1997 JUL CAHN
>A> AB NEOSAN PHARMS 400MG N74927 001 OCT 30, 1997 JUL CAHN
TABLET, EXTENDED RELEASE; ORAL
>A> AB EON 400MG N75943 001 JUL 26, 2002 JUL NEWA
>A> AB 500MG N75943 002 JUL 26, 2002 JUL NEWA
>A> AB 600MG N75943 003 JUL 26, 2002 JUL NEWA

FAMOTIDINE

INJECTABLE; INJECTION
FAMOTIDINE
AP BAXTER HLTHCARE 10MG/ML N75799 001 APR 30, 2002 APR NEWA
FAMOTIDINE PRESERVATIVE FREE
@ APOTHECON 10MG/ML N75708 001 APR 16, 2001 MAR WDAG
AP BAXTER HLTHCARE 10MG/ML N75789 001 APR 30, 2002 APR NEWA

FENOFIBRATE

CAPSULE; ORAL					
FENOFIBRATE (MICRONIZED)					
AB	TEVA	134MG	N75753	002	APR 09, 2002
AB		200MG	N75753	003	APR 09, 2002
TRICOR (MICRONIZED)					
AB	ABBOTT	134MG	N19304	003	JUN 30, 1999
AB	+	200MG	N19304	004	JUN 30, 1999

FENOPROFEN CALCIUM

CAPSULE; ORAL					
NALFON					
AB	+	RANBAXY	EQ 300MG BASE	N17604	002
NALFON 200					
AB	RANBAXY	EQ 200MG BASE	N17604	003	JUN CAHN

FENTANYL CITRATE

TROCHE/LOZENGE; ORAL					
FENTANYL					
AB	ANESTA	EQ 0.1MG BASE	N20195	007	OCT 30, 1995
AB		EQ 0.2MG BASE	N20195	001	OCT 04, 1993
AB		EQ 0.3MG BASE	N20195	002	OCT 04, 1993
AB		EQ 0.4MG BASE	N20195	003	OCT 04, 1993

FERRIC AMMONIUM CITRATE

>D>	FOR SOLUTION; ORAL				
>D>	FERRISELTZ				
>D>	+	AMERSHAM HLTH	600MG/PACKET	N20292	001
>A>	AB		600MG/PACKET	N20292	001

FLOXURIDINE

INJECTABLE; INJECTION					
FUDR					
AP	+	FAULDING	500MG/VIAL	N16929	001

FLUDEOXYGLUCOSE, F-18

INJECTABLE; INJECTION					
FLUDEOXYGLUCOSE F 18					
>D>	+	DOWNSTATE CLINCL	4-40mCi/ML	N20306	001
>A>	AB		4-40mCi/ML	N20306	001

FLUDROCORTISONE ACETATE

TABLET; ORAL					
FLORINEF					
AB	+	KING PHARMS	0.1MG	N10060	001
FLUDROCORTISONE ACETATE					
AB	IMPAX LABS	0.1MG	N40431	001	MAR 18, 2002

FLUNISOLIDE

SPRAY, METERED; NASAL					
FLUNISOLIDE					
AB	BAUSCH AND LOMB	0.025MG/SPRAY	N74805	001	FEB 20, 2002

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

		<u>FLUNISOLIDE</u> SPRAY, METERED; NASAL NASALIDE AB + IVAX RES	0.025MG/SPRAY	N18148 001	FEB CTEC
APR	NEWA				
APR	NEWA	<u>FLUOCINOLONE ACETONIDE</u> CREAM; TOPICAL SYNALAR-HP @ MEDICIS	0.2%	N16161 002	JUN DISC
APR	CFTG	SOLUTION; TOPICAL FLUONID @ ALLERGAN HERBERT	0.01%	N87158 001	MAR 17, 1983 MAY DISC
JUN	CAHN	<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN</u> CREAM; TOPICAL TRI-LUMA + HILL DERMAC	0.01%;4%;0.05%	N21112 001	JAN 18, 2002 JAN NEWA
JUN	CAHN				
		<u>FLUOXETINE HYDROCHLORIDE</u> CAPSULE; ORAL FLUOXETINE AB ALPHAPHARM	EQ 10MG BASE EQ 20MG BASE	N75577 001	JAN 29, 2002 JAN NEWA
JUN	DISC	AB BARR	EQ 10MG BASE	N75577 002	JAN 29, 2002 JAN NEWA
JUN	DISC	AB CARLSBAD	EQ 10MG BASE	N74803 002	JAN 30, 2002 JAN NEWA
JUN	DISC	AB DR REDDYS LABS INC	EQ 20MG BASE	N76022 001	JAN 30, 2002 JAN NEWA
JUN	DISC	AB EON	EQ 10MG BASE	N76022 002	JAN 30, 2002 JAN NEWA
JUL	DISC	AB IVAX PHARMS	EQ 20MG BASE	N75465 001	JAN 29, 2002 JAN NEWA
JUL	DISC	AB MALLINCKRODT	EQ 10MG BASE	N75465 002	JAN 29, 2002 JAN NEWA
APR	CAHN	AB MUTUAL PHARMA	EQ 20MG BASE	N75807 001	JAN 29, 2002 JAN NEWA
APR	CAHN	AB MYLAN	EQ 10MG BASE	N75807 002	JAN 29, 2002 JAN NEWA
JUL	DISC	AB RANBAXY	EQ 20MG BASE	N75245 002	JAN 31, 2002 JAN NEWA
JUL	DISC	AB SIDMAK LABS	EQ 10MG BASE	N75245 001	JAN 31, 2002 JAN NEWA
MAR	CFTG	AB SIEGFRIED	EQ 20MG BASE	N75658 001	JAN 29, 2002 JAN NEWA
MAR	NEWA	AB TEVA	EQ 10MG BASE	N75658 002	JAN 29, 2002 JAN NEWA
FEB	NEWA	AB WATSON LABS	EQ 20MG BASE	N75787 001	JAN 29, 2002 JAN NEWA
		AB FLUOXETINE HCL AB GENEVA PHARMS	EQ 40MG BASE EQ 10MG BASE EQ 20MG BASE	N75787 002	JAN 30, 2002 JAN NEWA
			EQ 20MG BASE	N75207 001	JAN 30, 2002 JAN NEWA
			EQ 40MG BASE	N75207 002	JAN 30, 2002 JAN NEWA
				N76165 001	FEB 01, 2002 FEB NEWA
				N76165 002	FEB 01, 2002 FEB NEWA
				N76001 001	JAN 29, 2002 JAN NEWA
				N76001 002	JAN 29, 2002 JAN NEWA
				N75464 001	JAN 30, 2002 JAN NEWA
				N75464 002	JAN 30, 2002 JAN NEWA
				N75452 001	JAN 29, 2002 JAN NEWA
				N75452 002	JAN 29, 2002 JAN NEWA
				N75452 003	JAN 29, 2002 JAN NEWA
				N75662 001	JAN 29, 2002 JAN NEWA
				N75662 002	JAN 29, 2002 JAN NEWA
				N75049 002	JAN 29, 2002 JAN NEWA
				N75049 003	JAN 29, 2002 JAN NEWA

FLUOXETINE HYDROCHLORIDE

SOLUTION; ORAL		>D>	
FLUOXETINE		>D>	
AA	ALPHARMA	EQ 20MG BASE/5ML	N75690 001 JAN 31, 2002 JAN NEWA
AA	MALLINCKRODT	EQ 20MG BASE/5ML	N75920 001 JAN 29, 2002 JAN NEWA
AA	NOVEX	EQ 20MG BASE/5ML	N75292 001 FEB 07, 2002 FEB NEWA
AA	PHARM ASSOC	EQ 20MG BASE/5ML	N76015 001 JAN 30, 2002 JAN NEWA
AA	HI TECH PHARMA	EQ 20MG BASE/5ML	N75525 001 JUN 27, 2002 JUN NEWA
TABLET; ORAL		>D>	
AB	BARR	EQ 10MG BASE	N75810 001 FEB 01, 2002 FEB NEWA
AB	DR REDDYS LABS INC	EQ 10MG BASE	N76006 001 JAN 30, 2002 JAN NEWA
AB	EON	EQ 10MG BASE	N76024 001 JAN 29, 2002 JAN NEWA
AB	TEVA	EQ 10MG BASE	N75872 001 JAN 29, 2002 JAN NEWA
AB	ZENITH GOLDLINE	EQ 10MG BASE	N75865 001 FEB 28, 2002 FEB NEWA

FLUPHENAZINE ENANTHATE

INJECTABLE; INJECTION		
PROLIXIN ENANTHATE		
@ APOTHECON	25MG/ML	N16110 001 JUN DISC

FLUVOXAMINE MALEATE

TABLET; ORAL			
FLUVOXAMINE MALEATE			
AB	+ EON	100MG	N75888 003 NOV 29, 2000 MAY CRLD
AB	MUTUAL PHARM	25MG	N76125 001 APR 29, 2002 APR NEWA
AB		50MG	N76125 002 APR 29, 2002 APR NEWA
AB		100MG	N76125 003 APR 29, 2002 APR NEWA
LUVOX			
@	SOLVAY	25MG	N20243 001 DEC 05, 1994 MAY DISC
@		50MG	N20243 002 DEC 05, 1994 MAY DISC
@		100MG	N20243 003 DEC 05, 1994 MAY DISC

FOLIC ACID

TABLET; ORAL			
FOLIC ACID			
AA	+ WATSON LABS	1MG	N80680 001 FEB CAHN

FOLLITROPIN ALFA/BETA

INJECTABLE; INJECTION		
GONAL-F		
@ SERONO	37.5 IU/VIAL	N20378 003 MAY 25, 2000 JUN DISC

FULVESTRANT

INJECTABLE; INTRAMUSCULAR			
FASLODEX			
+	ASTRAZENECA	50MG/ML	N21344 001 APR 25, 2002 APR NEWA

FURAZOLIDONE

>D>	SUSPENSION; ORAL		
>D> FUROXONE			
>D>	+ SHIRE LABS	50MG/15ML	N11323 002 JUL DISC
>A> @		50MG/15ML	N11323 002 JUL DISC

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

FURAZOLIDONE
TABLET; ORAL
FUROXONE
+ SHIRE LABS
@

100MG
100MG

N11270 002
N11270 002

JUL DISC
JUL DISC

GALLIUM CITRATE, GA-67
INJECTABLE; INJECTION
NEOSCAN
@ AMERSHAM HLTH

2mCi/ML

N17655 001

JUN DISC

GALLIUM NITRATE
INJECTABLE; INJECTION

GANITE
@ GENTA
@ SOLOPAK

25MG/ML
25MG/ML

N19961 002 JAN 17, 1991 JUL CAHN
N19961 002 JAN 17, 1991 JUL CAHN

GLATIRAMER ACETATE
FOR SOLUTION; SUBCUTANEOUS
COPAXONE
+ TEVA
INJECTABLE; SUBCUTANEOUS
+ TEVA

20MG/VIAL
20MG/ML

N20622 001 DEC 20, 1996 JUN CDER
N20622 002 FEB 12, 2002 JUN NEWA

GLIPIZIDE
TABLET, EXTENDED RELEASE; ORAL
GLUCOTROL XL
PFIZER

2.5MG
5MG

N20329 003 AUG 10, 1999 FEB CRLD
N20329 001 APR 26, 1994 FEB CRLD

GLUCAGON HYDROCHLORIDE
INJECTABLE; INJECTION
GLUCAGON
@ LILLY

EQ 1MG BASE/VIAL

N12122 001

JUN DISC

GLYBURIDE
TABLET; ORAL
GLYBURIDE
AB COREPHARMA
AB
AB

1.25MG
2.5MG
5MG

N76257 001 JUN 27, 2002 JUN NEWA
N76257 002 JUN 27, 2002 JUN NEWA
N76257 003 JUN 27, 2002 JUN NEWA

>D>
>D>
>D>
>A>

GONADORELIN ACETATE
INJECTABLE; INJECTION
LUTREPULSE KIT
+ FERRING
@
@

0.8MG/VIAL
0.8MG/VIAL
3.2MG/VIAL

N19687 001 OCT 10, 1989 JUL DISC
N19687 001 OCT 10, 1989 JUL DISC
N19687 002 OCT 10, 1989 JUN DISC

GONADORELIN HYDROCHLORIDE
INJECTABLE; INJECTION
FACTREL
@ WYETH AYERST

EQ 0.5MG BASE/VIAL

N18123 003 SEP 30, 1982 JUN DISC

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

A.P.L.

@ WYETH AYERST

20,000 UNITS/VIAL

N17055 003

JUN DISC

CHORIONIC GONADOTROPIN

@ STERIS

2,000 UNITS/VIAL

N17016 011

FEB 16, 1990 JUN DISC

GRANISETRON HYDROCHLORIDE

SOLUTION; ORAL

KYTRIL

@ ROCHE

EQ 2MG BASE/10ML

N21238 001

JUN 27, 2001 JUN DISC

GRISEOFULVIN, MICROCRYSTALLINE

TABLET; ORAL

GRISACTIN

@ WYETH AYERST

500MG

N60212 001

MAY DISC

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

GRISACTIN ULTRA

@ WYETH AYERST

165MG

N62438 001 NOV 17, 1983 MAY DISC

@

330MG

N62438 002 NOV 17, 1983 MAY DISC

GUANADREL SULFATE

TABLET; ORAL

HYLOREL

@ PHARMACIA AND UPJOHN

10MG

N18104 001 DEC 29, 1982 JUN DISC

@

25MG

N18104 002 DEC 29, 1982 JUN DISC

GUANETHIDINE MONOSULFATE

TABLET; ORAL

ISMELIN

@ NOVARTIS

EQ 10MG SULFATE

N12329 001

JUN DISC

@

EQ 25MG SULFATE

N12329 002

JUN DISC

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

TENEX

AB ESP PHARMA

EQ 1MG BASE

N19032 001 OCT 27, 1986 APR CAHN

AB +

EQ 2MG BASE

N19032 002 NOV 07, 1988 APR CAHN

@

EQ 3MG BASE

N19032 003 NOV 07, 1988 APR CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

@ ALPHARMA

EQ 2MG BASE/ML

N70318 001 APR 11, 1986 MAY DISC

HALOTHANE

LIQUID; INHALATION

FLUOTHANE

@ WYETH AYERST

99.99%

N11338 001

APR DISC

HALOTHANE

<u>HALOTHANE</u>					
LIQUID; INHALATION					
HALOTHANE					
AN + ABBOTT	99.99%		N83254 001		APR CTEC
<u>HEPARIN SODIUM</u>					
INJECTABLE; INJECTION					
HEP-LOCK					
AP + ELKINS SINK	10 UNITS/ML		N17037 007	JUN	CRLD
	100 UNITS/ML		N17037 006	JUN	CRLD
AP +					
HEPARIN LOCK FLUSH					
@ WYETH AYERST	10 UNITS/ML		N17007 008	JUN	DISC
@	100 UNITS/ML		N17007 009	JUN	DISC
HEPARIN SODIUM					
AP + ABBOTT	2,500 UNITS/ML		N88099 001 APR 28, 1983	JUN	CRLD
AP + AM PHARM PARTNERS	20,000 UNITS/ML		N17029 004	JUN	CRLD
@ WYETH AYERST	1,000 UNITS/ML		N17007 001	JUN	DISC
@	2,500 UNITS/ML		N17007 007	JUN	DISC
@	5,000 UNITS/ML		N17007 002	JUN	DISC
@	5,000 UNITS/0.5ML		N17007 010	JUN	DISC
@	7,500 UNITS/ML		N17007 003	JUN	DISC
@	10,000 UNITS/ML		N17007 004	JUN	DISC
@	20,000 UNITS/ML		N17007 006	JUN	DISC
<u>HEXACHLOROPHENONE</u>					
SOAP; TOPICAL					
GAMOPHEN					
@ ARBROOK	2%		N06270 003	JUN	DISC
SPONGE; TOPICAL					
E-Z SCRUB					
@ BECTON DICKINSON	450MG		N17452 001	JUN	DISC
<u>HISTRELIN ACETATE</u>					
>D>	INJECTABLE; INJECTION				
>D>	SUPPRELIN				
>D> + SHIRE LABS	EQ 0.2MG BASE/ML		N19836 001 DEC 24, 1991	JUL	DISC
>A>	@		N19836 001 DEC 24, 1991	JUL	DISC
>D>	+		N19836 002 DEC 24, 1991	JUL	DISC
>D>	+		N19836 002 DEC 24, 1991	JUL	DISC
>A> @			N19836 003 DEC 24, 1991	JUL	DISC
>D> +			N19836 003 DEC 24, 1991	JUL	DISC
>A> @			N19836 003 DEC 24, 1991	JUL	DISC
<u>HYDROCHLOROTHIAZIDE</u>					
TABLET; ORAL					
ESIDRIX					
AB + NOVARTIS	100MG		N11793 009	MAR	CRLD
HYDROCHLOROTHIAZIDE					
AB VINTAGE PHARMS	25MG		N40412 001 MAR 29, 2002	MAR	NEWA
AB	50MG		N40412 002 MAR 29, 2002	MAR	NEWA
HYDRODIURIL					
@ MERCK	25MG		N11835 003	MAR	DISC
@	50MG		N11835 006	MAR	DISC
@	100MG		N11835 007	MAR	DISC

HYDROCHLOROTHIAZIDE; LISINOPRIL
TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

>A> AB	EON	12.5MG;10MG
>A> AB		12.5MG;20MG
>A> AB	GENEVA PHARMS TECH	25MG;20MG
>A> AB		12.5MG;10MG
>A> AB		12.5MG;20MG
>A> AB	IVAX PHARMS	25MG;20MG
>A> AB		12.5MG;10MG
>A> AB		12.5MG;20MG
>A> AB	MYLAN	25MG;20MG
>A> AB		12.5MG;10MG
>A> AB		12.5MG;20MG
>A> AB	PUREPAC PHARM	25MG;20MG
>A> AB		12.5MG;10MG
>A> AB		12.5MG;20MG
>A> AB	RANBAXY	25MG;20MG
>A> AB		12.5MG;10MG
>A> AB		12.5MG;20MG
>A> AB	TEVA	25MG;20MG
>A> AB		12.5MG;10MG
>A> AB		12.5MG;20MG
>A> AB	WATSON LABS	25MG;20MG
>A> AB		12.5MG;20MG
>A> AB		12.5MG;10MG
>A> AB	WEST WARD	25MG;20MG
>A> AB		12.5MG;10MG
>A> AB		12.5MG;20MG
>A> AB		25MG;20MG

N76262 001	JUL 01, 2002	JUL	NEWA
N76262 002	JUL 01, 2002	JUL	NEWA
N76262 003	JUL 01, 2002	JUL	NEWA
N75926 001	JUL 01, 2002	JUL	NEWA
N75926 002	JUL 01, 2002	JUL	NEWA
N75926 003	JUL 01, 2002	JUL	NEWA
N75776 001	JUL 01, 2002	JUL	NEWA
N75776 002	JUL 01, 2002	JUL	NEWA
N75776 003	JUL 01, 2002	JUL	NEWA
N76113 001	JUL 01, 2002	JUL	NEWA
N76113 002	JUL 01, 2002	JUL	NEWA
N76113 003	JUL 01, 2002	JUL	NEWA
N76230 001	JUL 01, 2002	JUL	NEWA
N76230 002	JUL 01, 2002	JUL	NEWA
N76230 003	JUL 01, 2002	JUL	NEWA
N76007 001	JUL 01, 2002	JUL	NEWA
N76007 002	JUL 01, 2002	JUL	NEWA
N76007 003	JUL 01, 2002	JUL	NEWA
N75869 001	JUL 01, 2002	JUL	NEWA
N75869 002	JUL 01, 2002	JUL	NEWA
N75869 003	JUL 01, 2002	JUL	NEWA
N76194 001	JUL 01, 2002	JUL	NEWA
N76194 002	JUL 01, 2002	JUL	NEWA
N76265 001	JUL 08, 2002	JUL	NEWA
N76265 002	JUL 08, 2002	JUL	NEWA
N76265 003	JUL 08, 2002	JUL	NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE
TABLET; ORAL

UNIRETIC
SCHWARZ PHARMA 12.5MG;15MG

N20729 003 FEB 14, 2002 JUN NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL

INDERIDE LA 120/50 @ WYETH AYERST	50MG;120MG
INDERIDE LA 160/50 @ WYETH AYERST	50MG;160MG
INDERIDE LA 80/50 @ WYETH AYERST	50MG;80MG

N19059 002 JUL 03, 1985 JUN DISC

N19059 003 JUL 03, 1985 JUN DISC

N19059 001 JUL 03, 1985 JUN DISC

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL HYDROPRES 25 @ MERCK	25MG;0.125MG
HYDROPRES 50 @ MERCK	50MG;0.125MG

N11958 002

JUN DISC

N11958 003

JUN DISC

>D>

>A>

HYDROCORTISONE

TABLET; ORAL				
CORTEF				
+ PHARMACIA AND UPJOHN	5MG	N08697 003	MAY	CRLD
BP +	10MG	N08697 001	MAY	CRLD
BP +	20MG	N08697 002	MAY	CRLD

HYDROCORTISONE ACETATE

CREAM; TOPICAL				
MICORT-HC				
+ FERNDALE LABS	2%	N40398 001	MAR 29, 2002	MAR NEWA
INJECTABLE; INJECTION				
HYDROCORTISONE ACETATE				
+ STERIS	25MG/ML	N83128 001	JUN	CRLD
HYDROCORTONE				
@ MERCK	25MG/ML	N08228 001	JUN	DISC
@	50MG/ML	N08228 004	JUN	DISC

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL				
LOCOID				
+ FERNDALE LABS	0.1%	N18514 001	MAR 31, 1982	MAR CAHN
LOCOID LIPOCREAM				
+ FERNDALE LABS	0.1%	N20769 001	SEP 08, 1997	MAR CAHN
OINTMENT; TOPICAL				
LOCOID				
+ FERNDALE LABS	0.1%	N18652 001	OCT 29, 1982	MAR CAHN

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC				
ACHROMYCIN				
@ LEDERLE	1.5%;1%	N50272 001	JUN	DISC

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL				
SALUTENSIN-DEMI				
>D>	SHIRE LABS	25MG;0.125MG	N12359 004	JUL DISC
>A>	@	25MG;0.125MG	N12359 004	JUL DISC

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC				
PAREDRINE				
@ AKORN	1%	N00004 004	JUN	DISC

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION				
HYDROXYPROGESTERONE CAPROATE				
@ STERIS	250MG/ML	N17439 002	JUN	DISC

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL
HYDROXYZINE HCL
AA VINTAGE PHARMS 10MG/5ML N40391 001 APR 10, 2002 APR NEWA

IBUPROFEN

SUSPENSION/DROPS; ORAL
MOTRIN
⑧ MCNEIL 40MG/ML N20476 001 MAY 25, 1995 JUN DISC
TABLET; ORAL
⑧ MCNEIL CONS SPECLT 100MG N20418 001 NOV 16, 1994 JUN DISC
TABLET, CHEWABLE; ORAL
⑧ MCNEIL CONS SPECLT 50MG N20135 001 NOV 16, 1994 JUN DISC
⑧ 100MG N20135 002 NOV 16, 1994 JUN DISC

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
IDAMYCIN
AP + PHARMACIA AND UPJOHN 5MG/VIAL N50661 002 SEP 27, 1990 MAY CFTG
⑧ 5MG/VIAL N50661 002 SEP 27, 1990 JUN DISC
AP + 10MG/VIAL N50661 001 SEP 27, 1990 MAY CFTG
⑧ 10MG/VIAL N50661 001 SEP 27, 1990 JUN DISC
AP + 20MG/VIAL N50661 003 APR 25, 1995 MAY CFTG
⑧ 20MG/VIAL N50661 003 APR 25, 1995 JUN DISC
IDAMYCIN PFS
AP + PHARMACIA AND UPJOHN 1MG/ML N50734 001 FEB 17, 1997 MAY CFTG
IDARUBICIN HCL
AP GENSIA SICOR PHARMS 5MG/VIAL N65037 003 MAY 01, 2002 MAY NEWA
AP 10MG/VIAL N65037 002 MAY 01, 2002 MAY NEWA
+ 10MG/VIAL N65037 002 MAY 01, 2002 JUN CRLD
AP 20MG/VIAL N65037 001 MAY 01, 2002 MAY NEWA
+ 20MG/VIAL N65037 001 MAY 01, 2002 JUN CRLD
IDARUBICIN HCL PFS
AP GENSIA SICOR PHARMS 1MG/ML N65036 001 MAY 01, 2002 MAY NEWA

IFOSFAMIDE

INJECTABLE; INJECTION
IFOSFAMIDE
AM PHARM PARTNERS 1GM/VIAL N76078 001 MAY 28, 2002 MAY NEWA
+ 3GM/VIAL N76078 002 MAY 28, 2002 MAY NEWA

IFOSFAMIDE; MESNA

INJECTABLE; INTRAVENOUS
IFOSFAMIDE/MESNA KIT
+ GENSIA SICOR PHARMS 1GM /20ML(50MG/ML);1GM
/10ML(100MG/ML) N75874 001 FEB 26, 2002 FEB NEWA
+ 3GM /60ML(50MG/ML);1GM
/10ML(100MG/ML) N75874 002 FEB 26, 2002 FEB NEWA

>D>
>D>
>A>
>A>

INAMRINONE LACTATE
INJECTABLE; INJECTION
AMRINONE
AP + ABBOTT
INOCOR
@ SANOFI SYNTHELABO

EQ 5MG BASE/ML
EQ 5MG BASE/ML

N74616 001 AUG 03, 1998 JUN CRLD
N18700 001 JUL 31, 1984 JUN DISC

INDOCYANINE GREEN
INJECTABLE; INJECTION
CARDIO-GREEN
@ AKORN

50MG/VIAL

N11525 002 JUN DISC

INDOMETHACIN
CAPSULE; ORAL
INDOMETHACIN

25MG

N18829 002 AUG 06, 1984 JUL CAHN
N18829 001 AUG 06, 1984 JUL CAHN
N18829 002 AUG 06, 1984 JUL CAHN
N18829 001 AUG 06, 1984 JUL CAHN

>D> AB AMERSHAM HLTH 50MG
>D> AB PAR PHARM 25MG
>A> AB 50MG
>A> AB CAPSULE, EXTENDED RELEASE; ORAL
AB ABLE 75MG

N76114 001 FEB 06, 2002 FEB NEWA

SUPPOSITORY; RECTAL
INDOCIN
@ MERCK 50MG
INDOMETHEGAN
+ G AND W LABS 50MG

N17814 001 AUG 13, 1984 MAY DISC
N73314 001 AUG 31, 1992 MAY CRLD

INSULIN PORK
INJECTABLE; INJECTION
ILETIN I
@ LILLY

500 UNITS/ML

N17931 001 JUN DISC

IODIPAMIDE MEGLUMINE
INJECTABLE; INJECTION
CHOLOGRAFIN MEGLUMINE
@ BRACCO 10.3%

N09321 007 JUN DISC

IODIXANOL
INJECTABLE; INJECTION
VISIPAQUE 270
@ AMERSHAM HLTH 55%
VISIPAQUE 320
@ AMERSHAM HLTH 65.2%

N20808 001 AUG 29, 1997 JUN DISC

N20808 002 AUG 29, 1997 JUN DISC

IODOHIPPURATE SODIUM, I-131

INJECTABLE; INJECTION
HIPPURAN I 131
@ MALLINCKRODT 0.25mCi/ML

N16666 001 JUN DISC

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

IOFETAMINE HYDROCHLORIDE I-123

INJECTABLE; INJECTION

SPECTAMINE

@ IMP

1mCi/ML

N19432 001 DEC 24, 1987 JUN

IOHEXOL

INJECTABLE; INJECTION

OMNIPAQUE 210

@ AMERSHAM HLTH

45.3%

SOLUTION; URETHRAL

OMNIPAQUE 70

@ AMERSHAM HLTH

15.1%

N18956 006 JUN 30, 1989 JUN

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL

>D>	AP	FAULDING	61%
>A>		@	61%
>D>	AP		61%
>A>		@	76%
		ISOVUE-128	76%
		@ BRACCO	26%

N18956 007 JUN 01, 1994 JUN

IOTHALAMATE SODIUM

INJECTABLE; INJECTION

CONRAY 325

@ MALLINCKRODT

54.3%

N18735 005 OCT 21, 1986 JUN

OXILAN

INJECTABLE; INJECTION

OXILAN-300

GUERBET

62%

OXILAN-350

GUERBET

73%

N17685 001

JUN D

IPODEATE SODIUM

CAPSULE; ORAL

ORAGRAFIN SODIUM

@ BRACCO

500MG

N20316 001 DEC 21, 1995 JUN CAH

N20316 002 DEC 21, 1995 JUN CAH

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPATROPIUM BROMIDE

>A>	AN	ROXANE	0.02%
-----	----	--------	-------

N12967 001

JUN DISC

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISOPROTERENOL HCL

+ @ 3M

0.12MG/INH

N75867 001 JUL 22, 2002 JUL NEWA

N10375 004

JUN DISC

ISOPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

MEDIHALER-ISO

@ 3M

0.08MG/INH

N10375 003

JUN DISC

ISOSORBIDE

SOLUTION; ORAL

ISMOTIC

@ ALCON

100GM/220ML

N17063 001

JUN DISC

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISMO

>A> AB ESP PHARMA

20MG

N19091 001 DEC 30, 1991 JUL CAHN

>D> AB ROBINS AH

20MG

N19091 001 DEC 30, 1991 JUL CAHN

KETOCONAZOLE

TABLET; ORAL

KETOCONAZOLE

>D> AB APPLIED ANAL

200MG

N75341 001 JUL 27, 1999 JUL CAHN

>A> AB NEOSAN PHARMS

200MG

N75341 001 JUL 27, 1999 JUL CAHN

AB TORPHARM

200MG

N75912 001 JAN 10, 2002 JAN NEWA

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

AB MYLAN

100MG

N75679 003 FEB 20, 2002 FEB NEWA

AB

150MG

N75679 002 FEB 20, 2002 FEB NEWA

AB

200MG

N75679 001 FEB 20, 2002 FEB NEWA

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP AM PHARM PARTNERS

15MG/ML

N75784 001 JAN 11, 2002 JAN NEWA

AP

30MG/ML

N75784 002 JAN 11, 2002 JAN NEWA

KRYPTON, KR-81M

GAS; INHALATION

MPI KRYPTON 81M GAS GENERATOR

>D> AMERSHAM HLTH

N/A

N18088 001

JUL DISC

>A> @

N/A

N18088 001

JUL DISC

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HCL

>A> AP APOTEX

5MG/ML

N76051 001 JUL 05, 2002 JUL NEWA

LACTULOSE

SOLUTION; ORAL

LACTULOSE

AA NOVEX

10GM/15ML

N75911 001 FEB 21, 2002 FEB NEWA

LACTULOSE

SOLUTION; ORAL, RECTAL						
CEPHULAC						
>D> AA + AVENTIS PHARMS	10GM/15ML		N17657 001	JUL	DISC	
>A> @	10GM/15ML		N17657 001	JUL	DISC	
ENULOSE						
>D> AA ALPHARMA	10GM/15ML		N71548 001	AUG 15, 1988	JUL	CRLD
>A> AA +	10GM/15ML		N71548 001	AUG 15, 1988	JUL	CRLD

LAMOTRIGINE

TABLET, CHEWABLE; ORAL						
LAMICTAL CD						
+ GLAXOSMITHKLINE	25MG		N20764 002	AUG 24, 1998	MAR	CRLD
@	100MG		N20764 003	AUG 24, 1998	MAR	DISC

LEUCOVORIN CALCIUM

TABLET; ORAL						
LEUCOVORIN CALCIUM						
AB XANODYNE PHARM	EQ 15MG BASE		N71104 001	MAR 04, 1987	JUN	CAHN

LEUPROLIDE ACETATE

INJECTABLE; SUBCUTANEOUS						
ELIGARD						
+ ATRIX	7.5MG/VIAL		N21343 001	JAN 23, 2002	JAN	NEWA
>A> +	22.5MG/VIAL		N21379 001	JUL 24, 2002	JUL	NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION						
XOPENEX						
+ SEPRACOR	EQ 0.0105% BASE		N20837 003	JAN 30, 2002	JUN	NEWA

LEVOCARNITINE

SOLUTION; ORAL						
CARNITOR						
>D> @ SIGMA TAU	1GM/10ML		N18948 002	APR 27, 1988	JUN	DISC
>A> @	1GM/10ML		N19257 001	APR 10, 1986	JUL	CMFD
>A> +	1GM/10ML		N19257 001	APR 10, 1986	JUL	CMFD
>A> @	1GM/10ML		N19257 001	APR 10, 1986	JUN	DISC

LEVODOPA

TABLET; ORAL						
LARODOPA						
@ ROCHE	100MG		N16912 005		JUN	DISC
@	250MG		N16912 003		JUN	DISC
@	500MG		N16912 004		JUN	DISC

LEVOTHYROXINE SODIUM

TABLET; ORAL						
LEVO-T						
BX MOVA	0.025MG		N21342 001	MAR 01, 2002	MAR	NEWA
BX	0.05MG		N21342 002	MAR 01, 2002	MAR	NEWA
BX	0.075MG		N21342 003	MAR 01, 2002	MAR	NEWA
BX	0.088MG		N21342 004	MAR 01, 2002	MAR	NEWA

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

BX		0.1MG	N21342 005	MAR 01, 2002	MAR	NEWA
BX		0.112MG	N21342 006	MAR 01, 2002	MAR	NEWA
BX		0.125MG	N21342 007	MAR 01, 2002	MAR	NEWA
BX		0.15MG	N21342 008	MAR 01, 2002	MAR	NEWA
BX		0.175MG	N21342 009	MAR 01, 2002	MAR	NEWA
BX		0.2MG	N21342 010	MAR 01, 2002	MAR	NEWA
BX		0.3MG	N21342 011	MAR 01, 2002	MAR	NEWA
BX +	LEVOTHYROXINE SODIUM MYLAN	0.025MG	N76187 001	JUN 05, 2002	JUN	NEWA
AB		0.05MG	N76187 002	JUN 05, 2002	JUN	NEWA
AB		0.075MG	N76187 003	JUN 05, 2002	JUN	NEWA
AB		0.088MG	N76187 004	JUN 05, 2002	JUN	NEWA
AB		0.1MG	N76187 005	JUN 05, 2002	JUN	NEWA
AB		0.112MG	N76187 006	JUN 05, 2002	JUN	NEWA
AB		0.125MG	N76187 007	JUN 05, 2002	JUN	NEWA
AB		0.15MG	N76187 008	JUN 05, 2002	JUN	NEWA
AB		0.175MG	N76187 009	JUN 05, 2002	JUN	NEWA
AB		0.2MG	N76187 010	JUN 05, 2002	JUN	NEWA
AB		0.3MG	N76187 011	JUN 05, 2002	JUN	NEWA
AB +	NOVOTHYROX GENPHARM	0.025MG	N21292 001	MAY 31, 2002	MAY	NEWA
BX		0.05MG	N21292 002	MAY 31, 2002	MAY	NEWA
BX		0.075MG	N21292 003	MAY 31, 2002	MAY	NEWA
BX		0.088MG	N21292 004	MAY 31, 2002	MAY	NEWA
BX		0.1MG	N21292 005	MAY 31, 2002	MAY	NEWA
BX		0.112MG	N21292 006	MAY 31, 2002	MAY	NEWA
BX		0.125MG	N21292 007	MAY 31, 2002	MAY	NEWA
BX		0.137MG	N21292 008	MAY 31, 2002	MAY	NEWA
BX		0.15MG	N21292 009	MAY 31, 2002	MAY	NEWA
BX		0.175MG	N21292 010	MAY 31, 2002	MAY	NEWA
BX		0.2MG	N21292 011	MAY 31, 2002	MAY	NEWA
BX		0.3MG	N21292 012	MAY 31, 2002	MAY	NEWA
BX +	SYNTHROID ABBOTT	0.025MG	N21402 001	JUL 24, 2002	JUL	NEWA
>A>		0.05MG	N21402 002	JUL 24, 2002	JUL	NEWA
>A>	BX	0.075MG	N21402 003	JUL 24, 2002	JUL	NEWA
>A>	BX	0.088MG	N21402 004	JUL 24, 2002	JUL	NEWA
>A>	BX	0.1MG	N21402 005	JUL 24, 2002	JUL	NEWA
>A>	BX	0.112MG	N21402 006	JUL 24, 2002	JUL	NEWA
>A>	BX	0.125MG	N21402 007	JUL 24, 2002	JUL	NEWA
>A>	BX	0.137MG	N21402 008	JUL 24, 2002	JUL	NEWA
>A>	BX	0.15MG	N21402 009	JUL 24, 2002	JUL	NEWA
>A>	BX	0.175MG	N21402 010	JUL 24, 2002	JUL	NEWA
>A>	BX	0.2MG	N21402 011	JUL 24, 2002	JUL	NEWA
>A>	BX +	0.3MG				
AB	UNITHROID STEVENS J	0.025MG	N21210 001	AUG 21, 2000	JUN	CRLD
AB		0.05MG	N21210 002	AUG 21, 2000	JUN	CRLD
AB		0.075MG	N21210 003	AUG 21, 2000	JUN	CRLD
AB		0.088MG	N21210 004	AUG 21, 2000	JUN	CRLD
AB		0.1MG	N21210 005	AUG 21, 2000	JUN	CRLD
AB		0.112MG	N21210 006	AUG 21, 2000	JUN	CRLD
AB		0.125MG	N21210 007	AUG 21, 2000	JUN	CRLD
AB		0.15MG	N21210 008	AUG 21, 2000	JUN	CRLD

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

AB	0.175MG	N21210 009 AUG 21, 2000
AB	0.2MG	N21210 010 AUG 21, 2000
AB +	0.3MG	N21210 011 AUG 21, 2000

LIDOCAINE

AEROSOL; ORAL		
XYLOCAINE		
@ ASTRazeneca	10%	N14394 001
FILM, EXTENDED RELEASE; Buccal		
LIDOCAINE		
@ NOVEN	23MG/PATCH	N20575 001 MAY 21, 1996

LINCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL		
LINCOcin		
@ PHARMacia AND UPJOHN	EQ 250MG BASE	N50316 001
@	EQ 500MG BASE	N50316 002

LINEZOLID

TABLET; ORAL		
ZYVOX		
@ PHARMacia AND UPJOHN	400MG	N21130 001 APR 18, 2000

LISINOPRIL

TABLET; ORAL		
>A> LISINOPRIL		
>A> AB EON	2.5MG	N75994 001 JUL 01, 2002
>A> AB	5MG	N75994 002 JUL 01, 2002
>A> AB	10MG	N75994 003 JUL 01, 2002
>A> AB	20MG	N75994 004 JUL 01, 2002
>A> AB	30MG	N75994 005 JUL 01, 2002
>A> AB	40MG	N75994 006 JUL 01, 2002
>A> AB GENEVA PHARMS TECH	2.5MG	N75903 001 JUL 01, 2002
>A> AB	5MG	N75903 002 JUL 01, 2002
>A> AB	10MG	N75903 003 JUL 01, 2002
>A> AB	20MG	N75903 004 JUL 01, 2002
>A> AB	30MG	N75903 005 JUL 01, 2002
>A> AB	40MG	N75903 006 JUL 01, 2002
>A> AB IVAX PHARMS	2.5MG	N75752 001 JUL 01, 2002
>A> AB	5MG	N75752 002 JUL 01, 2002
>A> AB	10MG	N75752 003 JUL 01, 2002
>A> AB	20MG	N75752 004 JUL 01, 2002
>A> AB	30MG	N75752 005 JUL 01, 2002
>A> AB	40MG	N75752 006 JUL 01, 2002
>A> AB MYLAN	2.5MG	N76071 001 JUL 01, 2002
>A> AB	5MG	N76071 002 JUL 01, 2002
>A> AB	10MG	N76071 003 JUL 01, 2002
>A> AB	20MG	N76071 004 JUL 01, 2002
>A> AB	30MG	N76071 005 JUL 01, 2002
>A> AB	40MG	N76071 006 JUL 01, 2002
>A> AB PAR PHARM	2.5MG	N75743 001 JUL 01, 2002
>A> AB	5MG	N75743 002 JUL 01, 2002
>A> AB	10MG	N75743 003 JUL 01, 2002

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

1-40

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

1-42

LORATADINE

TABLET; ORAL

CLARITIN

>D>	AB	+	SCHERING	10MG	N19658 001	APR 12, 1993	JUL CT
>A>		+		10MG	N19658 001	APR 12, 1993	JUL CT

LOVASTATIN

TABLET; ORAL

LOVASTATIN

AB	CARLSBAD	10MG	N75991 001	JUN 05, 2002	JUN NEW
AB		20MG	N75991 002	JUN 05, 2002	JUN NEW
AB		40MG	N75991 003	JUN 05, 2002	JUN NEW
TABLET, EXTENDED RELEASE; ORAL					
ALTOCOR					
>A>	ANDRX	10MG	N21316 001	JUN 26, 2002	JUL CAH
>A>		20MG	N21316 002	JUN 26, 2002	JUL CAH
>A>		40MG	N21316 003	JUN 26, 2002	JUL CAH
>A>	+	60MG	N21316 004	JUN 26, 2002	JUL CAH
>D>	AURA LABS	10MG	N21316 001	JUN 26, 2002	JUL CAH
>D>		20MG	N21316 002	JUN 26, 2002	JUN NEW
>D>		20MG	N21316 003	JUN 26, 2002	JUL CAH
>D>		40MG	N21316 004	JUN 26, 2002	JUN NEW
>D>	+	40MG	N21316 001	JUN 26, 2002	JUL CAH
>D>	+	60MG	N21316 002	JUN 26, 2002	JUN NEW
>D>	+	60MG	N21316 003	JUN 26, 2002	JUL CAH
>D>	+	60MG	N21316 004	JUN 26, 2002	JUL CAH

LOXAPINE HYDROCHLORIDE

>D>	CONCENTRATE; ORAL				
>D>	LOXITANE C				
>D>	+	WATSON LABS	EQ 25MG BASE/ML	N17658 001	JUL DISC
>A>	@		EQ 25MG BASE/ML	N17658 001	JUL DISC
>D>	INJECTABLE; INJECTION				
>D>	LOXITANE IM				
>D>	+	WATSON LABS	EQ 50MG BASE/ML	N18039 001	JUL DISC
>A>	+	@	EQ 50MG BASE/ML	N18039 001	JUL DISC

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION; ORAL

LUMENHANCE

@ BRACCO

3.49MG/GM

N20686 001 DEC 19, 1997 JUN DISC

MASOPROCOL

CREAM; TOPICAL

ACTINEX

@ UNIV AZ CANCER CTR

10%

N19940 001 SEP 04, 1992 JUN DISC

MAZINDOL

TABLET; ORAL

MAZANOR

@ WYETH AYERST

1MG

N17980 002

APR DISC

MAZINDOL

TABLET; ORAL				
SANOREX	1MG	N17247 001	APR	CTEC
NOVARTIS	1MG	N17247 001	JUN	DISC
@	2MG	N17247 002	JUN	DISC
@				

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL				
LARIAM				
AB + ROCHE	250MG	N19591 001 MAY 02, 1989 FEB CFTG		
MEFLOQUINE HCL				
AB GENEVA PHARMS TECH	250MG	N76175 001 FEB 20, 2002 FEB NEWA		

MEGESTROL ACETATE

SUSPENSION; ORAL				
MEGESTROL ACETATE				
AB ROXANE	40MG/ML	N75997 001 FEB 15, 2002 FEB NEWA		

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION				
PERGONAL				
@ SERONO	75 IU/AMP;75 IU/AMP	N17646 001	JUN	DISC
@	150 IU/AMP;150 IU/AMP	N17646 002 MAY 20, 1985 JUN	DISC	
REPRONEX				
+ FERRING	75 IU/VIAL;75 IU/VIAL	N21047 001 AUG 27, 1999 JUN	CRLD	
+	150 IU/VIAL;150 IU/VIAL	N21047 002 AUG 27, 1999 JUN	CRLD	

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION				
MEPERGAN				
@ WYETH AYERST	25MG/ML;25MG/ML	N11730 001	JUN	DISC

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION				
WYAMINE SULFATE				
@ WYETH AYERST	EQ 15MG BASE/ML	N08248 002	JUN	DISC

MEPHENYTOIN

TABLET; ORAL				
MESANTOIN				
@ NOVARTIS	100MG	N06008 001	JUN	DISC

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL				
SOLAGE				
+ GALDERMA LABS	2%;0.01%	N20922 001 DEC 10, 1999 APR CAHN		

MESNA

INJECTABLE; INTRAVENOUS				
MESNEX				
AP + BAXTER HLTHCARE	100MG/ML	N19884 001 DEC 30, 1988 MAR CAHN		
TABLET; ORAL				

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

<u>MESNA</u>			
TABLET; ORAL			
MESNEX			
+ BAXTER HLTHCARE	400MG	N20855 001	MAR 21, 2002 JUN
+ BRISTOL MYERS SQUIBB	400MG	N20855 001	MAR 21, 2002 MAR
<u>MESORIDAZINE BESYLATE</u>			
INJECTABLE; INJECTION			
SERENTIL			
@ NOVARTIS	EQ 25MG BASE/ML	N16775 001	JUN
<u>MESTRANOL; NORETHINDRONE</u>			
TABLET; ORAL-28			
NORINYL 1+50 28-DAY			
AB WATSON LABS	0.05MG;1MG	N16659 001	JAN
<u>METAPROTERENOL SULFATE</u>			
SOLUTION; INHALATION			
ALUPENT			
@ BOEHRINGER INGELHEIM	5%	N17659 001	JUN D
METAPROTERENOL SULFATE			
AN MORTON GROVE	0.4%	N75586 001	MAY 30, 2002 MAY NE
AN	0.6%	N75586 002	MAY 30, 2002 MAY NE
<u>METAXALONE</u>			
TABLET; ORAL			
SKELAXIN			
+ ELAN PHARMS	400MG	N13217 001	JUN CAR
<u>METFORMIN HYDROCHLORIDE</u>			
TABLET; ORAL			
GLUCOPHAGE			
AB BRISTOL MYERS SQUIBB	500MG	N20357 001	MAR 03, 1995 JAN CFT
AB	850MG	N20357 002	MAR 03, 1995 JAN CFT
AB +	1GM	N20357 005	NOV 05, 1998 JAN CFT
METFORMIN HCL			
AB ALPHAPHARM	500MG	N75969 001	JAN 29, 2002 JAN NEWA
AB	850MG	N75969 002	JAN 29, 2002 JAN NEWA
AB	1GM	N75969 003	JAN 29, 2002 JAN NEWA
AB ANDRX PHARMS	500MG	N75961 001	JAN 25, 2002 JAN NEWA
AB	850MG	N75961 002	JAN 25, 2002 JAN NEWA
AB	1GM	N75961 003	JAN 25, 2002 JAN NEWA
AB BARR	500MG	N75971 001	JAN 25, 2002 JAN NEWA
AB	850MG	N75971 002	JAN 25, 2002 JAN NEWA
AB	1GM	N75971 003	JAN 25, 2002 JAN NEWA
AB CARACO	500MG	N75967 001	JAN 29, 2002 JAN NEWA
AB	850MG	N75967 002	JAN 29, 2002 JAN NEWA
AB	1GM	N75967 003	JAN 29, 2002 JAN NEWA
AB EON	500MG	N75965 001	JAN 25, 2002 JAN NEWA
AB	850MG	N75965 002	JAN 25, 2002 JAN NEWA
AB	1GM	N75965 003	JAN 25, 2002 JAN NEWA
AB GENEVA PHARMS	500MG	N75985 001	JAN 25, 2002 MAY CAHN
AB	850MG	N75985 002	JAN 25, 2002 MAY CAHN

AB		1GM	N75985 003	JAN 25, 2002	MAY	CAHN
AB	GENEVA PHARMS TECH	500MG	N75985 001	JAN 25, 2002	JAN	NEWA
AB		850MG	N75985 002	JAN 25, 2002	JAN	NEWA
AB		1GM	N75985 003	JAN 25, 2002	JAN	NEWA
AB	GENPHARM	500MG	N75973 001	JAN 25, 2002	JAN	NEWA
AB		850MG	N75973 002	JAN 25, 2002	JAN	NEWA
AB		1GM	N75973 003	JAN 25, 2002	JAN	NEWA
AB	GOLDLINE	500MG	N75972 001	JAN 24, 2002	JAN	NEWA
AB		625MG	N75972 005	JAN 24, 2002	JAN	NEWA
AB		750MG	N75972 004	JAN 24, 2002	JAN	NEWA
AB		850MG	N75972 002	JAN 24, 2002	JAN	NEWA
AB		1GM	N75972 003	JAN 24, 2002	JAN	NEWA
AB	MUTUAL PHARMA	500MG	N76038 001	FEB 21, 2002	FEB	NEWA
AB		850MG	N76038 002	FEB 21, 2002	FEB	NEWA
AB		1GM	N76038 003	FEB 21, 2002	FEB	NEWA
AB	MYLAN	500MG	N75976 001	JAN 24, 2002	JAN	NEWA
AB		850MG	N75976 002	JAN 24, 2002	JAN	NEWA
AB		1GM	N75976 003	JAN 24, 2002	JAN	NEWA
AB	PUREPAC PHARM	500MG	N76033 001	JAN 24, 2002	JAN	NEWA
AB		850MG	N76033 002	JAN 24, 2002	JAN	NEWA
AB		1GM	N76033 003	JAN 24, 2001	JAN	NEWA
AB	TEVA	500MG	N75978 001	JAN 25, 2002	JAN	NEWA
AB		850MG	N75978 002	JAN 25, 2002	JAN	NEWA
AB	TORPHARM	500MG	N75984 001	APR 23, 2002	APR	NEWA
AB		850MG	N75984 002	APR 23, 2002	APR	NEWA
AB		1GM	N75984 003	APR 23, 2002	APR	NEWA
AB	WATSON LABS	500MG	N75979 001	JAN 24, 2002	JAN	NEWA
AB		850MG	N75979 002	JAN 24, 2002	JAN	NEWA
AB		1GM	N75979 003	JAN 24, 2002	JAN	NEWA
AB	ZENITH GOLDLINE	500MG	N75975 001	JAN 24, 2002	JAN	NEWA
AB		625MG	N75975 004	JAN 24, 2002	JAN	NEWA
AB		750MG	N75975 005	JAN 24, 2002	JAN	NEWA
AB		850MG	N75975 002	JAN 24, 2002	JAN	NEWA
AB		1GM	N75975 003	JAN 24, 2002	JAN	NEWA

METHADONE HYDROCHLORIDE

>D>	SYRUP; ORAL			
>D>	DOLOPHINE HCL			
>D>	+ ROXANE	10MG/30ML	N06134 004	JUL DISC
>A>	ø	10MG/30ML	N06134 004	JUL DISC

METHAMPHETAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL				
DESOXYN				
ø	ABBOTT	5MG	N05378 004	JUN DISC
ø		10MG	N05378 003	JUN DISC
ø		15MG	N05378 005	JUN DISC

METHANTHELINE BROMIDE

TABLET; ORAL				
BANTHINE				
>D>	+ SHIRE LABS	50MG	N07390 001	JUL DISC
>A>	ø	50MG	N07390 001	JUL DISC

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

1-46

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

+ KING PHARMS	500MG/VIAL	N11559 001	FEB CAH
+	2.5GM/VIAL	N11559 002	FEB CAH
+	5GM/VIAL	N11559 003	FEB CAH

>A>
>D>METHOTREXATE SODIUM

INJECTABLE; INJECTION

FOLEX

+ PHARMACIA AND UPJOHN	EQ 50MG BASE/VIAL	N87695 002	APR 08, 1983	JUN CRD
+	EQ 100MG BASE/VIAL	N87695 003	APR 08, 1983	JUN CRD

METHOTREXATE SODIUM

@ LEDERLE	EQ 2.5MG BASE/ML	N11719 004	JUN DISC
@	EQ 50MG BASE/VIAL	N11719 003	JUN DISC
@	EQ 100MG BASE/VIAL	N11719 006	JUN DISC

TABLET; ORAL

>A> AB + CLONMEL HLTHCARE	EQ 2.5MG BASE	N08085 002	JUL CAH
>D> AB + LEDERLE	EQ 2.5MG BASE	N08085 002	JUL CAH

METHYLDOPA

SUSPENSION; ORAL

ALDOMET

@ MERCK	250MG/5ML	N18389 001	JUN DISC
---------	-----------	------------	----------

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

BX + CELLTECH PHARMS	20MG	N21259 001	APR 03, 2001	JUN CTEC
RITALIN LA				
BX NOVARTIS	20MG	N21284 001	JUN 05, 2002	JUN NEWA
	30MG	N21284 002	JUN 05, 2002	JUN NEWA

+ TABLET; ORAL

METHYLPHENIDATE HCL

AB PUREPAC PHARM	5MG	N40321 001	FEB 05, 2002	FEB NEWA
AB	10MG	N40321 002	FEB 05, 2002	FEB NEWA
AB	20MG	N40321 003	FEB 05, 2002	FEB NEWA

TABLET, EXTENDED RELEASE; ORAL

CONCERTA

+ ALZA	27MG	N21121 004	APR 01, 2002	JUN NEWA
--------	------	------------	--------------	----------

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

AB GENEVA PHARMS	4MG	N40194 001	OCT 31, 1997	MAY CAHN
------------------	-----	------------	--------------	----------

METRONIDAZOLE

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

>A> AP + GD SEARLE LLC	500MG/100ML	N18353 002	JUL CAHN
>D> AP + SCS	500MG/100ML	N18353 002	JUL CAHN

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

FLAGYL I.V.

>A> + GD SEARLE LLC
>D> + SCSEQ 500MG BASE/VIAL
EQ 500MG BASE/VIALN18353 001
N18353 001JUL CAHN
JUL CAHNMICONAZOLE NITRATE

CREAM, INSERT; TOPICAL, VAGINAL

MONISTAT DUAL- PAK
@ PERSONAL PRODS

1.2GM;2%

N20968 001 JUN 30, 1999 JUN DISC

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HCL

>A> AP ABBOTT
>A> AP ROSS LABS
AP SYRUP; ORAL
AA RANBAXY
AA ROXANE
VERSED
AA + ROCHEEQ 1MG BASE/ML
EQ 5MG BASE/ML
EQ 1MG BASE/ML
EQ 5MG BASE/ML
EQ 2MG BASE/ML
EQ 2MG BASE/ML
EQ 2MG BASE/MLN75857 001 JUL 22, 2002 JUL NEWA
N75857 002 JUL 22, 2002 JUL NEWA
N75856 001 JUN 13, 2002 JUN NEWA
N75856 002 JUN 13, 2002 JUN NEWA
N76058 001 MAR 15, 2002 MAR NEWA
N75873 001 APR 30, 2002 APR NEWA
N20942 001 OCT 15, 1998 MAR CFTGMIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

>A> + SHIRE LABS
>D> +
>A> +
>D> SHIRE PHARM5MG
10MG
10MG
10MG
5MG
5MGN19815 002 SEP 06, 1996 JUL CRLD
N19815 003 MAR 20, 2002 JUL CRLD
N19815 003 MAR 20, 2002 JUL CRLD
N19815 003 MAR 20, 2002 JUN NEWA
N19815 002 SEP 06, 1996 JUL CRLD
N19815 002 SEP 06, 1996 JUN CRLDMILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP ABBOTT
AP AM PHARM PARTNERS
AP BAXTER HLTHCARE CORP
AP BEDFORD
AP
AP
AP ESI LEDERLE
AP FAULDING
AP MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER
AP ABBOTT
AP +
AP BAXTER HLTHCARE
AP
AP ESI LEDERLEEQ 1MG BASE/ML
EQ 1MG BASE/ML
EQ 1MG BASE/ML
EQ 1MG BASE/ML
EQ 20MG /20ML (1MG/ML)
EQ 50MG /50ML (1MG/ML)
EQ 1MG BASE/ML
EQ 1MG BASE/ML
EQ 20MG BASE/100ML
EQ 40MG BASE/200ML
EQ 20MG BASE/100ML
EQ 40MG BASE/100ML
EQ 40MG BASE/200ML
EQ 20MG BASE/100MLN75884 001 MAY 28, 2002 MAY NEWA
N75936 001 MAY 28, 2002 MAY NEWA
N75852 001 MAY 28, 2002 MAY NEWA
N75660 001 MAY 28, 2002 MAY NEWA
N75660 002 MAY 28, 2002 MAY NEWA
N75660 003 MAY 28, 2002 MAY NEWA
N75530 001 MAY 28, 2002 MAY NEWA
N75830 001 MAY 28, 2002 MAY NEWA
N75885 001 MAY 28, 2002 MAY NEWA
N75885 002 MAY 28, 2002 MAY NEWA
N75834 001 MAY 28, 2002 MAY NEWA
N75834 002 MAY 28, 2002 MAY NEWA
N75834 002 MAY 28, 2002 JUN NEWA
N75510 001 MAY 28, 2002 MAY NEWA

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

1-48

MILRINONE LACTATE

INJECTABLE; INJECTION

PRIMACOR

AP + SANOFI SYNTHELABO	EQ 1MG BASE/ML	N19436 001 DEC 31, 1987 MAY CFTG
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER		
AP SANOFI SYNTHELABO	EQ 20MG BASE/100ML	N20343 003 AUG 09, 1994 MAY CFTG
AP +	EQ 40MG BASE/100ML	N20343 004 AUG 09, 1994 MAY CFTG
AP +	EQ 40MG BASE/200ML	N20343 004 AUG 09, 1994 JUN CFTG

MINOCYCLINE HYDROCHLORIDE

SUSPENSION; ORAL

MINOCIN

@ LEDERLE

EQ 50MG BASE/5ML

N50445 001

JUN DISC

MISOPROSTOL

TABLET; ORAL

CYTOTEC

>D> GD SEARLE LLC	0.1MG	N19268 003 SEP 21, 1990 JUL CFTG
>A> AB	0.1MG	N19268 003 SEP 21, 1990 JUL CFTG
>D> +	0.2MG	N19268 001 DEC 27, 1988 JUL CFTG
>A> AB +	0.2MG	N19268 001 DEC 27, 1988 JUL CFTG
MISOPROSTOL		
>A> AB IVAX PHARMS	0.1MG	N76095 001 JUL 10, 2002 JUL NEW
>A> AB	0.2MG	N76095 002 JUL 10, 2002 JUL NEW

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

@ ABBOTT

EQ 0.5MG BASE/ML

N20098 002 JAN 22, 1992 JUN DISC

MOMETASONE FUROATE

OINTMENT; TOPICAL

ELOCON

AB + SCHERING	0.1%	N19543 001 APR 30, 1987 MAR CFTG
MOMETASONE FUROATE		
AB CLAY PARK	0.1%	N76067 001 MAR 18, 2002 MAR NEW

MONOCTANOIN

LIQUID; PERfusion, BILIARY

MOCTANIN

@ ETHITEK

100%

N19368 001 OCT 29, 1985 JUN DISC

MONTELUKAST SODIUM

>A> GRANULE; ORAL

>A> SINGULAIR

>A> + MERCK

EQ 4MG BASE/PACKET

N21409 001 JUL 26, 2002 JUL NEW

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

ELAN PHARM

30MG

60MG

90MG

N21260 001 MAR 20, 2002 MAR NEW

N21260 002 MAR 20, 2002 MAR NEW

N21260 003 MAR 20, 2002 MAR NEW

120MG

N21260 004 MAR 20, 2002 MAR NEWA

+

NABUMETONETABLET; ORAL
NABUMETONE

AB	EON	500MG	N75280 001	FEB 25, 2002	FEB	NEWA
AB		750MG	N75280 002	FEB 25, 2002	FEB	NEWA
AB	INVAMED	500MG	N75590 001	FEB 25, 2002	FEB	NEWA
AB		750MG	N75590 002	FEB 25, 2002	FEB	NEWA

NAFCILLIN SODIUMCAPSULE; ORAL
UNIPEN

@ WYETH AYERST EQ 250MG BASE

N50111 001 JUN DISC

NALBUPHINE HYDROCHLORIDEINJECTABLE; INJECTION
NALBUPHINE HCL

>D>	+ ABBOTT	1.5MG/ML	N20200 001	MAR 12, 1993	JUL	DISC
>A>	@	1.5MG/ML	N20200 001	MAR 12, 1993	JUL	DISC

NALIDIXIC ACIDSUSPENSION; ORAL
NEGRAM

@ SANOFI SYNTHELABO 250MG/5ML

N17430 001 JUN DISC

NALTREXONE HYDROCHLORIDETABLET; ORAL
NALTREXONE HCL

AB	MALLINCKRODT	25MG	N76264 001	MAR 22, 2002	MAR	NEWA
		50MG	N76264 002	MAR 22, 2002	MAR	NEWA
+		100MG	N76264 003	MAR 22, 2002	MAR	NEWA

NAPROXEN SODIUMTABLET, EXTENDED RELEASE; ORAL
NAPRELAN

@ ELAN PHARM EQ 750MG BASE

N20353 003 JAN 05, 1996 JUN DISC

NEOMYCIN SULFATESOLUTION; ORAL
MYCIFRADIN

AA	+ PHARMACIA AND UPJOHN	EQ 87.5MG BASE/5ML	N50285 001	MAY	CFTG	
	@	EQ 87.5MG BASE/5ML	N50285 001	JUN	DISC	
AA	NEO-FRADIN					
	PHARMATEK	EQ 87.5MG BASE/5ML	N65010 001	MAY 23, 2002	MAY	NEWA
+		EQ 87.5MG BASE/5ML	N65010 001	MAY 23, 2002	JUN	CRDL

NEOMYCIN SULFATE; POLYMYXIN B SULFATEOINTMENT; OPHTHALMIC
STATROL

@ ALCON

SOLUTION/DROPS; OPHTHALMIC
@ ALCON EQ 3.5MG BASE/GM; 10,000 UNITS/GM

N50344 002 JUN DISC

EQ 3.5MG BASE/ML; 16,250 UNITS/ML

N50456 001 JUN DISC

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIASPAN

@ KOS 500MG

N20381 002 JUL 28, 1997 JUN DISC

NIASPAN TITRATION STARTER PACK

@ KOS 375MG;500MG;750MG

N20381 005 JUL 28, 1997 JUN DISC

NILUTAMIDE

TABLET; ORAL

NILANDRON

@ AVENTIS PHARMS 50MG

N20169 001 SEP 19, 1996 JUN DISC

>D> @ 150MG

N20169 002 APR 30, 1999 JUL DISC

>A> + 150MG

N20169 002 APR 30, 1999 JUL DISC

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

SULAR

+ FIRST HORIZON 10MG

N20356 001 FEB 02, 1995 MAR CARR

20MG

>D>

30MG

>A>

40MG

>A>

+ WHITEHALL ROBINS 10MG

N20356 001 FEB 02, 1995 FEB CARR

20MG

>A>

40MG

>A>

NITISINONE

CAPSULE; ORAL

ORFADIN

R R REGISTRATIONS 2MG

N21232 001 JAN 18, 2002 JAN NEW

5MG

>A>

10MG

>A>

SWEDISH ORPHAN 2MG

N21232 001 JAN 18, 2002 MAY CARR

5MG

>A>

10MG

>A>

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTIN

+ FIRST HORIZON 25MG/5ML

N09175 001 JAN CARR

NITROFURAZONE

CREAM; TOPICAL

FURACIN

>D> + SHIRE LABS 0.2%

N83789 001 JUL DISC

>A> @ 0.2%

N83789 001 JUL DISC

OINTMENT; TOPICAL

>D> AT + SHIRE LABS 0.2%

N05795 001 JUL DISC

>A> @ 0.2%

N05795 001 JUL DISC

NITROFURAZONE

>D> AT TARO 0.2%

N86156 001 JUL CRLD

>A> AT + 0.2%

N86156 001 JUL CRLD

NITROGLYCERIN
AEROSOL; SUBLINGUAL

NITROLINGUAL				
@ FIRST HORIZON	0.4MG/SPRAY	N18705 001	OCT 31, 1985	APR CAHN
@ POHL BOSKAMP	0.4MG/SPRAY	N18705 001	OCT 31, 1985	JUN CAHN
SPRAY, METERED; SUBLINGUAL				
NITROLINGUAL PUMPSPRAY				
+ FIRST HORIZON	0.4MG/SPRAY	N18705 002	JAN 10, 1997	APR CAHN
+ POHL BOSKAMP	0.4MG/SPRAY	N18705 002	JAN 10, 1997	JUN CAHN
TABLET; SUBLINGUAL				
NITROSTAT				
PFIZER PHARMS	0.4MG	N21134 002	MAY 01, 2000	JUN CAHN

NIZATIDINE

CAPSULE; ORAL

AXID				
>D>	LILLY	150MG	N19508 001	APR 12, 1988 JUL CFTG
>A>	AB	150MG	N19508 001	APR 12, 1988 JUL CFTG
>D>	+	300MG	N19508 002	APR 12, 1988 JUL CFTG
>A>	AB +	300MG	N19508 002	APR 12, 1988 JUL CFTG
>A>	NIZATIDINE			
>A>	AB EON	150MG	N76178 001	JUL 05, 2002 JUL NEWA
>A>	AB	300MG	N76178 002	JUL 05, 2002 JUL NEWA
>A>	AB GENPHARM	150MG	N75934 001	JUL 09, 2002 JUL NEWA
>A>	AB	300MG	N75934 002	JUL 09, 2002 JUL NEWA
>A>	AB MYLAN	150MG	N75806 001	JUL 05, 2002 JUL NEWA
>A>	AB	300MG	N75806 002	JUL 05, 2002 JUL NEWA
>A>	AB WATSON LABS	150MG	N75616 001	JUL 09, 2002 JUL NEWA
>A>	AB	300MG	N75616 002	JUL 09, 2002 JUL NEWA
>A>	AB ZENITH GOLDLINE	150MG	N75461 001	JUL 08, 2002 JUL NEWA
>A>	AB	300MG	N75461 002	JUL 08, 2002 JUL NEWA

NORETHINDRONE

TABLET; ORAL

NOR-QD

+ WATSON LABS (UTAH) 0.35MG

N17060 001 MAY CAHN

NORTRIPTYLINE HYDROCHLORIDE

SOLUTION; ORAL

AVENTYL HCL

AA + RANBAXY EQ 10MG BASE/5ML

N14685 001 JUN CAHN

NOVOBIOCIN SODIUM

CAPSULE; ORAL

ALBAMYCIN

@ PHARMACIA AND UPJOHN EQ 250MG BASE

N50339 001 JUN DISC

NYSTATIN

TABLET; ORAL

NILSTAT

@ LEDERLE 500,000 UNITS

N61151 001 JUN DISC

NYSTATIN

TABLET; VAGINAL
>D> NILSTAT
>D> AT LEDERLE 100,000 UNITS N61325 001 JUL DISC
>A> @ 100,000 UNITS N61325 001 JUL DISC

OFLOXACIN

INJECTABLE; INJECTION
FLOXIN
AP + JOHNSON RW 40MG/ML N20087 003 MAR 31, 1992 JAN CFTG
OFLOXACIN
AP BEDFORD 40MG/ML N75762 001 JAN 16, 2002 JAN NEWA

OLMESARTAN MEDOXOMIL

TABLET; ORAL
BENICAR
SANKYO 5MG N21286 001 APR 25, 2002 APR NEWA
20MG
+ 40MG N21286 003 APR 25, 2002 APR NEWA
N21286 004 APR 25, 2002 APR NEWA

OXANDROLONE

TABLET; ORAL
OXANDRIN
BIO TECH GEN 2.5MG N13718 001 JUN CRLD
+ 10MG N13718 002 NOV 05, 2001 JUN NEWA

OXAPROZIN

TABLET; ORAL
OXAPROZIN
AB CARACO 600MG N75844 001 JAN 03, 2002 JAN NEWA
AB IVAX PHARMS 600MG N75846 001 MAY 13, 2002 MAY NEWA
>A> AB TEVA 600MG N75849 001 JUL 03, 2002 JUL NEWA

PACLITAXEL

INJECTABLE; INJECTION
PACLITAXEL
AP ABBOTT 6MG/ML N76131 001 MAY 08, 2002 MAY NEWA

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
PAMIDRONATE DISODIUM
AP AESGEN 30MG/VIAL N75594 001 MAY 06, 2002 MAY NEWA
AP 90MG/VIAL N75594 002 MAY 06, 2002 MAY NEWA
AP AM PHARM PARTNERS 30MG/VIAL N75773 001 MAY 06, 2002 MAY NEWA
AP 30MG /10ML(3MG/ML) N76207 001 MAY 17, 2002 MAY NEWA
AP 90MG/VIAL N75773 002 MAY 06, 2002 MAY NEWA
AP 90MG /10ML(9MG/ML) N76207 002 MAY 17, 2002 MAY NEWA
AP BEDFORD 30MG /10ML(3MG/ML) N21113 001 MAR 04, 2002 MAY CDFR
AP + 90MG /10ML(9MG/ML) N21113 002 MAR 04, 2002 MAY CDFR
AP FAULDING 30MG /10ML(3MG/ML) N75841 001 JUN 27, 2002 JUN NEWA
AP 60MG /10ML(6MG/ML) N75841 002 JUN 27, 2002 JUN NEWA
AP 90MG /10ML(9MG/ML) N75841 003 JUN 27, 2002 JUN NEWA
AP GENSIA SICOR PHARMS 30MG /10ML(3MG/ML) N76153 001 MAR 27, 2002 MAY CDFR

>D>

>A>

AP		90MG /10ML(9MG/ML)	N76153 002	MAR 27, 2002	MAY	CDFR
	INJECTABLE; IV (INFUSION)					
AP	BEDFORD	30MG /10ML(3MG/ML)	N21113 001	MAR 04, 2002	MAR	NEWA
AP	+	90MG /10ML(9MG/ML)	N21113 002	MAR 04, 2002	MAR	NEWA
AP	GENSIA SICOR PHARMS	30MG /10ML(3MG/ML)	N76153 001	MAR 27, 2002	MAR	NEWA
AP		90MG /10ML(9MG/ML)	N76153 002	MAR 27, 2002	MAR	NEWA

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE; ORAL						
COTAZYM						
@ ORGANON	30,000USP UNITS;8,000USP UNITS;30,000USP UNITS		N20580 001	DEC 09, 1996	JUN	DISC

PARAMETHADIONE

CAPSULE; ORAL						
PARADIONE						
@ ABBOTT	150MG		N06800 003		JUN	DISC
@	300MG		N06800 001		JUN	DISC

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL						
PEN-VEE K						
@ WYETH AYERST	EQ 125MG BASE/5ML		N60007 001		MAY	DISC
@	EQ 250MG BASE/5ML		N60007 002		MAY	DISC

PENTAGASTRIN

INJECTABLE; INJECTION						
PEPTAVLON						
@ WYETH AYERST	0.25MG/ML		N17048 001		APR	DISC

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL						
ELMIRON						
>D>	+ ALZA	100MG	N20193 001	SEP 26, 1996	JUL	CAHN
>A>	+ JOHNSON AND JOHNSON	100MG	N20193 001	SEP 26, 1996	JUL	CAHN

PHENACEMIDE

TABLET; ORAL						
PHENURONE						
@ ABBOTT	500MG		N07707 001		JUN	DISC

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL						
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL						
@ ABLE	200MG;800MG;160MG		N21105 001	JUN 26, 2001	JUN	DISC

PHENDIMETRAZINE TARTRATE

TABLET; ORAL						
PHENDIMETRAZINE TARTRATE						
AA MIKART	35MG		N89452 001	OCT 30, 1991	MAR	CMFD

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HCL

AA VINTAGE PHARMS 37.5MG

N40377 001 JAN 04, 2002 JAN NEWA

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

PREFRIN-A

@ ALLERGAN 0.12%;0.1%

N07953 001

JUN DISC

PHENYTOIN

SUSPENSION; ORAL

PHENYTOIN

AB MORTON GROVE 125MG/5ML

N40420 001 APR 19, 2002 APR NEWA

PILOCARPINE

DRUG DELIVERY SYSTEM; OPHTHALMIC

OCUSERT PILO-40

@ AKORN 11MG

N17548 001

JUN DISC

INSERT, EXTENDED RELEASE; OPHTHALMIC

OCUSERT PILO-20

@ AKORN 5MG

N17431 001

JUN DISC

PIPECURONIUM BROMIDE

INJECTABLE; INJECTION

ARDUAN

@ ORGANON 10MG/VIAL

N19638 001 JUN 26, 1990 JUN DISC

PODOFILOX

SOLUTION; TOPICAL

CONDYLOX

AT + PADDICK 0.5%

N19795 001 DEC 13, 1990 JAN CFTG

AT PADDICK 0.5%

N75600 001 JAN 29, 2002 JAN NEWA

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB ANDRX PHARMS 10MEQ

N75604 001 APR 10, 2002 APR NEWA

AB 20MEQ

N75604 002 APR 10, 2002 APR NEWA

AB KV PHARM 20MEQ

N76044 001 APR 05, 2002 APR NEWA

PRAVASTATIN SODIUM

TABLET; INJECTION

PRAVACHOL

+ BRISTOL MYERS SQUIBB 80MG

N19898 008 DEC 18, 2001 MAR NEWA

TABLET; ORAL

BRISTOL MYERS SQUIBB 40MG

N19898 004 MAR 22, 1993 MAR CRLD

+ 80MG

N19898 008 DEC 18, 2001 APR CDFR

>D>

>D>

>A>

>D>

>A>

>D>

>A>

>A>

>A>

>D>

>D>

>D>

>A>

PREDNICARBATE

CREAM; TOPICAL
DERMATOP
+ DERMIC LABS 0.1% N20279 001 OCT 29, 1993 JUN CAHN

OINTMENT; TOPICAL
+ DERMIC LABS 0.1% N19568 001 SEP 23, 1991 JUN CAHN

PREDNISOLONE

SYRUP; ORAL
PREDNISOLONE
AA KV PHARM 15MG/5ML N40364 001 APR 10, 2002 APR NEWA

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

>D> METIMYD
>D> AT + SCHERING 0.5%;10% N10210 002 SEP 09, 1984 JUL DISC
@ 0.5%;10% N10210 002 SEP 09, 1984 JUL DISC

>A> SUSPENSION; OPHTHALMIC
ISOPTO CETAPRED
@ ALCON 0.25%;10% N87547 001 JUN DISC

SUSPENSION/DROPS; OPHTHALMIC
METIMYD
+ SCHERING 0.5%;10% N10210 001 JUL DISC
@ 0.5%;10% N10210 001 JUL DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL
ORAPRED
>D> + ASCENT PEDS EQ 15MG BASE/5ML N75117 001 DEC 14, 2000 JUL CFTG
>A> AA + EQ 15MG BASE/5ML N75117 001 DEC 14, 2000 JUL CFTG

PEDIAFRED
AA + CELLTECH PHARMS EQ 5MG BASE/5ML N19157 001 MAY 28, 1986 JUN CFTG

>A> PREDNISOLONE SODIUM PHOSPHATE
AA MORTON GROVE EQ 5MG BASE/5ML N75099 001 JUN 28, 2002 JUN NEWA
AA WE PHARMS EQ 15MG BASE/5ML N75250 001 JUL 12, 2002 JUL NEWA

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION
HYDELTRA-TBA
@ MERCK 20MG/ML N10562 001 JUN DISC

PREDNISONE

TABLET; ORAL
PREDNISONE
>A> AB VINTAGE PHARMS 5MG N40256 001 JUL 12, 2002 JUL NEWA
>A> AB 10MG N40256 002 JUL 12, 2002 JUL NEWA

PRIMIDONE

SUSPENSION; ORAL
MYSOLINE
>D> + XCEL PHARMS 250MG/5ML N10401 001 JUL DISC
>A> @ 250MG/5ML N10401 001 JUL DISC

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL
COMPAZINE
⑧ GLAXOSMITHKLINE EQ 10MG BASE
+ EQ 10MG BASE
⑧ EQ 15MG BASE
+ EQ 15MG BASE
⑧ EQ 30MG BASE

N11000 001 JUN DISC
N21019 001 OCT 06, 1999 JUN CRLD
N11000 002 JUN DISC
N21019 002 OCT 06, 1999 JUN CRLD
N11000 003 JUN DISC

PROGESTERONE

INSERT, EXTENDED RELEASE; INTRAUTERINE
PROGESTASERT
⑧ ALZA 38MG

N17553 001 JUN DISC

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
SPARINE
⑧ WYETH AYERST 50MG/ML
TABLET; ORAL
⑧ WYETH AYERST 25MG
⑧ 50MG

N10349 006 JUN DISC
N10348 001 JUN DISC
N10348 002 JUN DISC

>A>
>D>

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL
PHENERGAN
AB + WYETH AYERST 25MG
PROMETHAZINE HCL
AB G AND W LABS 25MG
SYRUP; ORAL
PHENERGAN FORTIS
⑧ WYETH AYERST 25MG/5ML

N10926 001 FEB CTEC
N40428 001 FEB 05, 2002 FEB NEWA
N08381 003 JUN DISC

>A>
>D>
>A>

PROPafenone HYDROCHLORIDE

TABLET; ORAL
PROPafenone HCL
AB KV PHARM 150MG
AB 225MG
AB 300MG

N76193 001 FEB 07, 2002 FEB NEWA
N76193 002 FEB 07, 2002 FEB NEWA
N76193 003 FEB 07, 2002 FEB NEWA

>D>

PROPOXYphene HYDROCHLORIDE

CAPSULE; ORAL
DARVON
AA + AAI PHARMA 32MG
AA + 65MG

N10997 001 JUN CAHN
N10997 003 JUN CAHN

>D>
>A>

PROPOXYphene NAPsylate

SUSPENSION; ORAL
DARVON-N
+ NEOSAN PHARMS 50MG/5ML
TABLET; ORAL
+ AAIPHARMA LLC 100MG

N16861 001 JUN CAHN
N16862 002 JUN CAHN

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL

⊕ LEDERLE	60MG
⊕	80MG
⊕	90MG
⊕ PUREPAC PHARM	10MG
⊕	20MG
⊕	40MG
⊕	60MG
⊕	80MG

N71495 001	DEC 31, 1987	FEB	DISC
N70128 001	JUL 30, 1985	MAY	CAHN
N71496 001	DEC 31, 1987	FEB	DISC
N70814 001	NOV 03, 1986	MAY	DISC
N70815 001	NOV 03, 1986	MAY	DISC
N70816 001	NOV 03, 1986	MAY	DISC
N70817 001	NOV 03, 1986	MAY	DISC
N70757 001	NOV 03, 1986	MAY	DISC

PYRAZINAMIDE

TABLET; ORAL

PYRAZINAMIDE

>A>	AB	+	CLONMEL	500MG
>D>	AB	+	LEDERLE	500MG

N80157 001	JUL	CAHN
N80157 001	JUL	CAHN

QUINETHAZONE

TABLET; ORAL

HYDROMOX

⊕ LEDERLE

50MG

N13264 001 APR DISC

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

ACIPHEX

>A>	⊕ EISAI MEDCL RES	10MG
>D>	⊕	20MG
>A>	+	20MG
	+	20MG
	+	20MG
>D>		10MG

N20973 001	MAY 29, 2002	JUL	DISC
N20973 002	AUG 19, 1999	JUL	CMFD
N20973 002	AUG 19, 1999	JUL	CMFD
N20973 002	AUG 19, 1999	MAY	CAHN
N20973 002	AUG 19, 1999	JUN	DISC
N20973 001	MAY 29, 2002	JUL	DISC

RAPACURONIUM BROMIDE

INJECTABLE; INJECTION

RAPLON

⊕ ORGANON

⊕

100MG/VIAL

200MG/VIAL

N20984 001 AUG 18, 1999 JUN DISC
N20984 002 AUG 18, 1999 JUN DISCRISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

>D>	+	PROCTER AND GAMBLE	30MG
>A>			30MG
>A>	+		35MG

N20835 001	MAR 27, 1998	JUL	CRLD
N20835 001	MAR 27, 1998	JUL	CRLD
N20835 003	MAY 25, 2002	JUL	NEWA

RITONAVIR

CAPSULE; ORAL

NORVIR

⊕ ABBOTT

+

100MG

100MG

N20680 001 MAR 01, 1996 JUN DISC
N20945 001 JUN 29, 1999 JUN CRLD

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ZEMURON

@ ORGANON

10MG/ML

N20214 002 MAR 17, 1994 JUN DISC

>A>
>A>
>A>
>A>SECOCARBITAL SODIUM

CAPSULE; ORAL

SECONAL SODIUM

+ RANBAXY

50MG

N86101 001 OCT 03, 1983 JUN CAHN

AA + 100MG

N86101 002 OCT 03, 1983 JUN CAHN

SECRETIN

FOR SOLUTION; INTRAVENOUS

SECREFLO

+ CHIRHOCLIN

16UGM/VIAL

N21209 001 APR 04, 2002 APR NEWA

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

SELEGILINE HCL

AB CLONMEL HLTHCARE

5MG

N75352 001 NOV 30, 1998 JUN CAHN

TABLET; ORAL

AB CLONMEL HLTHCARE

5MG

N74641 001 AUG 02, 1996 APR CAHN

SELENOMETHIONINE, SE-75

INJECTABLE; INJECTION

SELENOMETHIONINE SE 75

@ CIS

500uCi/ML

N17322 001 JUN DISC

SIMETHICONE-CELLULOSE

SUSPENSION; ORAL

SONORX

@ BRACCO

7.5MG/ML

N20773 001 OCT 29, 1998 JUN DISC

SIROLIMUS

TABLET; ORAL

RAPAMUNE

+ WYETH AYERST

1MG

N21110 001 AUG 25, 2000 JUN NEWA

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; ORAL

UCEPHAN

@ B BRAUN

100MG/ML;100MG/ML

N19530 001 DEC 23, 1987 JUN DISC

SODIUM IODIDE, I-131

CAPSULE; ORAL

IODOTOPE

@ BRACCO

1-150mCi

N10929 003 JUN DISC

SOLUTION; ORAL

@ BRACCO

7-106mCi/BOT

N10929 002 JUN DISC

>A> SODIUM OXYBATE
 >A> SOLUTION; ORAL
 >A> XYREM
 >A> + ORPHAN MEDCL 500MG/ML N21196 001 JUL 17, 2002 JUL NEWA

SOMATROPIN RECOMBINANT
 INJECTABLE; INJECTION
 NORDITROPIN
 @ NOVO NORDISK 4MG/VIAL N19721 001 MAY 08, 1995 JUN DISC
 @ 8MG/VIAL N19721 002 MAY 08, 1995 JUN DISC
 NUTROPIN AQ PEN
 BX + GENENTECH 5MG/ML N20522 002 APR 22, 2002 JUN NEWA
 SEROSTIM
 BX + SERONO 4MG/VIAL N20604 003 JUL 25, 1997 JUN CRLD
 BX 6MG/VIAL N20604 001 AUG 23, 1996 JUN CRLD
 SEROSTIM IN PLASTIC CONTAINER
 BX + SERONO 8.8MG/VIAL N20604 004 SEP 06, 2001 JUN NEWA
 TEV-TROVIN
 BX + BIO TECH GEN 5MG/ML N19774 002 JAN 04, 2002 JUN NEWA

SPECTINOMYCIN HYDROCHLORIDE
 INJECTABLE; INJECTION
 TROBICIN
 @ PHARMACIA AND UPJOHN EQ 4GM BASE/VIAL N50347 002 JUN DISC

SUCCINYLCHOLINE CHLORIDE
 INJECTABLE; INJECTION
 QUELICIN PRESERVATIVE FREE
 @ ABBOTT 50MG/ML N08845 002 JUN DISC

SULFAMETHIZOLE
 TABLET; ORAL
 THIOSULFIL
 @ WYETH AYERST 500MG N08565 004 JUN DISC

SULFAMETHOXAZOLE
 TABLET; ORAL
 GANTANOL
 @ ROCHE 500MG N12715 002 MAY CTEC

SULFAMETHOXAZOLE; TRIMETHOPRIM
 SUSPENSION; ORAL
 BACTRIM PEDIATRIC
 @ WOMEN FIRST HLTHCARE 200MG/5ML;40MG/5ML N17560 002 APR DISC
 SEPTRA
 AB + MONARCH PHARMS 200MG/5ML;40MG/5ML N17598 001 APR CRLD

SULFAPYRIDINE
 TABLET; ORAL
 SULFAPYRIDINE
 @ LILLY 500MG N00159 001 JUN DISC

<u>SULFASALAZINE</u>			
TABLET; ORAL			
	SULFASALAZINE		
AB	VINTAGE PHARMS	500MG	N40349 001 JAN 11, 2002 JAN NEWA
	TABLET, DELAYED RELEASE; ORAL		
	AZULFIDINE EN-TABS		
AB	+ PHARMACIA AND UPJOHN	500MG	N07073 002 APR 06, 1983 JAN CFTG
	SULFASALAZINE		
AB	VINTAGE PHARMS	500MG	N75339 001 JAN 11, 2002 JAN NEWA
<u>SULFISOXAZOLE ACETYL</u>			
SYRUP; ORAL			
	GANTRISIN		
@ ROCHE		EQ 500MG BASE/5ML	N09182 002 JUN DISC
<u>SUMATRIPTAN SUCCINATE</u>			
TABLET; ORAL			
	IMITREX		
	GLAXOSMITHKLINE	EQ 50MG BASE	N20132 003 JUN 01, 1995 JUN CRLD
+		EQ 100MG BASE	N20132 001 JUN 01, 1995 JUN CMFD
<u>SUPROFEN</u>			
SOLUTION/DROPS; OPHTHALMIC			
	PROFENAL		
@ ALCON		1%	N19387 001 DEC 23, 1988 JUN DISC
<u>TECHNETIUM TC-99M ALBUMIN COLLOID KIT</u>			
INJECTABLE; INJECTION			
	MICROLITE		
@ CIS		N/A	N18263 001 MAR 25, 1983 JUN DISC
<u>TECHNETIUM TC-99M ALBUMIN KIT</u>			
>D>	INJECTABLE; INJECTION		
>D>	TECHNETIUM TC 99M HSA		
>D>	AMERSHAM HLTH	N/A	N17775 001 JUL DISC
>A>	@	N/A	N17775 001 JUL DISC
<u>TECHNETIUM TC-99M RED BLOOD CELL KIT</u>			
INJECTABLE; INJECTION			
	RBC-SCAN		
@ CADEMA		N/A	N20063 001 JUN 11, 1992 JUN DISC
<u>TECHNETIUM TC-99M SODIUM PERTECHNETATE</u>			
SOLUTION; INJECTION, ORAL			
	SODIUM PERTECHNETATE TC 99M		
@ MALLINCKRODT		10-60mCi/ML	N17725 001 JUN DISC
<u>TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR</u>			
SOLUTION; INJECTION, ORAL			
	TECHNETIUM TC 99M GENERATOR		
@ AMERSHAM HLTH		830-1660mCi/GENERATOR	N17693 001 JUN DISC

>A> TEGASEROD MALEATE
 >A> TABLET; ORAL
 >A> ZELNORM
 >A> NOVARTIS 2MG N21200 001 JUL 24, 2002 JUL NEWA
 >A> + 6MG N21200 002 JUL 24, 2002 JUL NEWA

TERBINAFINE
 GEL; TOPICAL
 LAMISIL
 @ NOVARTIS 1% N20846 001 APR 29, 1998 JUN DISC

TERBUTALINE SULFATE
 INJECTABLE; INJECTION
 BRETHINE
 >A> + AAIPHARMA 1MG/ML N18571 001 JUL CAHN
 >D> + NEOSAN PHARMS 1MG/ML N18571 001 JUL CAHN
 >D> + 1MG/ML N18571 001 FEB CAHN

TABLET; ORAL
 >A> AB AAIPHARMA 2.5MG N17849 001 JUL CAHN
 >A> AB + 5MG N17849 002 JUL CAHN
 >D> AB NEOSAN PHARMS 2.5MG N17849 001 JUL CAHN
 AB 2.5MG N17849 001 FEB CAHN
 >D> AB + 5MG N17849 002 JUL CAHN
 AB + 5MG N17849 002 FEB CAHN

TESTOSTERONE
 FILM, EXTENDED RELEASE; TRANSDERMAL
 TESTODERM TTS
 BX + ALZA 5MG/24HR N20791 001 DEC 18, 1997 JAN CTNA

TETRACYCLINE HYDROCHLORIDE
 FIBER, EXTENDED RELEASE; PERIODONTAL
 ACTISITE
 + ALZA 12.7MG/FIBER N50653 001 MAR 25, 1994 FEB CAHN

>D> FOR SOLUTION; TOPICAL
 >D> TOPICYCLINE
 >D> + SHIRE LABS 2.2MG/ML N50493 001 JUL DISC
 >A> @ 2.2MG/ML N50493 001 JUL DISC

>D> INJECTABLE; INJECTION
 >D> ACHROMYCIN
 @ LEDERLE 250MG/VIAL N50273 002 JUN DISC
 >D> + 500MG/VIAL N50273 003 JUL DISC
 >A> @ 500MG/VIAL N50273 003 JUL DISC
 + 500MG/VIAL N50273 003 JUN CRLD

SUSPENSION; ORAL
 ACHROMYCIN V
 @ LEDERLE 125MG/5ML N50263 002 APR DISC
 SUMYCIN
 + APOTHECON 125MG/5ML N60400 001 APR CTEC

TABLET; ORAL
 @ PAR PHARM 50MG N61147 003 MAY CAHN
 @ 100MG N61147 002 MAY CAHN

+	250MG 500MG	N61147 001 N61147 004	MAY CAHN MAY CAHN
<u>HIMELPERAZINE MALATE</u>			
INJECTABLE; INJECTION			
TORECAN			
@ NOVARTIS	5MG/ML	N12754 002	JUN DISC
<u>HIDRODIAZINE</u>			
SUSPENSION; ORAL			
MELLARIL-S			
@ NOVARTIS	EQ 25MG HCL/5ML	N17923 001	JUN DISC
@	EQ 100MG HCL/5ML	N17923 002	JUN DISC
<u>IOTEPA</u>			
INJECTABLE; INJECTION			
THIOTEP A			
AM PHARM PARTNERS	15MG/VIAL	N75698 001	SEP 20, 2001 FEB CAHN
<u>THIOTHIXENE HYDROCHLORIDE</u>			
CONCENTRATE; ORAL			
THIOTHIXENE HCL INTENSOL			
@ ROXANE	EQ 5MG BASE/ML	N73494 001	JUN 30, 1992 JAN DISC
<u>GABINE HYDROCHLORIDE</u>			
ABLET; ORAL			
GABITRIL			
CEPHALON	16MG	N20646 003	SEP 30, 1997 JUN CRLD
@	20MG	N20646 004	SEP 30, 1997 JUN DISC
<u>ZAPARIN SODIUM</u>			
INJECTABLE; INJECTION			
INNOHEP			
LEO PHARM	20,000 IU/ML	N20484 001	JUL 14, 2000 JUL CAHN
	20,000 IU/ML	N20484 001	JUL 14, 2000 APR CAHN
PHARMION	20,000 IU/ML	N20484 001	JUL 14, 2000 JUL CAHN
<u>TIZANIDINE HYDROCHLORIDE</u>			
BLET; ORAL			
TIZANIDINE HCL			
DR REDDYS LABS INC	EQ 2MG BASE	N76286 001	JUL 03, 2002 JUL NEWA
	EQ 4MG BASE	N76286 002	JUL 03, 2002 JUL NEWA
EON	EQ 4MG BASE	N76280 002	JUN 27, 2002 JUN NEWA
PUREPAC PHARM	EQ 2MG BASE	N76283 001	JUL 12, 2002 JUL NEWA
	EQ 4MG BASE	N76283 002	JUL 12, 2002 JUL NEWA
TEVA	EQ 2MG BASE	N76284 001	JUL 03, 2002 JUL NEWA
	EQ 4MG BASE	N76284 002	JUL 03, 2002 JUL NEWA
ANAFLEX			
ELAN PHARMS	EQ 4MG BASE	N20397 001	NOV 27, 1996 JUN CFTG

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

AT NOVEX 0.3%

N65087 001 FEB 25, 2002 FEB NEWA

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

@ ASTRazeneca

EQ 40MG BASE/ML

@

EQ 40MG BASE/ML

N63120 001 OCT 31, 1994 FEB DISC

N63122 001 OCT 31, 1994 JAN DISC

TOLAZOLINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRISCOLINE

@ NOVARTIS

25MG/ML

N06403 005 FEB 22, 1985 JUN DISC

TOPIRAMATE

TABLET; ORAL

TOPAMAX

+ JOHNSON AND JOHNSON

25MG

@

50MG

@

100MG

@

200MG

@

300MG

@

400MG

N20505 004 DEC 24, 1996 JAN CAHN

N20505 005 DEC 24, 1996 JAN CAHN

N20505 001 DEC 24, 1996 JAN CAHN

N20505 002 DEC 24, 1996 JAN CAHN

N20505 003 DEC 24, 1996 JAN CAHN

N20505 006 DEC 24, 1996 JAN CAHN

TORSEMIDE

TABLET; ORAL

DEMADEX

AB ROCHE

5MG

AB

10MG

AB +

20MG

AB

100MG

N20136 001 AUG 23, 1993 MAY CFTG

N20136 002 AUG 23, 1993 MAY CFTG

N20136 003 AUG 23, 1993 MAY CFTG

N20136 004 AUG 23, 1993 MAY CFTG

TORSEMIDE

AB TEVA

5MG

AB

10MG

AB

20MG

AB

100MG

N76110 001 MAY 14, 2002 MAY NEWA

N76110 002 MAY 14, 2002 MAY NEWA

N76110 003 MAY 14, 2002 MAY NEWA

N76110 004 MAY 14, 2002 MAY NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HCL

>A>	AB	ABLE	50MG
>A>	AB	ASTA	50MG
	AB	CARACO	50MG
	AB	COREPHARMA	50MG
	AB	EON	50MG
	AB	MALLINCKRODT	50MG
	AB	MUTUAL PHARM	50MG
	AB	MYLAN	50MG
	AB	PUREPAC PHARM	50MG
>A>	AB	SIDMAK LABS	50MG

N75963 001 JUL 03, 2002 JUL NEWA

N75974 001 JUL 12, 2002 JUL NEWA

N75964 001 JUN 19, 2002 JUN NEWA

N76003 001 JUN 20, 2002 JUN NEWA

N75968 001 JUN 25, 2002 JUN NEWA

N75983 001 JUN 25, 2002 JUN NEWA

N76100 001 JUN 20, 2002 JUN NEWA

N75986 001 JUN 21, 2002 JUN NEWA

N75960 001 JUN 19, 2002 JUN NEWA

N75982 001 JUL 01, 2002 JUL NEWA

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

1-64

>A>	AB	TEVA	50MG			
	AB	TORPHARM	50MG	N75977 001	JUN 19, 2002	JUN NEWA
	AB	WATSON LABS	50MG	N75981 001	JUL 10, 2002	JUL NEWA
		ULTRAM		N75962 001	JUN 24, 2002	JUN NEWA
	+ AB	JOHNSON AND JOHNSON	50MG			
	@			N20281 002	MAR 03, 1995	FEB CAHN
	AB +	ORTHO MCNEIL PHARM	100MG	N20281 001	MAR 03, 1995	FEB CAHN
			50MG	N20281 002	MAR 03, 1995	JUN CTEC
		<u>TREPROSTINIL SODIUM</u>				
		INJECTABLE; SUBCUTANEOUS				
		REMODULIN				
		UNITED THERAP	1MG/ML			
			2.5MG/ML	N21272 001	MAY 21, 2002	MAY NEWA
			5MG/ML	N21272 002	MAY 21, 2002	MAY NEWA
		+	10MG/ML	N21272 003	MAY 21, 2002	MAY NEWA
				N21272 004	MAY 21, 2002	MAY NEWA
		<u>TRETINOIN</u>				
		GEL; TOPICAL				
		RETIN-A				
	AB +	JOHNSON AND JOHNSON	0.01%	N17955 001		JUN CFTG
		TRETINOIN				
	AB	SPEAR PHARMS	0.01%	N75589 001	JUN 11, 2002	JUN NEWA
		<u>TRIAMCINOLONE</u>				
		TABLET; ORAL				
		ARISTOCORT				
>D>		FUJISAWA HLTHCARE	1MG			
>A>	@		1MG	N11161 009		JUL DISC
>D>			2MG	N11161 009		JUL DISC
>A>	@		2MG	N11161 004		JUL DISC
>D>	BP +		2MG	N11161 004		JUL DISC
>A>	@		8MG	N11161 011		JUL DISC
			8MG	N11161 011		JUL DISC
		<u>TRIAMCINOLONE ACETONIDE</u>				
		INJECTABLE; INJECTION				
		KENALOG-10				
		APOTHECON	10MG/ML			
		KENALOG-40				
BP +		APOTHECON	40MG/ML	N12041 001		JUN CRLD
		TRIAMCINOLONE ACETONIDE				
	@	PARNELL		N14901 001		JUN CRLD
		SPRAY, METERED; NASAL				
		TRI-NASAL	3MG/ML			
	@	MURO	0.05MG/SPRAY	N19503 001	OCT 16, 1987	JUN DISC
		<u>TRIAMCINOLONE DIACETATE</u>		N20120 001	FEB 04, 2000	JUN DISC
		SYRUP; ORAL				
		ARISTOCORT				
>D>		FUJISAWA HLTHCARE	2MG/5ML			
>A>	@		2MG/5ML	N11960 004		JUL DISC
				N11960 004		JUL DISC

>D>

>D>

>A>

TRIFLUUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

VESPRIN

@ APOTHECON

10MG/ML

N11325 004

JUN DISC

@

20MG/ML

N11325 001

JUN DISC

TRILOSTANE

CAPSULE; ORAL

MODRASTANE

@ BIOENVISION

30MG

N18719 002 DEC 31, 1984 JUN CAHN

@

60MG

N18719 001 DEC 31, 1984 JUN CAHN

TRIMETHADIONE

CAPSULE; ORAL

TRIDIIONE

@ ABBOTT

300MG

N05856 005

JUN DISC

SOLUTION; ORAL

@ ABBOTT

200MG/5ML

N05856 002

JUN DISC

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TIGAN

+ KING PHARMS

300MG

N17531 006 DEC 13, 2001 JAN NEWA

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HCL

@ STERIS

100MG/ML

N87939 001 DEC 28, 1982 FEB DISC

TRIOXSALEN

TABLET; ORAL

TRISORALEN

@ ICN

5MG

N12697 001

JUN DISC

TRIPEENNAMINE CITRATE

ELIXIR; ORAL

PBZ

@ NOVARTIS

EQ 25MG HCL/5ML

N05914 004

JUN DISC

TRIPEENNAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PBZ-SR

@ NOVARTIS

100MG

N10533 001

JUN DISC

TRIPLE SULFA (SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE)

TABLET; VAGINAL

SULTRIN

@ ORTHO MCNEIL PHARM

184MG; 143.75MG; 172.5MG

N05794 002

JUN DISC

UREA, C-13

FOR SOLUTION; ORAL

>D>

PYLORI-CHEK BREATH TEST

>D>

+ ALIMENTERICS

100MG/VIAL

N20900 001 FEB 04, 1999 JUL DISC

>A>

@

100MG/VIAL

N20900 001 FEB 04, 1999 JUL DISC

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS					
BRAVELLE					
BX + FERRING	75 IU/VIAL			N21289 001	MAY 06, 2002
INJECTABLE; SUBCUTANEOUS				MAY	NEWA
FERTINEX					
BX + SERONO	75 IU/AMP			N19415 005	AUG 23, 1996
@	150 IU/AMP			MAY	CTEC

URSODIOL

CAPSULE; ORAL					
ACTIGALL					
@ WATSON PHARMS	150MG			N19594 001	DEC 31, 1987
AB +	300MG			FEB	CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL					
VALTREX					
@ GLAXOSMITHKLINE	EQ 500MG BASE			N20487 001	JUN 23, 1995
@	EQ 1GM BASE			MAR	DISC
				N20487 002	JUN 23, 1995
				MAR	DISC

VALSARTAN

CAPSULE; ORAL					
DIOVAN					
@ NOVARTIS	80MG			N20665 001	DEC 23, 1996
@	160MG			JUN	DISC
				N20665 002	DEC 23, 1996
				JUN	DISC

VECURONIUM BROMIDE

INJECTABLE; INJECTION					
NORCURON					
+ @ ORGANON	20MG/VIAL			N18776 003	JAN 03, 1992
				JUN	DISC

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL					
EFFEXOR XR					
WYETH AYERST	EQ 37.5MG BASE			N20699 001	OCT 20, 1997
	EQ 150MG BASE			MAY	CRLD
				N20699 004	OCT 20, 1997
				MAY	CRLD

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL					
VERELAN					
AB + ELAN DRUG	120MG			N19614 001	MAY 29, 1990
AB +	180MG			APR	CAHN
AB +	240MG			N19614 003	JAN 09, 1992
+	360MG			APR	CAHN
				N19614 002	MAY 29, 1990
				APR	CAHN
				N19614 004	MAY 10, 1996
				APR	CAHN

VITAMIN A PALMITATE

INJECTABLE; INJECTION					
AQUASOL A					
>A> + AAIPHARMA	EQ 50,000 UNITS BASE/ML			N06823 001	JUL
>D> + NEOSAN PHARMS	EQ 50,000 UNITS BASE/ML			CAHN	

VORICONAZOLE

INJECTABLE; IV (INFUSION)

VFEND	200MG/VIAL	N21267 001	MAY 24, 2002	MAY	NEWA
+ PFIZER					
TABLET; ORAL		N21266 001	MAY 24, 2002	MAY	NEWA
PFIZER	50MG	N21266 002	MAY 24, 2002	MAY	NEWA
+	200MG				

XENON, XE-127

GAS; INHALATION

XENON XE 127		N18536 001	OCT 01, 1982	JUN	DISC
@ MALLINCKRODT	5mCi/VIAL	N18536 002	OCT 01, 1982	JUN	DISC
@	10mCi/VIAL				

XYLOSE

>D>	POWDER; ORAL				
>D>	XYLOSE				
>D>	+ LYNE	25GM/BOT	N18856 001	MAR 26, 1987	JUL DISC
>A>	@	25GM/BOT	N18856 001	MAR 26, 1987	JUL DISC

ZILEUTON

TABLET; ORAL					
ZYFLO					
>D>	+ ABBOTT	300MG	N20471 001	DEC 09, 1996	JUL DISC
>A>	@	300MG	N20471 001	DEC 09, 1996	JUL DISC
	+	300MG	N20471 001	DEC 09, 1996	JUN CRLD

ZIPRASIDONE MESYLATE

INJECTABLE; INTRAMUSCULAR

GEODON					
+ PFIZER	EQ 20MG BASE/ML	N20919 001	JUN 21, 2002	JUN	NEWA

ZOLMITRIPTAN

TABLET, ORALLY DISINTEGRATING; ORAL

ZOMIG-ZMT					
+ ASTRazeneca	5MG	N21231 002	SEP 17, 2001	JUN	NEWA

>A>

>A>

>A>

>A>

ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

COREPHARMA 650MG

N76200 001 MAR 19, 2002 MAR NEWA

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONTAC 12 HOUR

@ GLAXOSMITHKLINE 8MG;75MG

N18099 001 JAN DISC

PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE

@ CENT PHARMS 8MG;75MG

N18809 001 MAY 07, 1984 FEB DISC

CIMETIDINE

TABLET; ORAL

CIMETIDINE

>A> TORPHARM 200MG

N74948 002 JUL 26, 2002 JUL NEWA

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

TORPHARM 10MG

N75610 001 MAR 12, 2002 MAR NEWA

>A> GUAIFENESIN

>A> TABLET, EXTENDED RELEASE; ORAL

>A> MUCINEX

>A> ADAMS LABS 600MG

N21282 001 JUL 12, 2002 JUL NEWA

IBUPROFEN

TABLET; ORAL

IBUPROFEN

PERRIGO 200MG

N75995 001 MAR 14, 2002 MAR NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

ADVIL COLD AND SINUS

WYETH CONS 200MG;30MG

N21374 001 MAY 30, 2002 MAY NEWA

SUSPENSION; ORAL

CHILDREN'S ADVIL COLD

WYETH CONS 100MG/5ML;15MG/5ML

N21373 001 APR 18, 2002 APR NEWA

TABLET; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HCL

PHARM FORM 200MG;30MG

N75588 001 APR 08, 2002 APR NEWA

INSULIN PURIFIED PORK

INJECTABLE; INJECTION

REGULAR PURIFIED PORK INSULIN

@ NOVO NORDISK 100 UNITS/ML

N18381 001 FEB DISC

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

VELOSULIN BR

+ NOVO NORDISK 100 UNITS/ML

N21028 001 JUL 19, 1999 JUN CMS2

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2002

2-2

<u>INSULIN SUSP ISOPHANE PURIFIED PORK</u> INJECTABLE; INJECTION NPH PURIFIED PORK ISOPHANE INSULIN @ NOVO NORDISK	100 UNITS/ML	N18623 001	FEB DISC
<u>INSULIN ZINC SUSP PURIFIED PORK</u> INJECTABLE; INJECTION LENTE @ NOVO NORDISK	100 UNITS/ML	N18383 001	FEB DISC
<u>KETOPROFEN</u> TABLET; ORAL KETOPROFEN PERRIGO	12.5MG	N75364 001 FEB 07, 2002 FEB NEWA	NO JULY 20
<u>MINOXIDIL</u> SOLUTION; TOPICAL MINOXIDIL EXTRA STRENGTH (FOR MEN) CLAY PARK NOVEX	5% 5%	N75737 001 MAR 15, 2002 MAR NEWA N75839 001 OCT 01, 2001 MAR CTNA	
<u>PSEUDOEPHEDRINE HYDROCHLORIDE</u> TABLET, EXTENDED RELEASE; ORAL SUDAFED 12 HOUR + WARNER LAMBERT	120MG	N73585 001 OCT 31, 1991 MAY CAHN	

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 7 JULY '02

FEB DISC

NO JULY 2002 APPROVALS

FEB DISC

FEB NEWA

MAR NEWA
MAR CTNA

AY CAHN



This data is provided to the Office of Generic Drugs from
the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List July 2002

Generic Name:	albuterol	Trade Name:	NONE ASSIGNED
Designated Indication:	Prevention of paralysis due to spinal cord injury	Date Designated:	3/12/2002
Sponsor:	MotoGen, Inc.	Market Approval Date:	Not currently Approved
Address:	3 Pine View Road Mount Kisco NY 10549		
Generic Name:	autologous antigen presenting cells pulsed with autologous tumor Ig idioype	Trade Name:	Mylovenge
Designated Indication:	Treatment of multiple myeloma	Date Designated:	4/18/2002
Sponsor:	Dendreon Corporation	Market Approval Date:	Not currently Approved
Address:	3005 First Avenue Seattle WA 98121		
Generic Name:	autologous tumor-derived gp96 heat shock protein-peptide complex	Trade Name:	Oncophage
Designated Indication:	Treatment of renal cell carcinoma	Date Designated:	5/10/2002
Sponsor:	Antigenics, Inc.	Market Approval Date:	Not currently Approved
Address:	34 Commerce Way Woburn MA 01702		
Generic Name:	aztreonam	Trade Name:	NONE ASSIGNED
Designated Indication:	Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis	Date Designated:	3/12/2002
Sponsor:	Corus Pharma	Market Approval Date:	Not currently Approved
Address:	2025 First Ave., Suite 800 Seattle WA 98121		
Generic Name:	Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL)	Trade Name:	NONE ASSIGNED
Designated Indication:	Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2	Date Designated:	2/11/2002
Sponsor:	Excorp Medical, Inc.	Market Approval Date:	Not currently Approved
Address:	Suite 235 7200 Hudson Blvd. Oakdale MN 55128		

Orphan Products Designations and Approvals List July 2002

Generic Name:	carbamic acid, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl]methoxy]-phenyl]iminomethyl]-ethyl ester	Trade Name:	NONE ASSIGNED
Designated Indication:	Management of cystic fibrosis		
Sponsor: Address:	Boehringer Ingelheim Pharmaceuticals, Inc 900 Ridgebury Road P.O. Box 368 Ridgefield CT 06877	Date Designated: Market Approval Date:	1/15/2002 Not currently Approved
Generic Name:	clofarabine	Trade Name:	Clofarex
Designated Indication:	Treatment of acute myelogenous leukemia		
Sponsor: Address:	Ilex Products, Inc. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263	Date Designated: Market Approval Date:	3/14/2002 Not currently Approved
Generic Name:	clofarabine	Trade Name:	Clofarex
Designated Indication:	Treatment of acute lymphoblastic leukemia		
Sponsor: Address:	Ilex Products, Inc. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263	Date Designated: Market Approval Date:	2/7/2002 Not currently Approved
Generic Name:	creatine	Trade Name:	Creapure
Designated Indication:	Treatment of amyotrophic lateral sclerosis		
Sponsor: Address:	Avicena Group, Inc. 580 California St. Suite 1600 San Francisco CA 94104	Date Designated: Market Approval Date:	2/12/2002 Not currently Approved
Generic Name:	genetically engineered herpes simplex virus (G207)	Trade Name:	NONE ASSIGNED
Designated Indication:	Treatment of malignant glioma		
Sponsor: Address:	MediGene, Inc. 9880 Campus Point Drive, Suite A San Diego CA 92121	Date Designated: Market Approval Date:	4/29/2002 Not currently Approved
Generic Name:	homoharringtonine	Trade Name:	NONE ASSIGNED
Designated Indication:	Treatment for chronic myelogenous leukemia		
Sponsor: Address:	American BioScience, Inc. 2730 Wilshire Blvd. #110 Santa Monica CA 90403	Date Designated: Market Approval Date:	2/8/2002 Not currently Approved

Orphan Products Designations and Approvals List
July 2002

Generic Name:	human anti-transforming growth factor beta 1 monoclonal antibody	Trade Name:	NONE ASSIGNED
Designated Indication:	Treatment of systemic sclerosis	Date Designated:	1/11/2002
Sponsor: Address:	Genzyme Corporation One Kendall Square Cambridge MA 02139	Market Approval Date:	Not currently Approved
Generic Name:	hyaluronic acid	Trade Name:	NONE ASSIGNED
Designated Indication:	Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency	Date Designated:	3/19/2002
Sponsor: Address:	Exhale Therapeutics, Inc. 1301 Shoreway Road Suite 320 Belmont CA 94002	Market Approval Date:	Not currently Approved
Generic Name:	I(131)-TM-601 (chlorotoxin)	Trade Name:	NONE ASSIGNED
Designated Indication:	treatment of malignant glioma	Date Designated:	2/14/2002
Sponsor: Address:	TransMolecular, Inc. 3800 Colonnade Parkway Suite 240 Birmingham AL 35243	Market Approval Date:	Not currently Approved
Generic Name:	lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococci)	Trade Name:	NONE ASSIGNED
Designated Indication:	Treatment of active chronic pouchitis	Date Designated:	1/15/2002
Sponsor: Address:	VSL Pharmaceuticals, Inc. 800 S. Frederick Avenue Gaithersburg MD 20877	Market Approval Date:	Not currently Approved
Generic Name:	lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)	Trade Name:	NONE ASSIGNED
Designated Indication:	Prevention of disease relapse in patients with chronic pouchitis	Date Designated:	1/15/2002
Sponsor: Address:	VSL Pharmaceuticals, Inc. 800 S. Frederick Ave. Gaithersburg MD 20877	Market Approval Date:	Not currently Approved
Generic Name:	lipase, amylase, and protease	Trade Name:	TheraCLEC-Total
Designated Indication:	Treatment of exocrine pancreatic insufficiency	Date Designated:	1/23/2002
Sponsor: Address:	Altus Biologics Inc. 625 Putnam Avenue Cambridge MA 02139	Market Approval Date:	Not currently Approved

Orphan Products Designations and Approvals List
July 2002

Generic Name:	N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea	Trade Name:	NONE ASSIGNED
Designated Indication:	Treatment of sickle cell disease		
Sponsor: Address:	NeuroSearch A/S 93 Pederstrupvej DK-2750 Ballerup Denmark	Date Designated: Market Approval Date:	5/13/2002 Not currently Approved
Generic Name:	nitazoxanide	Trade Name:	Cryptaz
Designated Indication:	Treatment of intestinal giardiasis		
Sponsor: Address:	Romark Laboratories, L.C. 6200 Courtney Campbell Causeway Suite 880 Tampa FL 33607	Date Designated: Market Approval Date:	2/14/2002 Not currently Approved
Generic Name:	octavalent Psuedomonas aeruginosa O-polysaccharide-toxin A conjugate	Trade Name:	Aerugen
Designated Indication:	Prevention of Psuedomonas aeruginosa infections in patients with cystic fibrosis		
Sponsor: Address:	Orphan Europe Immeuble "Le Wilson" 70 avenue du General de Gaulle, 92046 Paris France	Date Designated: Market Approval Date:	5/16/2002 Not currently Approved
Generic Name:	phenylephrine	Trade Name:	NONE ASSIGNED
Designated Indication:	Treatment of ileal pouch anal anastomosis related fecal incontinence		
Sponsor: Address:	S.L.A. Pharma Unit 3, Hill Farm Industrial Estate Leavesden, Watford United Kingdom WD25 7SA	Date Designated: Market Approval Date:	2/14/2002 Not currently Approved
Generic Name:	recombinant human endostatin protein	Trade Name:	NONE ASSIGNED
Designated Indication:	Treatment of metastatic melanoma		
Sponsor: Address:	EntreMed, Inc. 9640 Medical Center Drive Rockville MD 20850	Date Designated: Market Approval Date:	2/21/2002 Not currently Approved
Generic Name:	recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3	Trade Name:	SomatoKine
Designated Indication:	Treatment of growth hormone insensitivity syndrome		
Sponsor: Address:	Celtrix Pharmaceuticals, Inc. a subsidiary of 4851 Lake Brook Drive Glen Allen VA 23060	Date Designated: Market Approval Date:	5/17/2002 Not currently Approved

Orphan Products Designations and Approvals List
July 2002

Generic Name:	retroviral gamma-c cDNA containing vector	Trade Name:	NONE ASSIGNED
Designated Indication:	Treatment of X linked severe combined immune deficiency disease	Date Designated:	4/29/2002
Sponsor: Address:	AVAX technologies, Inc. 9200 Indian Creek Parkway Building 9, Suite 200 Overland Park KS 66210	Market Approval Date:	Not currently Approved
Generic Name:	rituximab	Trade Name:	Rituxan
Designated Indication:	Treatment of immune thrombocytopenic purpura	Date Designated:	3/12/2002
Sponsor: Address:	Genentech, Inc. 1 DNA Way South San Francisco CA 94080-4990	Market Approval Date:	Not currently Approved
Generic Name:	S(-)-3-[3-amino-phthalimido]-glutaramide	Trade Name:	NONE ASSIGNED
Designated Indication:	Treatment of multiple myeloma	Date Designated:	3/14/2002
Sponsor: Address:	EntreMed Incorporated 9640 Medical Center Dr. Rockville MD 20850	Market Approval Date:	Not currently Approved
Generic Name:	SS1(dsFv)-PE38	Trade Name:	NONE ASSIGNED
Designated Indication:	Treatment of malignant mesothelioma	Date Designated:	2/11/2002
Sponsor: Address:	NeoPharm Incorporated 150 Field Drive Suite 195 Lake Forest IL 60045	Market Approval Date:	Not currently Approved
Generic Name:	SS1(dsFv)-PE38	Trade Name:	NONE ASSIGNED
Designated Indication:	Treatment of epithelial ovarian cancer	Date Designated:	2/11/2002
Sponsor: Address:	NeoPharm, Inc. 150 Field Drive Suite 195 Lake Forest IL 60045	Market Approval Date:	Not currently Approved
Generic Name:	TGF(beta)2-specific phosphorothioate antisense oligodeoxynucleotide	Trade Name:	Oncomun
Designated Indication:	Treatment of malignant glioma	Date Designated:	6/5/2002
Sponsor: Address:	Antisense Pharma GmbH Josef-Engert-Str. 9 93053 Regensberg Germany	Market Approval Date:	Not currently Approved

Orphan Products Designations and Approvals List July 2002

NO JULY

Generic Name:	tinidazole	Trade Name:	NONE ASSIGNED
Designated Indication:	Treatment of giardiasis		
Sponsor: Address:	Presutti Laboratories, Inc. 1607 N. Douglas Ave. Arlington Heights IL 60004	Date Designated: Market Approval Date:	4/18/2002 Not currently Approved
Generic Name:	toralizumab	Trade Name:	NONE ASSIGNED
Designated Indication:	Treatment of immune thrombocytopenic purpura		
Sponsor: Address:	IDEC Pharmaceuticals Corporation 3030 Callan Road San Diego CA 92121	Date Designated: Market Approval Date:	3/14/2002 Not currently Approved

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JULY 2002 ADDITIONS



PRESCRIPITION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 * PED and PED represent Pediatric Exclusivity

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	EXCL CODE	EXCLUS EXPIRES
>ADD>						
021205 001	ABACAVIR SULFATE;TRIZIVIR	6417191	MAR 28,	2016	U-248	
>ADD>		6417191*PED	SEP 28,	2016	U-248	
020503 001	ALBUTEROL SULFATE; PROVENTIL-HFA	6352684	NOV 28,	2009	NP	JUN 11, 2005
021212 001	ALPROSTADIL;CAVERJECT				NP	JUN 11, 2005
021212 002	ALPROSTADIL;CAVERJECT				NS	JUN 20, 2005
020364 005	AMLDIPIINE BESYLATE;LOTREL					
>ADD>						
021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 10	4410520	AUG 11,	2003	I-352	APR 03, 2005
021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 20	4572909	JUL 31,	2006	D-77	APR 22, 2005
021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 30	4879303	MAR 25,	2007	D-77	APR 22, 2005
>ADD>		6162802	DEC 19,	2017	D-77	APR 22, 2005
>ADD>		6322819	NOV 27,	2018	D-77	APR 22, 2005
021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 10	6322819	NOV 27,	2018	D-77	APR 22, 2005
021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 20	6322819	NOV 27,	2018	D-77	APR 22, 2005
021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 30	5925760	AUG 04,	2017	D-77	APR 22, 2005
>ADD>						
020883 001	ARGATROBAN;ARGATROBAN, ATORVASTATIN CALCIUM;LIPIATOR					
020702 001	ATORVASTATIN CALCIUM;LIPIATOR					
020702 002	ATORVASTATIN CALCIUM;LIPIATOR					
020702 003	ATORVASTATIN CALCIUM;LIPIATOR					
020702 004	ATORVASTATIN CALCIUM;LIPIATOR					
020911 002	BECLOMETHASONE DIPROPIONATE;QVAR 40					
020911 001	BECLOMETHASONE DIPROPIONATE;QVAR 80	6352684	NOV 28,	2009	NPP	MAY 10, 2005
021275 001	BIMATOPROST;LUMIGAN	6403649	SEP 21,	2012	U-446	NPP
020490 001	BRIMONIDINE TARTRATE;ALPHAGAN					DEC 20,
020613 001	BRIMONIDINE TARTRATE;ALPHAGAN					JUN 20,
021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P					DEC 20,
018731 001	BUSPIRONE HYDROCHLORIDE;BUSPAR					JUN 20,
018731 002	BUSPIRONE HYDROCHLORIDE;BUSPAR					DEC 20,
018731 003	BUSPIRONE HYDROCHLORIDE;BUSPAR					JUN 20,
018731 004	BUSPIRONE HYDROCHLORIDE;BUSPAR					DEC 20,

PREScription AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 * PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	EXCL CODE	EXCL CODE	EXCLUSIVITY	
020954 001	BUSULFAN; BUSULFEX	5430057 5559148	SEP 30, 2013 MAY 24, 2015	U-263 U-264	ODE NDF	FEB 04, FEB 04,	2006 2002	
>ADD> >ADD>	019881 001	BUTOCONAZOLE NITRATE; GYNAZOLE-1	5430057*PED 5559148*PED	MAR 30, NOV 24,	2014 2015	U-263 U-264	PED PED	
020838 001	CANDESARTAN CILEXETIL; ATACAND	4551148	NOV 30, NOV 05,	2010 2002	U-457			
020838 002	CANDESARTAN CILEXETIL; ATACAND	5196444	JUN 04,	2012	U-3			
020838 003	CANDESARTAN CILEXETIL; ATACAND	5196444	JUN 04,	2012	U-3			
020838 004	CANDESARTAN CILEXETIL; ATACAND	5196444	JUN 04,	2012	U-3			
021093 001	CANDESARTAN CILEXETIL; ATACAND HCT	5196444	JUN 04,	2012	U-3			
021093 002	CANDESARTAN CILEXETIL; ATACAND HCT	5196444	JUN 04,	2012	U-3			
>ADD> >ADD>	021222 001	CEFDITOREN PIVOXIL; SPECTRACEF	4839350	JUN 13,	2006			
019835 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4918068	JUN 13,	2006				
019835 002	CETIRIZINE HYDROCHLORIDE; ZYRTEC	5958915	OCT 14,	2016				
020346 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358	JUN 25,	2007				
020369 001	CIPROFLOXACIN HYDROCHLORIDE; CILOXAN	4525358*PED	DEC 25,	2007				
020822 001	CITALOPRAM HYDROBROMIDE; CELEXA	4525358	JUN 25,	2007				
020822 002	CITALOPRAM HYDROBROMIDE; CELEXA	4525358	DEC 25,	2007				
020822 003	CITALOPRAM HYDROBROMIDE; CELEXA	4525358	JUN 25,	2007				
021046 001	CITALOPRAM HYDROBROMIDE; CELEXA	4670444	DEC 09,	2003	U-223	NCE	JUL 17, 2003	
>ADD>	020839 001	CLOPIDOGREL BISULFATE; PLAVIX	6429210 6100274	JUN 10, JUL 07,	2019 2019	NCE PC	JAN 17, JUL 17,	2004 2003
021165 001	DESLORATADINE; CLARINEX							
021312 001	DESOGESTREL; KARIVA							
075863 001	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN	6355656	DEC 04,	2015				
021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN	6355656	DEC 04,	2015				
021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN	6355656	DEC 04,	2015				
021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN	6280704	JUL 30,	2013				
>ADD> >ADD>	021191 001	DIMYRISTOYL LECITHIN; IMAGENT	6280705	JUL 30,	2013			
>ADD>	021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN	6287539	JUL 30,	2013			
>ADD>	021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN	5605673	FEB 25,	2014			
>ADD>	021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN	5626833	MAY 16,	2014			
>ADD>	021191 001	DIMYRISTOYL LECITHIN; IMAGENT	5639443	JUN 17,	2014			
>ADD>	021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN	5695741	DEC 09,	2014			
>ADD>	021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN	5720938	FEB 24,	2015			
>ADD>	021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN	5798091	AUG 25,	2015			

**PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
AND Pediatric EXCLUSIVITY**

* PED and PEP represent pediatric data

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

PREScription AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 * PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/ PED EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD> 021379 001	LEUPROLIDE ACETATE; ELIGARD	5599552	FEB 04, 2014	NP	JUL 24, 2005	
>ADD>		5733950	OCT 03, 2008			
>ADD>		5739176	OCT 03, 2008			
>ADD>		4938763	OCT 03, 2008			
>ADD>		5278201	JAN 11, 2011			
>ADD>		5324519	OCT 20, 2011			
>ADD>		6375978	DEC 17, 2018			
>ADD>		6395292	JAN 30, 2017			
>ADD>		6335369	JAN 18, 2021	U-433		
>ADD>		6429230	JAN 18, 2021	U-433		
>ADD>		5138069	AUG 11, 2009		I-357	APR 08, 2003
>ADD>		5153197	OCT 06, 2009	U-3		I-357
>ADD>		5608075	MAR 04, 2014			I-305
>ADD>		5138069*PED	FEB 11, 2010			FEB 02, 2003
>ADD>		5153197*PED	APR 06, 2010	U-3		I-357
>ADD>		5608075*PED	SEP 04, 2014			APR 08, 2003
>ADD>		5153197	OCT 06, 2009	U-3		I-357
>ADD>		5138069	AUG 11, 2009			APR 08, 2003
>ADD>		5608075	MAR 04, 2014			I-357
>ADD>		5138069*PED	FEB 11, 2010			APR 08, 2003
>ADD>		5153197*PED	APR 06, 2010	U-3		I-357
>ADD>		5608075*PED	SEP 04, 2014			U-448
>ADD>		5138069	AUG 11, 2009			I-450
>ADD>		5153197	OCT 06, 2009	U-3		U-447
>ADD>		5608075	MAR 04, 2014			U-448
>ADD>		5138069*PED	FEB 11, 2010			U-448
>ADD>		5153197*PED	APR 06, 2010	U-3		U-450
>ADD>		5608075*PED	SEP 04, 2014			U-447
>ADD>		6406715	OCT 31, 2017			U-448
>ADD>		6080428	MAY 27, 2017			U-447
>ADD>		6129930	SEP 20, 2013			U-448
>ADD>		6406715	OCT 31, 2017			U-448
>ADD>		6080428	SEP 20, 2013			U-450
>ADD>		6129930	MAY 27, 2017			U-447
>ADD>		6129930	SEP 20, 2013			U-448

PREScription AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 * PED and PED represent Pediatric Exclusivity

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME NUMBER	PATENT NUMBER	PATENT/PED EXCL USE CODE			EXCLUS CODE EXPIRES		
			PATENT EXPIRES	EXCL	USE CODE	EXCLUS CODE	EXPIRES	
>ADD> 021316 001	LOVASTATIN; ALTOCOR	5916595	DEC 12, 2017	U-456	NDF	JAN 30,	2005	
>ADD> 021316 002	LOVASTATIN; ALTOCOR	6080778	MAR 23, 2018	NDF	JAN 30,	2005		
>ADD> 021316 003	LOVASTATIN; ALTOCOR	5916595	DEC 12, 2017	U-456	NDF	JAN 30,	2005	
>ADD> 021316 004	LOVASTATIN; ALTOCOR	6080778	MAR 23, 2018	U-456	NDF	JAN 30,	2005	
>ADD> 019643 002	LOVASTATIN; MEVACOR	5916595	DEC 12, 2017	U-456	PED	AUG 14,	2005	
019643 003	LOVASTATIN; MEVACOR	6080778	MAR 23, 2018	U-456	PED	FEB 14,	2005	
019643 004	LOVASTATIN; MEVACOR	4933456	NOV 27, 2011	PC	NCE	APR 13,	2005	
>ADD> 020652 001	MANGAFODIPIR TRISODIUM; TESLASCAN	6353029	AUG 24, 2020	U-189	NDF	MAR 21,	2005	
076175 001	MEFLOQUINE HYDROCHLORIDE; MEFLOQUINE HCL	6407128	DEC 03, 2021	PED	JUN 15,	2004		
>ADD> 020938 002	MELOXICAM; MOBIC			I-320	DEC 15,	2003		
020922 001	MEQUINOL; SOLAGE			W	JUN 15,	2004		
>ADD> 020855 001	MESNA; MESNEX			PED	JUN 15,	2004		
013217 001	METAXALONE; SKELAXIN			I-320	DEC 15,	2003		
020357 001	METFORMIN HYDROCHLORIDE; GLUCOPHAGE			W	DEC 15,	2003		
020357 002	METFORMIN HYDROCHLORIDE; GLUCOPHAGE			W	JUN 15,	2004		
020357 003	METFORMIN HYDROCHLORIDE; GLUCOPHAGE			PED	JUN 15,	2004		
020357 004	METFORMIN HYDROCHLORIDE; GLUCOPHAGE			I-320	DEC 15,	2003		
020357 005	METFORMIN HYDROCHLORIDE; GLUCOPHAGE			W	DEC 15,	2003		
021121 004	METHYLPHENIDATE HYDROCHLORIDE; CONCERTA	4519801	JUL 12, 2002	NP	I-320	DEC 15,	2003	
		4612008	SEP 16, 2003	U-372	W	JUN 15,	2004	
		4783337	SEP 16, 2003		W	AUG 01,	2003	
		5082668	SEP 16, 2003		NP			

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

* PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/EXPIRES	PATENT/PED EXCL USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD> 020381 003	NIACIN; NIASPAN	6406715	OCT 31, 2017	U-450		
>ADD> 020381 004	NIACIN; NIASPAN	6406715	OCT 31, 2017	U-450		
>ADD> 020381 005	NIACIN; NIASPAN TITRATION ST	6406715	OCT 31, 2017	U-450		
020076 004	NICOTINE; HABITROL	6129930	SEP 20, 2013	U-354	D-71	NOV 12, 2002
020076 005	NICOTINE; HABITROL				D-71	NOV 12, 2002
020076 006	NICOTINE; HABITROL				D-71	NOV 12, 2002
020555 001	NIZATIDINE; AXID AR	4375547	APR 12, 2002			
021008 001	OCTREOTIDE ACETATE; SANDOSTATIN LAR	6395292	JAN 30, 2017			
021286 001	OLMESARTAN MEDOXOMIL; BENICAR					
021286 003	OLMESARTAN MEDOXOMIL; BENICAR					
021286 004	OLMESARTAN MEDOXOMIL; BENICAR					
>ADD> 019810 001	OMEPRAZOLE; PRILOSEC	4636499*PED	NOV 30, 2005			
>ADD> 019810 002	OMEPRAZOLE; PRILOSEC	6166213*PED	APR 19, 2019			
>ADD> 019810 003	OMEPRAZOLE; PRILOSEC	4636499*PED	NOV 30, 2005			
>ADD> 020766 001	ORLISTAT; XENICAL	6166213*PED	APR 19, 2019			
021285 001	OXCARBAZEPINE; TRILEPTAL	4998089	JUN 18, 2009			
020553 001	OXYCODONE HYDROCHLORIDE; OXYCONTIN					
020553 002	OXYCODONE HYDROCHLORIDE; OXYCONTIN					
020553 003	OXYCODONE HYDROCHLORIDE; OXYCONTIN					
020553 004	OXYCODONE HYDROCHLORIDE; OXYCONTIN					
020553 005	OXYCODONE HYDROCHLORIDE; OXYCONTIN					

PRESCRIPTION AND OTC DRUG PRODUCT

WARRANT AND EXCLUSIVITY DATA

*PED and PED represent Pediatric Endocrinology.

THE PRACTICAL EXCLUSIVITY

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
and may represent Pediatric Exclusivity

*PED and PED represent Pediatric Exclusion

PREScription AND OTC DRUG PRODUCT
PATIENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

* PED and PED represent Pediatric Exclusivity

INGREDIENT NAME; TRADE NAME

PATENT/PED EXCL USE EXCLUS
EXPIRES CODE CODE SYDIBES

APPL/ PROD
NUMBER

PAROXETINE HYDROCHLORIDE: PAXIL

4721723	DEC 29,	2006	U-12	I-261	MAY 17,	2002
5872132	MAY 19,	2015	I-326	APR 13,	2004	
5900423	MAY 19,	2015	I-345	DEC 14,	2004	
5789449	JAN 06,	2009	U-285	PED OCT 13,	2004	
6063927	APR 23,	2019	PED	JUN 14,	2005	
6080759	MAY 19,	2015	PED	NOV 17,	2002	

ADD>

PRESCRIPTION AND OTC DRUG PRODUCT

RESCRIPTION AND EXCLUSIVITY DATA

PAIENI AND EXCLUSIVITY DATA

PED represent Pediatric Exclusivity

5900423*PED	NOV 19,	2015
6063927*PED	OCT 23,	2019
6080759*PED	NOV 19,	2015
6121291*PED	SEP 17,	2017
6121291*PED	NOV 19,	2015
6133289*PED	JUL 15,	2018
5872132	MAY 19,	2015
5900423	MAY 19,	2015
5789449	JAN 06,	2009
4721723	DEC 29,	2006
6062927	APR 23,	2019
6080759	MAY 19,	2015
6121291	MAR 17,	2017
6133289	MAY 19,	2015
6172233	JAN 15,	2018
6121291	MAR 17,	2017
4721723*	PED JUN 29,	2007
5789449*	PED JUL 06,	2009
5872132*	PED NOV 19,	2015
5900423*	PED NOV 19,	2015
6063927*	PED OCT 23,	2019
6080759*	PED NOV 19,	2015
6121291*	PED SEP 17,	2017
6121291*	PED SEP 17,	2017
6133289*	PED NOV 19,	2015
6172233*	PED JUL 15,	2018
5872132	MAY 19,	2015
5900423	MAY 19,	2015
5789449	JAN 06,	2009
4721723	DEC 29,	2006
6062927	APR 23,	2019
6080759	MAY 19,	2015
6121291	MAR 17,	2017
6133289	MAY 19,	2015
6172233	JAN 15,	2018
6121291	MAR 17,	2017
4721723*	PED JUN 29,	2007
5789449*	PED JUL 06,	2009
5872132*	PED NOV 19,	2015
5900423*	PED NOV 19,	2015
6063927*	PED OCT 23,	2019
6080759*	PED NOV 19,	2015
6121291	MAR 17,	2017
6133289	MAY 19,	2015
6172233	JAN 15,	2018
5872132*	PED JUN 29,	2007
5900423*	PED DEC 13,	2006
5789449*	PED JUL 06,	2009
5872132*	PED NOV 19,	2015
5900423*	PED NOV 19,	2015
6063927*	PED OCT 23,	2019
6080759*	PED NOV 19,	2015
6121291*	PED SEP 17,	2017
6133289*	PED NOV 19,	2015
6172233*	PED NOV 19,	2015

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
PED and PED represent Pediatric Exclusivity

* PED and PED represent paediatric extrusion

PREScription AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 * PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCLUS CODE	EXCLUS EXPRES
020629 001 021302 001	PENCICLOVIR SODIUM;DENAVIR PIMECROLIMUS;ELIDEL	5075445 6352998 6352998*PED	SEP 24, 2010 OCT 26, 2015 APR 26, 2016			
021073 001 021073 002 021073 003 019898 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS PIOGLITAZONE HYDROCHLORIDE;ACTOS PIOGLITAZONE HYDROCHLORIDE;ACTOS PRAVASTATIN SODIUM;PRAVACHOL	6303640 6303640 4346227 5180589	AUG 09, 2016 AUG 09, 2016 OCT 20, 2005 JUL 09, 2008	U-425 U-425 U-425 I-281	JUN 09, 2003 JAN 18, 2003 JAN 18, 2003 JAN 18, 2003	
		5030447 5622985 4346227*PED 5180589*PED 5622985*PED 5030447*PED	JUL 09, 2008 APR 22, 2014 APR 20, 2006 JAN 09, 2009 OCT 22, 2014 JAN 09, 2009	I-304 I-287 U-335 D-51 D-70 U-335	JAN 18, 2003 FEB 10, 2003 JAN 18, 2003 JAN 18, 2003 DEC 18, 2004 PED	
		5180589 5622985 4346227*PED 5180589*PED 5622985*PED 5030447*PED	JUL 09, 2008 APR 22, 2014 APR 20, 2006 JAN 09, 2009 OCT 22, 2014 JAN 09, 2009	U-335 D-51 U-335 D-70 U-335 PED	JUN 09, 2003 JAN 18, 2003 JAN 18, 2003 DEC 18, 2004 JUL 18, 2003 PED	
		4346227 5030447 5180589 5622985 4346227*PED 5180589*PED 5622985*PED 5030447*PED	OCT 20, 2005 JUL 09, 2008 JUL 09, 2008 APR 22, 2014 APR 20, 2006 JAN 09, 2009 OCT 22, 2014 JAN 09, 2009		I-281 I-304 I-287 U-335 D-51 JAN 18, 2003 D-70 U-335	
019898 003	PRAVASTATIN SODIUM;PRAVACHOL	4346227 5030447 5180589 5622985 4346227*PED 5180589*PED 5622985*PED 5030447*PED	JUL 09, 2008 APR 22, 2014 APR 20, 2006 JAN 09, 2009 OCT 22, 2014 JAN 09, 2009 JUL 18, 2003 JUL 18, 2003	PED PED PED PED PED PED PED PED	JUN 18, 2005 JAN 18, 2003 FEB 10, 2003 JAN 18, 2003 DEC 18, 2004 DEC 09, 2003 JUL 18, 2003 AUG 10, 2003	
019898 004	PRAVASTATIN SODIUM;PRAVACHOL	4346227 5030447 5180589 5622985 4346227*PED 5180589*PED 5622985*PED 5030447*PED	OCT 20, 2005 JUL 09, 2008 JUL 09, 2008 APR 22, 2014 APR 20, 2006 JAN 09, 2009 OCT 22, 2014 JAN 09, 2009		I-281 I-304 I-287 U-335 D-51 D-70 U-335 PED	
		5180589 5622985 4346227*PED 5180589*PED 5622985*PED 5030447*PED	JUL 09, 2008 APR 22, 2014 APR 20, 2006 JAN 09, 2009 OCT 22, 2014 JAN 09, 2009		JUN 09, 2003 JAN 18, 2003 D-51 D-70 U-335 PED	

**PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

**PED and PED represent Pediatric exclusivity

INGREDIENT NAME: TRADE NAME

APPL/PROD
NUMBER

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

APPLI/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUS EXPIRES
>ADD> >ADD>	RABEPRAZOLE SODIUM;ACIPHEX	5035899	APR 04, 2009	U-385	NCE	AUG 19, 2004
020973 001	RALOXIFENE HYDROCHLORIDE;EVISTA	5045552	SEP 03, 2008	U-385	I-346	FEB 12, 2005
020815 001	RIBAVIRIN;REBETOL	4418068	APR 03, 2003			
020903 001	RILUZOLE;RILUTEK	617074	NOV 01, 2016	U-454		
020599 001	RISEDRONATE SODIUM;ACTONEL	617074*PED	MAY 01, 2017	U-454		
020835 001	RISEDRONATE SODIUM;ACTONEL	5527814	JUN 18, 2013			
020835 002	RISEDRONATE SODIUM;ACTONEL			D-73	MAY 17,	2005
020835 003	RISEDRONATE SODIUM;ACTONEL	5994329	JUL 17, 2018	U-353	D-74	MAY 17, 2005
		6015801	JUL 17, 2018	U-353	D-73	MAY 17, 2005
				D-74	MAY 17,	2005
>ADD> >ADD>	RISPERIDONE;RISPERDAL					
020272 001	RISPERIDONE;RISPERDAL			M-15	MAR 03,	2005
020272 002	RISPERIDONE;RISPERDAL			M-15	MAR 03,	2005
020272 003	RISPERIDONE;RISPERDAL			M-15	MAR 03,	2005
020272 004	RISPERIDONE;RISPERDAL			M-15	MAR 03,	2005
020272 005	RISPERIDONE;RISPERDAL			M-15	MAR 03,	2005
020272 007	RISPERIDONE;RISPERDAL			M-15	MAR 03,	2005
020272 008	RISPERIDONE;RISPERDAL			M-15	MAR 03,	2005
020588 001	RIZATRIPTAN BENZOATE;MAXALT	5298520	JUN 29, 2012	U-240		
020864 001	RIZATRIPTAN BENZOATE;MAXALT	5298520	JUN 29, 2012	U-240		
020864 002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JUN 29, 2012	U-240		
020865 001	RIZATRIPTAN BENZOATE;MAXALT	5298520	JUN 29, 2012	U-240		
020865 002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JUN 29, 2012	U-240		
021042 001	ROFECOXIB;VIOXX	5691374	MAY 18, 2015	U-240		
021042 002	ROFECOXIB;VIOXX	6063811	MAY 06, 2017	U-266	U-266	U-266
021042 003	ROFECOXIB;VIOXX	5691374	MAY 18, 2015	U-266	U-266	U-266
021052 001	ROFECOXIB;VIOXX	6063811	MAY 06, 2017	U-266	U-266	U-266
021052 002	ROFECOXIB;VIOXX	5691374	MAY 18, 2015	U-266	U-266	U-266
020658 001	ROPINIROLE HYDROCHLORIDE;REQUIP	5691374	MAY 18, 2015	U-266	U-266	U-266
020658 002	ROPINIROLE HYDROCHLORIDE;REQUIP	6063811	MAY 06, 2017	U-266	U-266	U-266
020658 003	ROPINIROLE HYDROCHLORIDE;REQUIP	5691374	MAY 18, 2015	U-266	U-266	U-266
020658 004	ROPINIROLE HYDROCHLORIDE;REQUIP	6063811	MAY 06, 2017	U-266	U-266	U-266
020658 005	ROPINIROLE HYDROCHLORIDE;REQUIP	5691374	MAY 18, 2015	U-266	U-266	U-266
020658 006	ROPINIROLE HYDROCHLORIDE;REQUIP	6063811	MAY 06, 2017	U-266	U-266	U-266
020658 007	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007	4452808	DEC 07, 2007	4452808
020692 001	SALMETEROL XINAFOATE;SEREVENT	4452808	DEC 07, 2007	4452808	DEC 07, 2007	4452808
020828 001	SAQUINAVIR;FORTOVASE	6352717	NOV 16, 2019	I-348	MAR 22,	2005
		6008228	JUN 06,			

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
Pediatric Exclusivity

***PED and PED represent Pediatric Extent

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES		EXCL USE CODE		EXCL CODE		EXCLUSIVITY CODE	
			EXPIRES	PATENT NUMBER	CODE	CODE	CODE	CODE	CODE	CODE
021075 001	SOMATROPIN RECOMBINANT; NUTROPIN DEPOT	5912015	MAR 12,	2012						
021075 002	SOMATROPIN RECOMBINANT; NUTROPIN DEPOT	5912015	MAR 12,	2012						
021075 003	SOMATROPIN RECOMBINANT; NUTROPIN DEPOT	5912015	MAR 12,	2012	ODE	AUG 23,	2003			
020604 004	SOMATROPIN RECOMBINANT; SEROSTIM									
020677 001	SPARFLOXACIN ZAGAM	4795751	FEB 04,	2010						
020132 001	SUMATRIPTAN SUCCINATE; IMITREX	6368627	MAR 02,	2012						
020132 002	SUMATRIPTAN SUCCINATE; IMITREX	6368627	MAR 02,	2012						
020132 003	SUMATRIPTAN SUCCINATE; IMITREX	6368627	MAR 02,	2012						
017970 001	TAMOXIFEN CITRATE; NOLVADEX	4536516*PED	AUG 20,	2002						
017970 002	TAMOXIFEN CITRATE; NOLVADEX	4536516	AUG 20,	2003						
019785 001	TECHNETIUM TC-99M SESTAMIBI KIT; CARDIOLITE	4536516*PED	FEB 20,	2003						
019785 003	TECHNETIUM TC-99M SESTAMIBI KIT; MIRALUMA	4452774	DEC 21,	2004	NCE	JUL 24,	2007			
021200 001	TEGASEROD MALEATE; ZELNORM	4452774	DEC 21,	2004	NCE	JUL 24,	2007			
021200 002	TEGASEROD MALEATE; ZELNORM									
020846 001	TERBINAFINE; LAMISIL	4755534	DEC 30,	2006	U-445					
		4680291	JUL 14,	2004	U-445					
020791 001	TESTOSTERONE; TESTODERM TTIS	6348210	NOV 10,	2019						
020785 001	THALIDOMIDE; THALOMID	6315720	OCT 23,	2020						
020697 001	TOLCAPONE; TASMAR	5236952	JAN 29,	2012						
020697 002	TOLCAPONE; TASMAR	5236952	JAN 29,	2012						
021228 001	TOLTERODINE TARTRATE; DETROL LA	5559269	NOV 05,	2013	U-318					
021228 002	TOLTERODINE TARTRATE; DETROL LA	5559269	NOV 05,	2013	U-318					
021272 001	TREPROSTINIL SODIUM; REMODULIN	5153222	OCT 06,	2009	U-455	NCE	MAY 21,	2007		
021272 002	TREPROSTINIL SODIUM; REMODULIN	5153222	OCT 06,	2009	U-455	NCE	MAY 21,	2009		
021272 003	TREPROSTINIL SODIUM; REMODULIN	5153222	OCT 06,	2009	U-455	NCE	MAY 21,	2007		
021272 004	TREPROSTINIL SODIUM; REMODULIN	5153222	OCT 06,	2009	U-455	NCE	MAY 21,	2007		
021289 001	UROFOLLITROPIN; BRAVELLE	4957924	JUN 23,	2009	ODE	MAY 21,	2009			
020550 001	VALACYCLOVIR HYDROCHLORIDE; VALTREX	5879706	JAN 19,	2016	NP	MAY 06,	2005			
020550 002	VALACYCLOVIR HYDROCHLORIDE; VALTREX	6107302	JAN 19,	2016						
		4957924	JUN 23,	2009						
		5879706	JAN 19,	2016						
		6107302	JAN 19,	2016						
020593 001	VALPROATE SODIUM; DEPACON	6294197	JUN 18,	2017						
021283 001	VALSARTAN; DIOVAN	6294197	JUN 18,	2017						
021283 002	VALSARTAN; DIOVAN	6294197	JUN 18,	2017						
021283 003	VALSARTAN; DIOVAN	6294197	JUN 18,	2017						
>ADD>	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	6419958	MAR 20,	2017						
020699 001	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	6403120	MAR 20,	2017	D-72	JAN 24,	2005			

PREScription AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME NUMBER	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020699 002	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	6419958 6403120	MAR 20, 2017 MAR 20,	U-459 U-451	MAY 02, 2004
>ADD>	020699 003	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	6419958 6403120	MAR 20, 2017 MAR 20,	U-459 U-451	MAY 02, 2004
>ADD>	020699 004	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	6419958 6403120	MAR 20, 2017 MAR 20,	U-459 U-451	MAY 02, 2004
>ADD>	021119 001	VERTEPORFIN; VISUDYNE	4883790	JAN 20, 2007		
>ADD>	020388 001	VINORELBINE TARTRATE; NAVELBINE	4307100*PED	JUL 08, 2002		
>ADD>	021266 001	VORICONAZOLE; VENDE	4307100*PED	JAN 08, 2003		
	021266 002	VORICONAZOLE; VENDE			NCE	MAY 24, 2007
	021267 001	VORICONAZOLE; VEND			NCE	MAY 24, 2007
	021036 001	ZANAMIVIR; RELEZA	6294572	DEC 15, 2014		
	020825 001	ZIPRASIDONE HYDROCHLORIDE; GEODON	6150366	MAY 27, 2019		
	020825 002	ZIPRASIDONE HYDROCHLORIDE; GEODON	6150366	MAY 27, 2019		
	020825 003	ZIPRASIDONE HYDROCHLORIDE; GEODON	6150366	MAY 27, 2019		
	020825 004	ZIPRASIDONE HYDROCHLORIDE; GEODON	6399777	APR 01, 2017	NCE	FEB 05, 2006
	020919 001	ZIPRASIDONE MESYLATE; GEODON	4831031	MAR 02, 2007	NDF	JUN 21, 2005
>ADD>			6110918	MAR 26, 2017		
>ADD>	021223 001	ZOLEDRONIC ACID; ZOMETA	6232304	APR 01, 2017	I-361	FEB 22, 2005
>ADD>	021231 001	ZOLMITRIPTAN; ZOMIG-ZMT			NCE	NOV 25, 2002
	020789 001	ZONISAMIDE; ZONEGRAN	5466699 6342515	NOV 14, 2012 DEC 21, 2018	U-438	



PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 22ND EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

- W EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.3 OF SUPPLEMENT WAIVED EXCLUSIVITY

REFERENCES NEW DOSING SCHEDULE

- D-71 EIGHT WEEK DOSING REGIMEN
- D-72 INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
- D-73 ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-74 ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-75 INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
- D-76 FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
- D-77 ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)

NEW INDICATION

- I-348 LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
- I-349 ACUTE CORONARY SYNDROME
- I-350 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
- I-351 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
- I-352 ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
- I-353 TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
- I-354 MANAGEMENT OF POST HERPETIC NEURALGIA
- I-355 PREMENSTRUAL DYSPHORIC DISORDER
- I-356 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
- I-357 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
- I-358 TREATMENT OF PANIC DISORDER
- I-359 TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE
- I-360 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE

- I-361 TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS,
IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE
PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
- I-362 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA

B-2

MISCELLANEOUS EXCLUSIVITY CODES

- M-15 LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
- M-16 CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
- M-17 INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
- M-18 INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
- M-19 INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER

PATENT USE CODES

- U-438 TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
- U-439 TREATMENT OF OBESITY
- U-440 METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
- U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
- U-442 METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
- U-443 MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
- U-444 METHOD OF TREATING
- U-445 USE AS AN ANTIMYCOTIC AGENT
- U-446 TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
- U-447 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-448 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-449 USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
- U-450 INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS, SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
- U-451 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
- U-452 USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
- U-453 TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
- U-454 METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
- U-455 TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
- U-456 METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
- U-457 METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
- U-458 METHOD OF USE OF IMAGENT
- U-459 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
- U-460 INTENTIONALLY LEFT BLANK
- U-461 METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE

New 22nd Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

22nd EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code

*8392

Charge your order.
It's easy!



Yes, enter my subscription as follows:

Subscriptions of APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, ADP, and the monthly Cumulative Supplements, for \$105.00 per year.

The total cost of my order is \$ _____. Price includes regular shipping and handling and is subject to change.
International customers please add 40%.

For privacy protection, check the box below:

Do not make my name available to other mailers.

Please choose method of payment:

Check payable to Superintendent of Documents
 GPO Deposit Account 1111111111111111

VISA or MasterCard

1111111111111111

Company or personal name _____

Additional address/attention line _____

Street address _____

City, State, ZIP Code _____

Daytime phone including area code _____

Purchase Order No. (optional) _____

(Credit card expiration date)

(Authorizing Signature) _____

(10/01)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To FAX your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.

Thank you for your order!

ST. LOUIS COLLEGE OF PHARMACY



3 2201 90038 9921

RM301.45 .A66 2002 July suppl.

Approved drug products with
therapeutic equivalence

C:355661 M:174736 O:12937927

Library Use Only

LIBRARY

ST. LOUIS COLLEGE OF PHARMACY

4588 PARKVIEW PL.

ST. LOUIS, MO. 63110

